UBC DEPARTMENT OF MEDICINE

2004

ANNUAL REPORT
**TABLE OF CONTENTS**

INTRODUCTION......................................................................................................................3

MISSION STATEMENT..........................................................................................................7

ORGANIZATION CHART......................................................................................................9

UBC DEPARTMENT OF MEDICINE COMMITTEES...............................................................11
Department Heads, Associate Heads, UBC Division Heads,
Educational Program Directors & Associate Directors......................................................13
Committee for Appointments, Reappointments, Promotion and Tenure..........................15
Teaching Effectiveness Office...........................................................................................19

DIVISION REPORTS......................................................................................................21
Allergy & Immunology......................................................................................................23
Cardiology........................................................................................................................27
Critical Care Medicine.....................................................................................................35
Dermatology.......................................................................................................................39
Endocrinology...................................................................................................................43
Gastroenterology...............................................................................................................47
General Internal Medicine...............................................................................................51
Geriatric Medicine...........................................................................................................55
Hematology........................................................................................................................59
Infectious Diseases..........................................................................................................63
Medical Oncology............................................................................................................69
Nephrology........................................................................................................................75
Neurology..........................................................................................................................79
Physical Medicine & Rehabilitation.................................................................................95
Respiratory Medicine.......................................................................................................99
Rheumatology...................................................................................................................103

EDUCATIONAL PROGRAMS......................................................................................109
Clinical Investigator Program........................................................................................111
Continuing Medical Education Program.........................................................................115
Graduate Studies Program in Experimental Medicine....................................................117
HIV/AIDS Research Program........................................................................................121
Postgraduate Education Program....................................................................................127
Undergraduate Education Program................................................................................129

PUBLICATIONS.........................................................................................................131

GRANTS AND RESEARCH AWARDS..........................................................................185
INTRODUCTION

Graydon S. Meneilly, MD, FRCPC
Eric W. Hamber Professor & Head
UBC Department of Medicine

I am pleased to provide this overview for the 2004 annual report on behalf of the UBC Department of Medicine. This report is also available on the internet at www.medicine.ubc.ca.

Overview

The UBC Department of Medicine provides research, teaching and clinical services related to the nature, cause and prevention of adult diseases. We are the largest Department in the Faculty of Medicine and we consist of sixteen divisions: Allergy and Immunology, Cardiology, Critical Care, Dermatology, Endocrinology, Gastroenterology, Geriatric Medicine, Internal Medicine, Hematology, Infectious Diseases, Medical Oncology, Nephrology, Neurology, Physical Medicine and Rehabilitation, Respiratory Medicine and Rheumatology.

People

As you read through this document you encounter the many different aspects of our Department and the things we have achieved over the past year. I would like to take this opportunity to highlight some of the wonderful accomplishments of our members. Recruitment and retention are a large part of our business. We have appointed 3 Professors, 4 Associate Professors, 8 Assistant Professors, 1 Clinical Associate Professor, 10 Clinical Assistant Professors, 21 Clinical Instructors and 4 Associate Members. We have promoted 12 Faculty members effective July 1, 2004.

Our faculty received 16 CIHR Scholarship/Scientist awards, 27 Michael Smith Scholarships/Scientist awards, 6 CRC Scientist awards and 16 Scholarship/Scientist awards from other peer reviewed agencies.
I am particularly pleased to announce the appointment of Dr. Paul Man as Associate Head of Medicine at UBC and Chair, Department of Medicine, Providence Health Care in March 2004. Paul is already taking a major leadership role in the activities of the Department.

In addition, the following Division Heads and Program Directors have also been appointed: **Paul Keown**, Head, UBC Division of Nephrology, March 1, 2004; **Chris Buller**, Head, UBC Division of Cardiology, January 1, 2004; **Mark FitzGerald**, Head, VGH Division of Respiratory Medicine, July 1, 2004; **Larry Dian**, Acting Head, Division of Geriatric Medicine, July 1, 2004; **Joseph Connors**, Acting Head, Division of Medical Oncology (while Susan O'Reilly is on sabbatical); **Adeera Levin and Anita Palepu**, Directors, Clinical Investigator Program, July 1, 2004; **Vince Duronio**, Director, Experimental Medicine Program, July 1, 2004; **Doris Doudet**, Associate Head, Research, Vancouver Acute, July 1, 2004; **John Mancini**, Director, CME Program, March 1, 2004; **Mark Roberts**, Director, Postgraduate Education Program, October 1, 2004; **Roger Wong**, Associate Director, Postgraduate Education Program, October 1, 2004; **Barry Kassen**, Associate Director, Postgraduate Education Program, October 1, 2004; **Rose Hatala**, Associate Director, Postgraduate Education Program, October 1, 2004; **Janet Kushner-Kow**, Director, Expansion & New Programs, Undergraduate Education Program, July 1, 2004.

**Awards**

The Department extends its warmest congratulations to these outstanding individuals who received the following Departmental awards. The Fay R. Dirks Awards for Excellence in Teaching were awarded to **Drs. Hartmut Henning (Cardiology) and John Kelsall (Rheumatology)**. The Martin M. Hoffman Awards for Excellence in Research were awarded to **Drs. Gary Quamme (Nephrology) and Stephen van Eeden (Respiratory)**. The Donald M. Whitelaw Awards for Outstanding Grand Rounds were given to **Drs. Philip Teal (Neurology) and John Webb (Cardiology)**. The Master Teacher Awards were given to **Drs. Gillian Gibson (Neurology) and Clifford Chan-Yan (Nephrology)**.

In addition, members of the department were recognized by the faculty and other bodies for their excellence in teaching and research. **Dr. Peter Pare (Respiratory)** was awarded the UBC Izaak Walton Killam Research Prize in the Senior Science category. **Dr. Yu Tian Wang (Neurology)** was awarded the UBC Izaak Walton Killam Research Prize in the Junior Science category. **Dr. Jerilynn Prior (Endocrinology)** was awarded the UBC Medical Alumni Association Honorary Alumni Award. **Dr. Theo van Rijn (Physical Medicine & Rehabilitation)** was awarded the First Annual Theo van Rijn Award for Outstanding Contribution to the UBC Physical Medicine & Rehabilitation Residency Program. **Dr. Peter Tsang (Hematology)** was awarded the PAR-BC Award for Excellence in Clinical Teaching. **Dr. John Schrader (Hematology)** was awarded the CSCI Distinguished Scientist Award. **Dr. Tony Chow (Infectious Diseases)** was awarded the Janssen Ortho-Canadian Infectious Disease Society Distinguished Service Award. **Dr. Richard Arseneau (General Internal Medicine)** was awarded the Leadership Award in the BC 2004 Innovations Awards in Educational Technology. **Dr. Barry Kassen (General Internal Medicine)** was awarded the Osler Award for Excellence in GIM. **Dr. Eric Yoshida (Gastroenterology)** was awarded the Astra Zeneca Canada Teaching Award in Gastroenterology. **Dr. Alastair McLeod (Dermatology)** was awarded the Canadian Dermatology Association Award of Merit. **Dr. Richard Crawford (Dermatology)** was awarded the Canadian Dermatology Association Residents and Fellows Section Teaching...
Award. Dr. Alastair Carruthers (Dermatology) was elected Vice-President of the American Society for Dermatologic Surgery. Dr. Hugh Chaun (Gastroenterology) became Governor of the American College of Gastroenterology representing the region of the Western Provinces. Dr. Diane Lacaille (Rheumatology) was elected to the Young Investigator Subcommittee of the American College of Rheumatology (ACR) Committee on Research.

One of the Department's most important strategic initiatives is the creation of the Academic Enhancement Endowment Fund and the Academic Enhancement Fund competition process. These awards are provided in an effort to ensure greater protected research time for individuals undertaking meritorious research. This fund has taken on greater importance as the endowment has grown and as the awards have increased. The recipients of the Academic Enhancement Endowment Fund awards in 2004 were Drs. Jolanda Cibere (Rheumatology), Vinay Dhingra (Critical Care), Kevin McElwee (Dermatology), Kerry Savage (Medical Oncology), and Jennifer Wilson (Respiratory). Recipients are termed Departmental Scholars.

Research

Once again the department was extremely successful in attracting research support. The department received $21,563,014 in peer reviewed grants and $19,150,111 in non-peer reviewed grants.

In order to move forward the Department has implemented a strategic planning process in Research and has appointed a new Associate Head Research at VGH and UBC, Dr. Doris Doudet. The culmination of these plans within the next academic year will give the Department a framework for success.

Summary

In closing I would like to take this opportunity to once again acknowledge the contributions of all Faculty and Staff and to thank them for their hard work, outstanding achievements and dedication to the success of the Department of Medicine.

Sincerely,

Graydon S. Meneilly, MD, FRCPC
Eric W. Hamber Professor & Head
UBC Department of Medicine
MISSION STATEMENT

We, the members of the Department of Medicine of the University of British Columbia, will work with all our partners to provide the highest possible standard of excellence in patient care, teaching and research. We will pursue this mission while emphasizing open communication and ethical behavior, and while recognizing that it is a privilege to provide responsible and innovative stewardship of human, financial and all other resources. We will always:

1. respect the dignity, individuality and needs of our patients,
2. strive to discover new knowledge that will advance state-of-the-art care,
3. ensure effective and innovative teaching of our students,
4. optimize our organization to promote both professional and personal fulfillment,
5. value the efforts and achievements of teams and individuals who work to face the challenges of modern medicine.

These activities will ensure the respect of our peer organizations and recognition as a world-class Department of Medicine.
ORGANIZATION CHART

Dean
UBC Faculty of Medicine

Head
UBC Department of Medicine

Associate Heads,
UBC Dept. of Medicine
Heads, Hosp. Dept. of Medicine

Heads & Directors of Divisions
& Programs of UBC
Department of Medicine

Heads & Directors of Divisions
& Programs of the Hospital
Departments of Medicine

Members, Divisions & Programs
of the Hospital Departments of
Medicine
UBC DEPARTMENT OF MEDICINE COMMITTEES
DEPARTMENT HEADS, ASSOCIATE HEADS, UBC DIVISION HEADS, EDUCATIONAL PROGRAM DIRECTORS & ASSOCIATE DIRECTORS

DEPARTMENT HEADS

Graydon S. Meneilly, MD, FRCPC
Eric W. Hamber Professor & Head
Department of Medicine UBC & Vancouver Acute

S. F. Paul Man, MD, FRCPC
Chair, Department of Medicine,
Providence Health Care

UBC ASSOCIATE HEADS

Dr. Harvey Lui, Associate Head of Medicine, Vancouver Acute
Dr. S. F. Paul Man, Associate Head of Medicine, Providence Health Care, (March 1, 2004 -
Dr. Doris Doudet, Associate Head Research, Vancouver Acute (July 1, 2004 -)
Dr. Peter Paré, Associate Head Research, Providence Health Care

UBC DIVISION HEADS

Allergy & Immunology Dr. Robert Schellenberg
Cardiology Dr. Chris Buller
Critical Care Medicine Dr. John Fenwick
Dermatology Dr. Harvey Lui
Endocrinology & Metabolism Dr. David Thompson
Gastroenterology Dr. Urs Steinbrecher
General Internal Medicine Dr. Iain Mackie, (Acting)
Geriatric Medicine Dr. Graydon Meneilly, (Jan-June 30, 2004)
Dr. Larry Dian, (Acting) (July 1, 2004 -)

Hematology/Bone Marrow Transplantation Dr. Michael Barnett
Infectious Diseases Dr. Neil Reiner
Medical Oncology Dr. Susan O'Reilly, (on sabbatical)
Dr. Joseph Connors, (Acting), (July 1, 2004 -)
Nephrology Dr. Eugene C. Cameron, (Jan-Feb 28, 2004)
Dr. Paul Keown, (March 1, 2004 -)
Neurology Dr. Howard Feldman
Physical Medicine & Rehabilitation Dr. Theo Van Rijn
Respiratory Medicine Dr. John Fleetham
Rheumatology Dr. John Esdaile
EDUCATIONAL PROGRAM DIRECTORS & ASSOCIATE DIRECTORS

Clinical Investigator Program Directors
Dr. Anita Palepu, (July 1, 2004 - )
Dr. Adeera Levin, (July 1, 2004 - )

Continuing Medical Education Director
Dr. Graydon S. Meneilly, (Interim)
(Jan-Feb 28, 2004)
Dr. G. B. John Mancini, (March 1, 2004 - )

Graduate Studies Program in Experimental Medicine Director
Dr. Norman Wong, (Jan-June 30, 2004)
Dr. Vince Duronio, (July 1, 2004 - )

HIV/AIDS Research Program Director
Dr. Julio Montaner

Postgraduate Education Program Director
Dr. Iain Mackie, (Jan - Sept 30, 2004)
Dr. J. Mark Roberts, (Oct 1, 2004 - )

Associate Directors
Dr. Roger Wong, (Oct 1, 2004 - )
Dr. Rose Hatala, (Oct 1, 2004 - )
Dr. Barry Kassen, (Oct 1, 2004 - )

Undergraduate Education Program Director
Dr. Grant Stiver

Associate Directors
Dr. Jim Dunne, 3rd year, St Paul's
Dr. Jim Busser, 3rd year, VGH
Dr. Reva Adler, 4th year
Dr. Janet Kushner-Kow, Expansion & New Programs, (July 1, 2004 - )
COMMITTEE FOR APPOINTMENTS, REAPPOINTMENTS, PROMOTION AND TENURE

Chair: Dr. G. S. Meneilly, Professor
Co-Chair: Dr. H. Lui, Professor
Administrative Secretary: Ellen Wong (Jan to Feb/04), Jeannie Stacey (Mar to Dec/04)

January 2004 to December 2004:
Dr. K. Gelmon, Clinical Professor, Medical Oncology
Dr. B. Koehler, Clinical Professor, Rheumatology
Dr. N. Murray, Clinical Professor, Medical Oncology
Dr. D. Ricci, Clinical Professor, Cardiology
Dr. D. Doudet, Professor, Neurology
Dr. J. Esdaile, Professor, Rheumatology
Dr. K. Humphries, Professor, Hematology
Dr. H. Lui, Professor, Dermatology

January 2004 to June 2004:
Dr. R. Levy, Associate Professor, Respiratory Medicine
Dr. YT Wang, Professor, Neurology
Dr. V. Bernstein, Clinical Professor, Cardiology
Dr. L. Lawson, Clinical Professor, Respiratory Medicine

July 2004 to December 2004:
Dr. N. Buskard, Clinical Professor, Hematology
Dr. J. Cairns, Professor, Cardiology
Dr. P Hoskins, Clinical Professor, Medical Oncology
Dr. J. Mancini, Professor, Cardiology
Dr. P. Keown, Professor, Nephrology

This dedicated group of committed Departmental members is charged with facilitating the career advancement of our members while upholding consistent and rigorous standards as set out by UBC. As usual, this Committee invested a great deal of thoughtful energy to support the additions and promotions listed below. We are very proud of the following:

NEW APPOINTMENTS

Anderson, Helen, Medical Oncology, Clinical Assistant Professor
Baillie, Hector, General Internal Medicine, Clinical Assistant Professor
Barton, Jason, Neurology, Professor
Bergman, Jamess, Dermatology, Clinical Assistant Professor
Boutilier, Elaine, Medical Oncology, Clinical Instructor
Briere, Hannah, Neurology, Clinical Assistant Professor
Broady, Rzewyn, Hematology, Clinical Instructor
Buller, Christopher, Cardiology, Professor
Chapman, Kristine, Neurology, Clinical Instructor
Chatur, Nazira, Gastroenterology, Clinical Instructor
Cibere, Jolanda, Rheumatology, Assistant Professor
Cook, Victoria, Respiratory Medicine, Assistant Professor
Deutscher, Timothy, General Internal Medicine, Clinical Instructor
Eng, Janice, Physical Medicine & Rehabilitation, Associate Member
Fung, Michelle, Endocrinology & Metabolism, Clinical Instructor
Gill, Karamjit, Medical Oncology, Clinical Assistant Professor
Gill, Sharlene, Medical Oncology, Assistant Professor
Haber, Richard, Dermatology, Clinical Associate Professor
Hallam, Bradley, Neurology, Clinical Instructor
Hsiung, Ging-Yuek (Robin), Neurology, Assistant Professor
Kenyon, Michael, General Internal Medicine, Clinical Instructor
Kopec, Jacek, Rheumatology, Associate Member
Lai, Kevin, General Internal Medicine, Clinical Instructor
Laskin, Janessa, Medical Oncology, Clinical Assistant Professor
Lee, Philip, Geriatric Medicine, Clinical Instructor
Leger, Chantal, Hematology, Clinical Instructor
Leitch, Heather, Hematology, Clinical Assistant Professor
Li, David, Neurology, Associate Member
Man, SF Paul, Respiratory Medicine, Professor
McElwee, Kevin, Dermatology, Assistant Professor
McKeown, Martin, Neurology, Associate Professor
O’Connor, Russell, Physical Medicine and Rehabilitation, Clinical Instructor
Phillips, Elizabeth, Infectious Diseases, Associate Professor
Ramji, Alnoor, Gastroenterology, Clinical Instructor
Richmond, Allistair, General Internal Medicine, Clinical Assistant Professor
Rossi, Sikina, Dermatology, Clinical Instructor
Savage, Kerry, Medical Oncology, Assistant Professor
Saw, Jacqueline, Cardiology, Clinical Assistant Professor
Sin, Donald, Respiratory Medicine, Associate Professor
Skinnider, Doug, No Division, Clinical Instructor
Smythe, Penelope, Neurology, Clinical Instructor
Son, Wai Kon, General Internal Medicine, Clinical Instructor
Souliere, Sheila, Medical Oncology, Clinical Instructor
Tebbutt, Scott, Respiratory Medicine, Clinical Assistant Professor
Telford, Jennifer, Gastroenterology, Clinical Assistant Professor
Towle, Angela, No Division, Assistant Professor
Tremlett, Helen, Neurology, Assistant Professor
Walker, Shannon, No Division, Clinical Instructor
Williams, Dorothy, No Division, Clinical Instructor
Winkler, Lawrence, General Internal Medicine, Clinical Instructor
Wong, Graham, Cardiology, Clinical Assistant Professor
Wood, Evan, Infectious Diseases, Clinical Assistant Professor
Yassi, Annalee, Physical Medicine and Rehabilitation, Associate Member
PROMOTIONS

Professor:
Chalmers, Andrew, Rheumatology

Associate Professor:
Sahl, Baljinder, Gastroenterology
Tyndall, Mark, Infectious Diseases

Clinical Associate Professor:
Gray, James, Gastroenterology
Kunimoto, Brian, Dermatology
Shojania, Kamran, Rheumatology

Clinical Assistant Professor:
Jastrzebski, Jacek, Nephrology
Kiaii, Mercedeh, Nephrology
Li, Charles, Hematology
Rabinowitz, Alan, Cardiology
Singh, Rajinder, Nephrology
Traboulsee, Anthony, Neurology
TEACHING EFFECTIVENESS OFFICE

Dr. James Busser
Chair; Member, UBC Division of General Internal Medicine

Mrs. Jennifer Golinski
Administrator; Undergraduate Education, UBC Department of Medicine

Reports to:
Committee for Appointments, Reappointments, Promotions and Tenure

Functions:

1. Provides Faculty member with "Guidelines" for producing necessary back-up documentation to Teaching Dossier.

2. Meets with Faculty member to discuss necessary back-up documentation and process involved in review for promotion/tenure/reappointment.

3. Liaises with various program offices: Undergraduate, Postgraduate, Continuing Medical Education, Graduate Studies to obtain information regarding teaching effectiveness of candidate. Where necessary, requests additional peer review of teaching.

4. Reviews teaching dossier, back-up documentation, peer review and prepares draft report for Committee for Appointments, Reappointments, Promotions and Tenure.

5. Forwards draft report to Faculty member to ensure that important information has not been omitted.

6. Finalizes report and forwards to Committee for Appointments, Reappointments, Promotions and Tenure.

In the year 2003, the Teaching Effectiveness Committee prepared 19 letters on behalf of GFT and Clinical Faculty. Subsequent promotions for these faculty have included:

(1) Associate Professor
(6) Clinical Assistant Professor
(3) Clinical Associate Professor

In the year 2004 we met with another 18 faculty, and have prepared 18 letters to support their review and/or consideration of promotion.
DIVISION REPORTS
ALLERGY & IMMUNOLOGY

Dr. R. Robert Schellenberg  
Professor & Head

Faculty Members

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor &amp; Head</td>
<td>Schellenberg, Dr. Robert</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Mandl, Dr. Michael</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Stark, Dr. Donald</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Wong, Dr. HC George</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Kanani, Dr. Amin</td>
<td>Vancouver</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Stephenson, Dr. Mary</td>
<td></td>
</tr>
</tbody>
</table>

Divisional Overview

Our small division is involved in providing clinical teaching in allergy and immunology at all levels. This includes major initiatives in patient education, CME programs for physicians, and elective rotations for residents and medical students. Despite not offering a training program at UBC, members are involved nationally in the nucleus committee of the Royal College as well as the examination committee for our subspecialty. Members are actively involved with lay organizations in medical advisory positions as well as in educational initiatives.

Teaching

All members of the Division are actively involved in teaching students, residents, community physicians and lay persons.

Dr. Schellenberg provides a lecture to Medicine I students on the basic mechanisms of allergic inflammation as well as for the Pathology 521 course. All members actively participate in case-based subspecialty teaching seminars for Med III / IV students. All members provide individual office-based teaching of students who have chosen an elective rotation in the subspecialty. In addition, each member teaches in the Clinical Skills block for Med I students and conducts Bedside teaching sessions with Med II students. The month-long elective rotation for residents in Internal Medicine and its subspecialties has become increasingly popular in the recent year. Major initiatives have been undertaken in community medical education to physicians, other health care professionals and to the lay public.
CME programs organized by Dr. George Wong through the auspices of the UBC Community Programs are given in various communities in British Columbia and the Northwest Territories. These have received excellent evaluations and are highly appreciated by physicians in outlying areas. Each member contributes to these programs.

Dr. Michael Mandl has continued to expand his asthma education program initiated through the Health Transition Fund to raise awareness and specific information in management of asthma in communities in BC. Five geographical sites have been targeted for evaluation of the effectiveness of this intensive education program to the public.

Dr. George Wong has developed specific expertise in evaluation of complementary and alternative medicine practices and has presented a number of interesting papers on these aspects at meetings in the USA and Canada.

Dr. Mandl and Dr. Schellenberg have been involved in video conference initiatives to provide information to the lay public in various communities in BC and provide a forum to answer questions from those participating at other sites.

Research

The members at St. Paul’s hospital have a major interest in management of primary immune deficiency and have initiated a number of research projects as well as interactions with the lay organization. Dr. Amin Kanani is the principal investigator on a new grant-in-aid (co-investigators Dr. Stark and Dr. Schellenberg) from Bayer Inc. study evaluating the quality of life and health outcome parameters of patients with primary immunodeficiency using two different dosing regimens of IVIG to determine optimal dosing requirements.

Dr. Stark is the principal investigator in a study evaluating a new IV immunoglobulin product.

Dr. Wong is conducting studies assessing the use and potential harmful effects of herbal and Chinese medicines.

Dr. Schellenberg is continuing studies of the mechanisms of excessive airway narrowing in asthma with emphasis on the role of degradative enzyme effects on extracellular matrix components in the airway wall using laser capture microdissection and molecular biologic techniques.

Clinical Services

All members are actively involved in providing clinical consultative services in Allergy and Immunology to the community. Dr. Mandl has outreach clinics in Dease Lake, Stewart, Hazelton, Bella Bella, Campbell River, Parksville and Bamfield. Dr. Stark provides outreach clinics in Prince George and Sechelt. He has been active with the hospitals in establishing protocols for the management of latex allergy in hospitals. Dr. Wong has had a specific interest in complimentary medicine practices and the potential harmful effects of specific treatments.
National and International Initiatives

Drs. Stark and Schellenberg co-chaired the local arrangements committee for the highly successful World Allergy Congress (International Congress of Allergy and Clinical Immunology) in Vancouver in September 2003. All members were involved in this large undertaking. Dr. Schellenberg was a member of the International Program Planning Committee for this meeting.

Dr. Schellenberg completed his 2-year term as president of the Canadian Society of Allergy and Clinical Immunology in Oct. ’04 and remains on its Board of Directors. He is also the deputy chair of the Royal College Examination Committee for this subspecialty and is the program director for the annual scientific meeting of the Canadian Society of Allergy and Clinical Immunology. In addition, he is a member of the Medical Advisory Committee of the Canadian Immune Deficiency Patient Organization.

Dr. Stark chairs the Nucleus Committee for Clinical Immunology and Allergy of the Royal College of Physicians and Surgeons of Canada.

Dr. Stark and Dr. Schellenberg are members of the Board of Directors for the Canadian Foundation for Allergy and Clinical Immunology, a charitable organization of which Dr. Stark was the founder.

All members are actively involved in local, national and international committees dealing with their areas of interest.
CARDIOLOGY

Dr. Christopher E. Buller
Clinical Professor & Head

Faculty Members

Clinical Professor & Head  Buller, Dr. Christopher  SPH/VA
Professor  Rabkin, Dr. Simon  VA
Professor  Mancini, Dr. G B John  VA
Professor  Kerr, Dr. Charles  SPH
Professor  Cairns, Dr. John  VA
Assistant Professor  Humphries, Dr. Karin  SPH
Clinical Professor  Bernstein, Dr. Victoria  VA
Clinical Professor  Dodek, Dr. Arthur  SPH
Clinical Professor  Hamburger, Dr. Jaap  VA/SPH
Clinical Professor  Huckell, Dr. Victor  VA
Clinical Professor  Penn, Dr. Ian  VA
Clinical Professor  Ricci, Dr. Donald  VA
Clinical Associate Professor  Carere, Dr. Ronald  SPH
Clinical Associate Professor  Fung, Dr. Anthony  VA
Clinical Associate Professor  Gin, Dr. Kenneth  VA
Clinical Associate Professor  Ignaszewski, Dr. Andrew  SPH
Clinical Associate Professor  Kiess, Dr. Marla  SPH
Clinical Associate Professor  Macdonald, Dr. Ian  SPH
Clinical Associate Professor  Thompson, Dr. Christopher  SPH
Clinical Associate Professor  Webb, Dr. John  SPH
Clinical Associate Professor  Yeung-Lai-Wah, Dr. John  SPH
Clinical Assistant Professor  Aymong, Dr. Eve  SPH
Clinical Assistant Professor  Chan, Dr. Sammy  SPH
Clinical Assistant Professor  Heilbron, Dr. Brett  SPH
Clinical Assistant Professor  Isserow, Dr. Saul  VA
Clinical Assistant Professor  Jue, Dr. John  VA
Clinical Assistant Professor  Lee, Dr. Pui Kee  VA
Clinical Assistant Professor  Rabinowitz, Dr. Alan  SPH
Clinical Assistant Professor  Saw, Dr. Jacqueline  VA
Clinical Assistant Professor  Straatman, Dr. Lynn  SPH
Clinical Assistant Professor  Wong, Dr. Graham  VA
Clinical Instructor  Munt, Dr. Bradley  SPH
Clinical Instructor: Tung, Dr. Kei Kwong (Stanley) SPH
Adjunct Professor: Lear, Dr. Scott SPH
Professor (Emeritus): Mizgala, Dr. Henry Vancouver
*Associate Professor (Emeritus): Henning, Dr. Hartmut VA
Clinical Professor (Emeritus): Boone, Dr. John SPH
Clinical Professor (Emeritus): Kavanagh-Gray, Dr. Doris West Vancouver
Clinical Professor (Emeritus): Peretz, Dr. Dwight VA
Clinical Professor (Emeritus): Shaw, Dr. Melville Vancouver
Clinical Professor (Emeritus): Walters, Dr. Max

*Appointed to Honorary Staff at VHHSC July 1st

**Divisional Overview**

The Division of Cardiology consists of 32 active faculty including 28 clinical faculty and 7 full-time faculty distributed over two large tertiary programs at St. Paul’s Hospital and Vancouver Acute (including UBC site). Beginning January 1st 2004, Dr. Christopher Buller was appointed Sauder Family Heart & Stroke Foundation Chair in Cardiology and Head, UBC Division of Cardiology, as well as Head, Divisions of Cardiology at both St. Paul’s and Vancouver Acute. Dr. Donald Ricci was appointed Associate Division Head, Vancouver Acute.

The UBC Division of Cardiology provides a complete range of tertiary and quaternary cardiology sub-specialty services and programs, including ambulatory and inpatient consultative cardiology, cardiac intensive care, electrophysiology, cardiac ultrasound, interventional cardiology, nuclear cardiology, adult congenital heart disease, atherosclerosis risk reduction and cardiac rehabilitation.

**Teaching**

**Undergraduate:**

Cardiovascular clinical assessment constitutes a core skill set for general physicians and many specialists and thus undergraduate teaching of the cardiovascular history and physical examination constitutes a substantial teaching load. The Division of Cardiology provided 90 hours of structured bedside teaching, and an additional 33.5 hours in seminars, lectures and case-based learning sessions during 2004. Reflecting the make-up of our Division, the substantial majority of this teaching was provided by our clinical faculty. Beginning in 2003, Dr. Saul Isserow has developed and implemented standardized instruction in the method of clinical examination for the undergraduate curriculum. To further advance undergraduate clinical skills teaching, the Division supports creating Directors of Undergraduate Education within Divisions or groups of Divisions carrying large undergraduate teaching loads. These positions would be responsible not only for optimizing the clinical content of the curriculum, but also for improving teaching effectiveness and consistency through application of objective metrics.
Postgraduate:

The UBC Postgraduate Program in Cardiology (Ken Gin, Director) continues to expand with 4 Ministry funded residents and 7 externally funded residents. In 2004, the Division itself funded one additional resident using internal resources, and negotiated the creation of another 3-year position through partnership with the Healthy Heart Society. In all, our program enjoys 12 core residents in cardiology distributed over the three-year Royal College program.

Academic aspects of the program continue to strengthen with an extensive weekly curriculum of structured bedside teaching, internal and guest faculty lectures, resident-led presentations, and journal club reviews of contemporary literature comprising 6-10 hours of structured teaching weekly. A highly rated course in cardiac epidemiology was created and presented by division member Karin Humphries. Research mentoring has been enhanced by the appointment of two hospital-based Postgraduate Research Directors, John Jue and Sammy Chan.

All UBC candidates who took the Royal College examinations in Cardiology were successful. Moreover, all of our core program graduates from 2003 have secured positions for advanced subspecialty training. A scheduled Royal College review of the program will occur in 2005.

9 subspecialty trainees are also enrolled in a variety of sub-specialty programs including Interventional Cardiology, Electrophysiology, Echocardiography, Heart Function/Transplant.

Continuing Medical Education

Internal Rounds

Across sites, the Division of Cardiology presents a rich curriculum of regular lectures and rounds. Cardiology Grand Rounds is presented weekly at each hospital. In addition, a variety of city-wide and hospital-based rounds are held regularly as follows:

- Interventional Cardiology (weekly, city-wide)
- Combined Cardiology/Cardiac Surgery (weekly, both sites)
- M&M (weekly at SPH, monthly at VH)
- Echocardiography (weekly, VGH)
- Resident Noon rounds (weekly, SPH)
- Research Rounds (bi-weekly, SPH)
- Journal Club (monthly, city-wide)
- UBC City-Wide Rounds (bi-monthly)

Distinguished Speakers in Cardiovascular Medicine

This year saw the initiation of a new monthly series of guest lectures entitled Distinguished Speakers in Cardiovascular Medicine. Hosted jointly with the UBC Division of Cardiac Surgery, this program is directed by Drs. Ken Gin and Andrew Ignaszewski and brings prominent experts to Vancouver for 1-2 days of academic activity and interaction including research seminars,
resident teaching, and the *Distinguished Speaker Lecture* itself. A broad range of academic and regional community cardiovascular specialists attend this special lecture. It affords a unique opportunity for basic scientists, clinical and academic physicians, cardiac surgeons, and faculty from pharmacy and other allied health disciplines to meet and interact. The inaugural lecture in this series was presented by Dr. Peter Liu of the University of Toronto entitled “*How Much Molecular Genetics Do Clinical Cardiologists Require?*” The series is supported by unrestricted educational grants from industry, but control of the agenda and speaker selection rests entirely with the Division.

**Course & Convention Leadership**

**The 14th Annual Whistler Course (January 2004)**
Christopher Buller, Course Director

This 3-day course aimed at General Cardiologists from BC and Ontario was co-hosted in 2004 by the Division of Cardiology at St. Michael’s Hospital, University of Toronto and held at Chateau Whistler.

**The 5th Annual Innovations in Interventional Cardiology Course (December 2004)**
Ronald Carere, Course Director

This 3-day course for Interventional Cardiologists attracts attendees from across Canada. It emphasizes technology uptake and utilization and the underlying health care policy decisions.

**Annual Practical Cardiology Course Vancouver (September 2004)**
Vicki Bernstein, Course Director

This one-day course serves as a Cardiology update for family physicians and general internists and has been chaired by Dr. Bernstein for more than a decade and showcases our diverse Divisional faculty. Always well subscribed (with attendance at around 120 per session) it consistently receives outstanding reviews. In 2005 Dr. Bernstein will pass the reigns of Course Director to Dr. Brett Heilbron.

**Trans-Catheter Therapeutics Convention, Washington DC (September 2004)**
Jaap Hamburger, Vancouver broadcast coordinator

The excellence and diversity of our city-wide UBC Interventional Cardiology program resulted in a second invitation to broadcast live interventional procedures to this preeminent international course. Six cases were presented by our group over a four hour broadcast window.

**CME Committee**

The Division created a formal CME committee in 2004 chaired by Dr. Rabkin, and including Drs. Heilbron, Isserow, Ignaszewski, Huckell and Mancini. This committee is charged with developing an annual provincial conference for community internists and cardiologists, as well as coordinating other CME activities.
Research

Dr. Eve Aymong continues to focus on understanding the pathophysiology of cardiogenic shock with a competitive pilot grant investigating a variety of biomarkers as part of the multicenter SHOCK-2 clinical trial. Other areas of interest include clinical outcomes of patients undergoing cardiac catheterization and angioplasty. In addition, she has collaborated with both Vancouver and New York based investigators on several grants in patients with cardiac disease that are currently under review by CIHR and the NIH.

Dr. Christopher Buller is active in clinical trials and outcomes research. His interest in occluded coronary arteries and the ‘open artery hypothesis’ has led to his inclusion on the Executive Steering Committee, Operations Committee and Publications Committee of the NIH/NHLBI funded Open Artery Trial, an international multi-center clinical trial initiated in 1998 and scheduled for completion in 2007. Dr. Buller directs all aspects of the trial related to PCI (the experimental strategy), is Co-Director of the Core Angiographic Laboratory, and is Co-principal Investigator of the NIH/NHLBI funded angiographic substudy TOSCA-2. Dr. Buller will also be the Canadian Principal Investigator for the NIH/NHLBI funded FREEDOM trial, a 120 centre international trial comparing drug eluting stent to coronary bypass surgery in patients with diabetes and multi-vessel coronary heart disease.

Dr. Sammy Chan is active in clinical trials and mechanistic research. His area of interest is preventive cardiology and endothelial function. He has recently collaborated in the Canadian wide MARGAUX study. He was awarded a 2 year grant in aid from the Heart & Stroke Foundation of BC and Yukon for a proposal involving aging, endothelial progenitor cells and endothelial function.

Dr. Jaap Hamburger is centrally involved in translational research addressing myocardial repair by autologous bone marrow stem cells in both small (mouse) and large (pig) animal models. This project operates in collaboration with the Terry Fox laboratory (BC Cancer Agency), the Jack Bell Laboratory and ICapture. Dr. Hamburger has also organized existing cardiovascular clinical research facilities and expertise into a pilot network termed CardiABC intended to support and facilitate locally developed clinical trials. Local network participants include an Angiographic Core Laboratory (Dr. John Mancini), Nuclear Cardiology Core Laboratory (Dr. Anthony Fung), ECG Core Laboratory (Dr. Marla Kiess), Cardiovascular Pathology Core Laboratory (Dr. B. McManus). In 2004, CardiABC successfully conducted its first multi center trial, the CRAFT on behalf of Kerberos, a California based device company. The study was performed in hospitals in Vancouver, Toronto and Montreal.

Dr. Karin Humphries’ areas of interest include sex differences in CVD presentation, treatment and outcomes; Health Services research focused on secondary prevention; population-based rates of treatment, including PCI, CABG, and pharmacological therapy; and atrial fibrillation. Dr. Humphries has led B.C.’s team of contributors to the Canadian Cardiovascular Outcomes Research Team (CCORT) project. A growing area of interest for Karin is investigator-driven randomized controlled trials. With her advanced theoretical and extensive practical knowledge, she supports and informs many such initiatives within the Division. As Principal Investigator, Dr. Humphries presently holds a New Investigator Award from the Michael Smith Foundation.
Dr. Charles Kerr is a clinical electrophysiologist and carries out an active research program in cardiac arrhythmia management. His main area of interest has been atrial fibrillation (AF). He has directed the Canadian Registry of Atrial Fibrillation since 1990. CARAF I has followed 1100 patients from their initial diagnosis of AF over 10 years, providing insight into progression of disease and clinical and laboratory outcomes. CARAF II has followed a more recent cohort to more carefully evaluate medical therapy provided by community physicians. He is also involved in drug trials of new antiarrhythmic and antithrombotic agents, as well as research trials of pacemakers and defibrillators.

Dr. John Mancini has been active in clinical trials through his Cardiovascular Imaging Research Core Laboratory which provides measurements of endothelial dysfunction (brachial artery ultrasound), carotid ultrasound, quantitative coronary intravascular ultrasound and quantitative coronary angiography. In addition, Dr. Mancini has expanded his research interests to include both clinical and molecular projects attempting to unravel the interplay between pulmonary diseases and cardiovascular events. Clinical projects assessing the impact of Chronic Positive Airway Pressure on carotid atherosclerosis and endothelial dysfunction in patients with Obstructive Sleep Apnea are underway. Cellular and molecular projects assessing the effects of statins and angiotensin receptor blockers on animal models and in-vitro cellular models of lung injury are also underway.

Dr. Jaqueline Saw arrived as a recruit from the Cleveland Clinic in 2004. She has research interests in several areas of cardiovascular medicine. Aspirin and clopidogrel resistance is being evaluated in a substudy of BRIEF-PCI (a locally developed multicenter RCT) and in ELAPSE, a dedicated study of clopidogrel resistance developing during long-term administration and due to start enrollment in 2005. Dr. Saw is also involved in outcome studies evaluating both co-morbidities and therapies in patients undergoing percutaneous peripheral arterial and carotid revascularization procedures.

Dr. John Webb is director of interventional cardiology research at St. Paul's Hospital. Myocardial infarction and cardiogenic shock have been an interest with a number of publications in these fields. Last year saw two multicenter studies completed as overall principle investigator. A major focus has been the development, animal and initial human trials of a number of interventional devices. Landmarks this year include the development of a transarterial aortic valve implantation procedure, the first successful percutaneous aortic valve implantations in North America and the first ever percutaneous mitral annuloplasty procedures. A number of additional valvular procedures are under development.

Dr. Graham C. Wong is active in clinical trials of acute coronary care with a particular focus on optimizing epicardial reperfusion. He is also interested in population-based outcomes following mechanical and pharmacological reperfusion for ST elevation myocardial infarction. Dr. Wong is currently the principal investigator for the inflammatory markers substudy of the BRIEF PCI study comparing an abbreviated versus a standard infusion of eptifibatide following percutaneous coronary intervention. Ongoing research projects include a comparison of outcomes for octogenarians undergoing fibrinolytic therapy and primary angioplasty for ST elevation MI. Dr. Wong is also the senior investigator on a submitted grant proposal in collaboration with the Department of Emergency Medicine that is investigating the predictors of delayed door to balloon time for primary angioplasty.
Dr. John Yeung has a major research interest in the mechanisms of clinical arrhythmias and in developing the techniques for both mapping and ablating complex myocardial arrhythmic circuits. Currently he is evaluating modulation of vagus nerve inputs to the left atrium in patients who undergo linear pulmonary vein ablation for atrial fibrillation. Other interests include the role of implantable cardioverter defibrillator (ICD) devices and biventricular pacing (cardiac resynchronization).

Clinical Sub-Programs

- **Healthy Heart Program (risk reduction and rehabilitation)**  
  o Andrew Ignaszewski** Saul Isserow*
- **Cardiac Electrodiagnostics**  
  o Marla Kiess** John Jue*
- **Acute Coronary Care**  
  o Alan Rabinowitz** Graham Wong*
- **Interventional Cardiology & Cardiac Catheterization**  
  o John Webb** Donald Ricci*
- **Cardiac Ultrasound**  
  o Christopher Thompson** John Jue*
- **Heart Function and Cardiac Transplantation**  
  o Andrew Ignaszewski**
- **Adult Congenital Heart Disease**  
  o Marla Kiess**
- **Arrhythmia Management**  
  o Charles Kerr**
- **Consultative Cardiology (inpatient and outpatient)**

** SPH Director  *VGH Director

Administration

Substantial program budgets and operational complexity have led to the development of the Heart Centre program at St. Paul’s (Ronald Carere, Medical Director) and the Cardiac Sciences program at Vancouver Hospital (Donald Ricci, Medical Director). These hospital-based programmatic structures are superimposed upon traditional academic Divisional/Departmental structures. The resulting matrix relies upon close collaboration between divisional and program leaders who report through independent lines.

In 2004, Vancouver Coastal Health Authority identified Cardiovascular Sciences as a program warranting regional coordination through the One Acute Network initiative. A search process led to the selection of one of our Division members (Dr. Ronald Carere) to lead this important work. Region-wide planning subcommittees have been created in most sub-program areas and are chaired by members of the Division from both SPH and VH sites.
Future Directions

Optimal distribution of specialized Cardiology sub-programs across our two sites remains an important but difficult ongoing discussion within the Division. Centralization of certain sub-programs at one site has advantages with regard to critical mass, efficiency, and academic interaction. Conversely, rapid progress in clinical science and practice has moved certain subspecialties from the realm of esoteric to that of mainstream tertiary service. As examples, the capacity for on-site programs in Electrophysiology and advanced heart failure (Heart Function) have been identified as critical needs for VH by the VH-based Division. Addressing those needs not only requires significant new capital, operational and human resources, but also coordination and planning in partnership with existing programs at the alternate site.

The proposal for a new Legacy hospital at False Creek site has opened discussion regarding the feasibility and desirability of combining VH-based and SPH-based cardiac programs to create a single, city-wide institute-like program. While the facility opportunities created by such a venture are enormous, so too are the challenges.

The progress of clinical science and technology in cardiology continues to accelerate and is creating both opportunities and strains. Examples of key trends in our specialty include:

- explosive growth in evidence-based demand for expensive technologies, including implantable defibrillators, cardiac re-synchronization therapy, drug-eluting coronary stents, and ventricular assist devices
- advances in percutaneous cardiac procedures including ASD/PFO closure devices, valve replacement and repair, complex multi-vessel PCI
- extension of interventional cardiology into non-cardiac vascular territories, including carotid, renal and peripheral vascular disease
- an epidemic of heart failure as new therapies extend survival in all common types of heart disease upstream
- improved survival of children with complex congenital heart disease requiring rapid expansion of capacity for their long-term care as adults
- adoption of clinical nurse practitioners to improve efficiency and quality, and to extend existing physician manpower within both inpatient and outpatient settings
- an imminent revolution in non-invasive anatomic and functional cardiac imaging (cardiac CT angiography, cardiac MRI)

Special Honours and Awards

Dr. Hartmut Henning: The Fay R. Kirks Award for Excellence in Teaching

Dr. John Webb: The Donald M. Whitelaw Award for Outstanding Grand Rounds Presentation

Dr. Ian Penn: Funding for STAAR study (UBC Office of the Vice President Research: $3,600
CRITICAL CARE MEDICINE

Dr. John Fenwick
Clinical Assistant Professor & Head

Faculty Members

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Assistant Professor &amp; Head</td>
<td>Fenwick, Dr. John</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Russell, Dr. James</td>
<td>SPH</td>
</tr>
<tr>
<td>Professor</td>
<td>Walley, Dr. Keith</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Dodek, Dr. Peter</td>
<td>SPH</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Dorscheid, Dr. Delbert</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Tsang, Dr. John</td>
<td>VGH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Chittock, Dr. Dean</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Dhingra, Dr. Vinay</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Forrest, Dr. David</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Grant, Dr. Gregory</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Keenan, Dr. Sean</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Ronco, Dr. Juan</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Craig, Dr. Katherine</td>
<td>VA</td>
</tr>
<tr>
<td>Visiting Scientist</td>
<td>Wattanathum, Dr. Anan</td>
<td>SPH</td>
</tr>
</tbody>
</table>

Divisional Overview

The UBC Division of Critical Care Medicine is multidisciplinary in structure, with 13 faculty members, all qualified critical care specialists from Medicine, Surgery and Anaesthesia backgrounds participating in patient care at St. Paul’s, Royal Columbian and Vancouver Hospital. The two-year Critical Care Medicine subspecialty training program is fully accredited and accepts two trainees per year. The Research Program in Critical Care Medicine is comprehensive, spanning from molecular and cellular biology through large animal models to clinical research in critically ill adults. The basic science research program is based in the Cardiopulmonary Laboratories at St. Paul’s Hospital and the Jack Bell Research Institute at Vancouver Hospital. The clinical research program is focused in the intensive care units of St. Paul’s and Vancouver Hospital.

Teaching

The University of British Columbia Adult Critical Care Medicine Training Program, under the direction of Dr. Juan Ronco, continued at the British Columbia Children’s, St. Paul’s and
Vancouver Hospitals. In 2004 there were 5 trainees in the Adult Critical Care Medicine Fellowship Training Program. Trainees entering the program in 2004 will be the first to receive subspecialty certification through examination by the Royal College of Physicians and Surgeons of Canada. Under the Direction of Dr. Juan Ronco, the Division hosted the 4th annual National Acute Critical Events Simulation (ACES) Program. The ACES Program is offered to all first-year residents entering Canadian Critical Care Medicine Training.

The ICU rotations for specialty residents from Medicine, Anaesthesia and Surgery continued to be highly rated at both St. Paul’s and Vancouver Hospital. Under the direction of Dr. Vinay Dhingra participation in the SCCM Critical Care Support Course was expanded to include core residents from all Departments.

Research

The Research Program in Critical Care Medicine is comprehensive, spanning from molecular and cellular biology through large animal models to clinical research in critically ill adults. The basic science research program is based in the Cardiopulmonary Laboratories at St. Paul’s Hospital and the Jack Bell Research Institute at Vancouver Hospital. The clinical research program is focused in the intensive care units of St. Paul’s and Vancouver Hospitals.

The basic science research program continues to investigate corticosteroid and ischemia/reperfusion induced airway epithelial cell apoptosis (Dr. Dorscheid), endothelins and the mechanism of hypoxemia in acute pulmonary embolism (Dr. Tsang), the molecular and cellular biology of leukocyte induced myocardial dysfunction in septic shock (Dr. Walley) and immunomodulation in the treatment of sepsis and acute lung injury (Drs. Russell and Walley).

The clinical research program remains strong at St. Paul’s and Vancouver Hospital with studies on the role of genotype on phenotype in sepsis and systemic inflammatory states (Drs. Walley and Russell), genetics of ARDS (Dr. Russell), mechanisms of exercise-induced hypoxemia (Drs. Russell and Walley), glucose control and outcomes in the critically ill (Drs. Dhingra, Chittock, Ronco, Dodek and Fenwick), clinical studies of therapeutic interventions for viral infections (Dr. Grant), recognition, quantification and treatment of delirium in the ICU (Dr. Chittock), the role of organizational factors in outcomes of critical care (Drs. Dodek and Keenan), treatment of catheter related bloodstream infections (Drs. Ronco and Dhingra), role of non-invasive ventilation in critical illness (Dr. Keenan), effect of sedation and agitation on duration of mechanical ventilation (Dr. Chittock), adrenal function in sepsis (Drs. Fenwick, Chittock and Ronco), communication and decision making in end of life care (Dr. Dodek), post cardiac arrest decision making (Dr. Forrest), ventilator associated pneumonia (Dr. Dodek), fluid resuscitation in septic shock (Dr. Dhingra), vasopressin in septic shock (Drs. Russell, Walley, Chittock and Ronco) and blood transfusion and cerebral oxygenation in head injury (Drs. Chittock and Fenwick).

Clinical Services

The ICUs at St. Paul’s and Vancouver Hospital continued to experience an increase in occupancy and workload with over 1700 admissions at the two sites. The ICU at St. Paul’s Hospital added 4 new beds for a total of 15 and the ICU at VGH added 3 new beds for a total of
27. Division members from St. Paul’s and VGH participated in the development of a regional integrated critical care service delivery model. Collaborative strategies to improve funding for critical care services at both sites continue to be developed.

**Future Directions**

In 2005, under the direction of Dr. Dean Chittock, the Division will hold the second annual Canadian Critical Care Conference at Whistler, BC. Under the direction of Dr. Vinay Dhingra, the Division will continue to expand the implementation of the SCCM Fundamentals in Critical Care Medicine Support Course as part of the core residency training program. It is anticipated that the SCCM course will, in the future, become a successful CME activity within the Department of Medicine, attracting critical care providers from around the province. Drs. Ronco and Dingra, in collaboration with the Center for Excellence in Surgical Education and Innovation, continue to develop simulator models for the teaching of technical and patient management skills to critical care trainees. The Division continues to develop a strategy to strengthen its University Multidisciplinary Program and has begun to explore the possibility of Departmental status within the Faculty of Medicine.

**Special Honours and Awards**

Dr. Dean Chittock organized and served as a session moderator at the Canadian Critical Care Conference, Whistler, BC.

Dr. Vinay Dhingra received a Department of Medicine Departmental Scholar Award and was an invited speaker at the Canadian Critical Care Conference, Whistler, BC.

Dr. Peter Dodek was an invited speaker at the Toronto Critical Care Medicine Symposium, Toronto, Ontario, the Canadian Critical Care Conference, Whistler, BC, the Centre Hospitalier Universitaire Lapeyronie, the Centre Hospitalier Universitaire St. Eloi, Montpellier, France, the Fondation Hospital St. Joseph and Hospital Henri Mondor, Paris, France and the Centre Hospitalier Universitaire Caremeau, Nimes, France.

Dr. Del Dorscheid was an invited speaker and Chair of the VanSeaPort Respiratory Research Conference, Crystal Mountain, Washington and an invited speaker at the Canadian Critical Care Conference, Whistler, BC.

Dr. Sean Keenan was an invited speaker at the Advances in Respiratory and Critical Care Medicine Conference, Whistler, BC and the American College of Chest Physicians Annual Meeting, Seattle, Washington.

Dr. Juan Ronco was an invited speaker at the Canadian Critical Care Conference, Whistler, BC, the Advances in Respiratory and Critical Care Medicine Conference, Whistler, BC, and the Toronto Critical Care Medicine Symposium, Toronto, Ontario.

Dr. Jim Russell was an invited speaker at the Australia and New Zealand Intensive Care Society Annual Meeting, Melbourne, Australia, the Society of Critical Care Medicine Annual Congress, Orlando, Florida, the Toronto Critical Care Medicine Symposium, Toronto, Ontario, and
Scientific Advisor and Convenor, Rocky Mountain Critical Care Conference, Lake Louise, Alberta.

Dr. John Tsang was an invited speaker for the Department of Medicine, University of Washington, Seattle, Washington.

Dr. Keith Walley was an invited speaker at the Society of Critical Care Medicine Annual Congress, Orlando, Florida, the American Burn Association Annual Meeting, Vancouver, BC and the Rocky Mountain/American College of Internal Medicine Meeting, Banff, Alberta.
### DERMATOLOGY

**Dr. Harvey Lui**  
**Professor & Head**

#### Faculty Members

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor &amp; Head</td>
<td>Lui, Dr. Harvey</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Ho, Dr. Vincent</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>McLean, Dr. David</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Rivers, Dr. Jason</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Dutz, Dr. Jan</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Kitson, Dr. C.</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Li, Dr. Gang</td>
<td>VA</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>McElwee, Dr. Kevin</td>
<td>VA</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Zhou, Dr. Youwen</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Professor</td>
<td>Carruthers, Dr. Alastair</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Professor</td>
<td>Shapiro, Dr. Jerry</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Professor</td>
<td>Warshawski, Dr. Laurence</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Conklin, Dr. Robert</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Haber, Dr. Richard</td>
<td>Victoria</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Kunimoto, Dr. Brian</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Ongley, Dr. Roberta</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Schlappner, Dr. Otto</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Bergman, Dr. James</td>
<td>Vancouver</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Gregory, Dr. Brian</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Kenny, Dr. Patrick</td>
<td>Royal Jubilee</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Morton, Dr. Charles</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Prihoda, Dr. Marie</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Thomas, Dr. D. Richard</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Tuyp, Dr. Evert</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Zloty, Dr. David</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Amiss, Dr. John</td>
<td>Victoria</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Au, Dr. Sheila</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Davis, Dr. Anne</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Hong, Dr. Chih-ho</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Rossi, Dr. Sikina</td>
<td>Victoria</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Shokravi, Dr. Mohammad</td>
<td>North Vancouver</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Ball, Dr. Nigel</td>
<td>VA</td>
</tr>
</tbody>
</table>
In 2004 the Division of Dermatology formally recruited new faculty members within the Island and Northern Medical Programs, and launched the first of a series of “pilot” clerkships for undergraduate medical students in Victoria. This initiative represents the first concrete step towards expanding our Division in concert with the overall medical school expansion. Another major milestone for the Division was that 2004 marked the first year that all of our research laboratories achieved funding support from the Canadian Institutes of Health Research.

The other overarching divisional initiative in 2004 was the formal discussion within the Faculty of Medicine surrounding the creation of the UBC Department of Dermatology and Skin Science. This has been a longstanding goal of the Division of Dermatology and was supported this year by the Department of Medicine. Early in 2004 the Dean of Medicine agreed to receive a proposal for creating a new department from the current division, and in the fall of 2004, the Faculty Executive Committee agreed to pursue this in greater detail. Among other things, departmental status will facilitate greater academic opportunities for Dermatology and Skin Science, enhance fundraising efforts, assist with faculty and trainee recruitment, and provide recognition of the unique scope and accomplishments of our academic unit.

Teaching

Undergraduate: Dr. Jerry Shapiro, Director. Over the last year Dr. Shapiro has attended innumerable committee meetings and worked tirelessly on the medical school expansion project. Over the next several years, we will eventually need to find clerkship experiences for twice the current number of medical students. “Pilot” rotations are being tested in advance of the full rollout of Dermatology Clerkships in the expanded medical school by the fall of 2006. Following the initial successful pilots in Victoria in 2004, additional pilot programs will be set up in Prince George and the Fraser Valley in 2005.

Postgraduate: Directors: Dr. Jason Rivers (January-September), Dr. Larry Warshawski (September- ). Dr. Jason Rivers completed his term as Postgraduate Program Director in 2004 and has been succeeded by Dr. Larry Warshawski. During Dr. Rivers’ overall term, the training program earned full Royal College accreditation status and graduated the first dermatology residents in our joint training program with the University of Manitoba. Other milestones included an overhaul of the core resident rotations to better reflect the changing face of dermatologic practice. We are grateful to Dr. Rivers for his dedication to training our next generation of dermatologists in his leadership role. Dr. Larry Warshawski has initiated work on expanding the number of training slots in dermatology, both through CARMS and re-entry pathways.
All three of our graduates in 2004, Dr. Michelle Withers, Dr. Hana Alkhayat, and Dr. Rochelle VanDeVelde, were successful with their Royal College examinations in Dermatology. Dr. Alkhayat has stayed on as a Clinical Research Fellow in Photomedicine and Lasers at UBC.

Advanced clinical fellows in hair, micrographic surgery, dermatopathology, and photomedicine rounded out our clinical trainees in Dermatology. These fellowships combine clinical training with research and the fellows hail from New York, Korea, Toronto, and Saudi Arabia.

Experimental Medicine: The Division continues to attract a very healthy number of graduate students, particularly in the Skin Cancer Biology Laboratory under Dr. Gang Li. Graduate students interact with the clinical program in a number of ways including the Annual UBC Dermatology Research Day and the MEDI 535 Journal Club course that is run in conjunction with the residency program under the direction of Dr. Jan Dutz.

Continuing Medical Education: CME courses offerings for 2004 included:

- Spring Dermatology Update for Family Physicians (March 5-6, 2004)
  Course Director: Dr. Brian Kunimoto

- Dermatology Update 2004 (November 14-16, 2004)
  Course Director: Dr. Stuart Maddin

- Living Well with Diabetes (November 20-21, 2004)
  Course Co-Director: Dr. Brian Kunimoto

Research

All of our dermatology and skin research laboratories achieved national level (e.g. CIHR, NCIC) peer-reviewed funding in 2004. UBC Dermatology Research Day (March 13, 2004) was well attended by scientists, clinicians, clinical and graduate student trainees, as well as nurses and ancillary staff.

Dr. Kevin McElwee joined the Division of Dermatology as an Assistant Professor. He will work with Dr. Jerry Shapiro in the UBC Hair Treatment and Research Program, and has expertise in autoimmune follicular disorders and hair biology. Dr. McElwee’s recruitment to UBC helps to solidify UBC’s reputation as the most comprehensive academic hair biology and treatment centre in North America. Dr. McElwee’s recruitment was supported in part through the generosity of the VGH & UBC Hospital Foundation as well as patient donations to the hair program.

In the fall of 2004, several Division of Dermatology members helped to convene and lead two CIHR-sponsored workshops in Vancouver and Toronto on future Canadian directions in skin research. The “CIHR Skin Health Research Priority Workshop” brought together, for the first time in Canada, scientists, clinicians, patients, industry, and government to brainstorm ideas on how to best advance the skin research agenda. Recommendations from the workshop included the establishment of a patient advocacy alliance, defining four key areas of research, and building capacity through training and research networks. Dr. Dutz and Lui served as the co-chairs of the workshop.
Clinical Services

A generous donation from the Hamzavi Foundation to the Division of Dermatology in 2004 will be used to establish a vitiligo treatment facility at the Skin Care Centre. Planning also got underway for new clinic facilities at VGH for the Wound Healing Clinic in the new Academic Ambulatory Care Centre. The overall clinical program at VGH will remain at the Skin Care Centre. Dermatology services as a whole continue to be in high demand, particularly for skin cancer screening and treatment.

Special Honours and Awards

Dr. Kevin McElwee, Appointment as Assistant Professor and Departmental Scholar Award, Department of Medicine

Dr. W. Alastair McLeod, Award of Merit, Canadian Dermatology Association

Dr. Richard Crawford, Promotion to Clinical Professor and Teaching Award, Residents & Fellows Section, Canadian Dermatology Association

Dr. Richard Haber, Appointment as Clinical Associate Professor

Dr. Sikina Rossi, Appointment as Clinical Instructor

Dr. Nhiem Nguyen, Practitioner of the Year, BC Dermatology Society

Dr. Youwen Zhou, Departmental Scholar Award, Department of Medicine

Dr. Alastair Carruthers: Elected as Vice-President, American Society for Dermatologic Surgery

Dr. Harvey Lui, President-Elect, Canadian Dermatology Association

Dr. Hana Alkhayat, Resident Teaching Award, Residents & Fellows Section, Canadian Dermatology Association

Ms. Alison Karst, Trainees awards from the Michael Smith Foundation for Health Research and the Natural Sciences and Engineering Research Council (supervisor Dr. Gang Li)
ENDOCRINOLOGY

Dr. David Thompson
Clinical Assistant Professor & Head

Faculty Members

Clinical Assistant Professor & Head   Thompson, Dr. David   VA
Professor                          Prior, Dr. Jerilynn    VA
Clinical Professor                 Wilkins, Dr. Graeme     VA
Clinical Associate Professor       Tildesley, Dr. Hugh    SPH
Clinical Assistant Professor       Bebb, Dr. Richard       SPH
Clinical Assistant Professor       Dahl, Dr. Marshall      VA
Clinical Assistant Professor       Elliott, Dr. Thomas      VA
Clinical Assistant Professor       Kendler, Dr. David       VA
Clinical Assistant Professor       Kreisman, Dr. Stuart     SPH
Clinical Assistant Professor       Wallace, Dr. Clarissa     VA
Clinical Instructor               Gill, Dr. Sabrina        SPH
Clinical Instructor               Johnson, Dr. Michelle     SPH
Clinical Instructor               Kong, Dr. Jason          VA
Clinical Instructor               Mase, Dr. Robert         SPH
Clinical Instructor               Sirrs, Dr. Sandra        VA
Associate Member                  Bondy, Dr. Greg           SPH
Associate Member                  Kitson, Dr. Hilary        VA
Associate Member                  Rothstein, Dr. Ralph      C&W Health Centre
Associate Member                  Stewart, Dr. Laura       C&W Health Centre
Adjunct Professor                 Finegood, Dr. Diane       Burnaby
Professor (Emeritus)               Dawson, Dr. Keith       Vancouver
Associate Professor (Emeritus)     Cairns, Dr. Alexander    VA

Divisional Overview

The UBC Division of Endocrinology continued to expand with the addition of one new faculty member in 2004. The clinical activity in both outpatient and inpatient settings is growing to meet increased demand. Most faculty members are involved in clinical research and participate in fundraising activities to help support the many activities of the division. Division members also serve on a large number of local, provincial, national and international committees for clinical and research activities.
Teaching

The division remained very active in teaching at both an undergraduate and postgraduate level.

**Undergraduate:** Medical students are able to choose a selective in endocrinology where they get exposure to endocrine ambulatory clinics including general endocrinology offices and the diabetes centre. Several faculty members (Drs. Sirrs, Gill, Fung, Prior, Bondy) and the endocrine fellows served as tutors in the endocrinology and metabolism problem based learning sessions. Endocrinologists are heavily involved in both the endocrinology and musculoskeletal blocks, providing lectures and case materials as well as serving as PBL tutors.

With the expansion of the medical school, it is anticipated that the division will have to double its capacity to provide endocrinology selectives to medical students, as well as provide teaching to students at sites where there are no endocrinologists.

**Postgraduate:** The UBC division provided endocrinology electives to 36 rotating residents from internal medicine in the 2004 / 5 academic year. Electives were also provided to residents from other programs (e.g. genetics, dermatology, family practice) and to residents from out of province. The evaluations of the endocrinology rotation by internal medicine residents have improved markedly. Endocrinology rotations at VH are the highest rated among UBC rotations with a service requirement, and rotations at SPH are now rated 6 overall. The strengths of the rotations include their emphasis on a mix of both ambulatory and inpatient responsibilities and a structured academic half day component to provide appropriate teaching.

The division had two subspecialty residents in the second year of their program in 2004 / 5. The current level of funded subspecialty training positions in adult endocrinology is 0.5 positions/year. With the projected increase of postgraduate training positions to accommodate the medical school expansion, it is anticipated that the division will have funding for 1 adult subspecialty resident per year in 2006 with an increase to 2 training positions per year after that.

Community

The division participates in a number of continuing medical education activities. Some, such as the Diabetes Directors Symposium and the BC Endocrine Days, have been running for a number of years. In addition, division members give many invited lectures to community physicians.

Research

The islet cell program was very active during the past year and is now among the leading programs in the world in this area. Research is being carried out at both basic and clinical levels, involving collaborations with other active centres.

Many division members are participating in a number of multi-centre trials involving various aspects of diabetes, lipid and cardiovascular outcomes. Dr. Kreisman is involved in an NIH trial in the management of cystic fibrosis and diabetes.
The Women’s Health research program, led by Drs. Prior and Gill, continues to expand and the related Osteoporosis research continues at a very active level.

Dr. Sirrs remains heavily involved in Adult Metabolic Diseases clinical research.

Both divisions have established fundraising programs to provide support for research and educational activities.

**Clinical Services**

The demand for both outpatient and inpatient services continues to grow at both sites. We are developing new multidisciplinary clinics, especially in collaboration with nephrology, bone marrow and solid organ transplantation. Improved management of inpatient diabetes is being recognized throughout the hospital as important in improving quality of care and this will require the division to develop new strategies to accomplish this important goal.

**Awards**

Dr. Keith Dawson: Canadian Diabetes Association Outstanding Dedication Award 2004
Dr. G.E. Wilkins: Career Award for Teaching Excellence from UBC

**Future Directions**

In addition to expanding the above activities, there appear to be several areas that the division will focus on over the next year. Detailed planning will be required to ensure adequate undergraduate training in endocrinology as the medical school expands both in number of students and the sites where they are being trained. Optimal inpatient diabetes care throughout the hospital will place an increased demand on the resources of both the division and the diabetes centre staffs. There is considerable interest in developing a regional approach to diabetes care that will result in patients receiving the care that they need in the most appropriate setting. It is increasingly recognized that certain groups, such as the elderly, require diabetes care that is tailored to their special needs. Proper design and implementation of such a program will require a great deal of work and resources. The St. Paul’s division plans to establish a multidisciplinary approach for the assessment and treatment of osteoporosis.
## Faculty Members

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor &amp; Head</td>
<td>Steinbrecher, Dr. Urs</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Freeman, Dr. Hugh</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Salh, Dr. Baljinder Singh</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Yoshida, Dr. Eric</td>
<td>VA</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Tai, Dr. Isabella</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Professor</td>
<td>Halparin, Dr. Lawrence</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Byrne, Dr. Michael</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Gray, Dr. James</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Kwan, Dr. Peter</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Weiss, Dr. Alan</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Amar, Dr. Jack</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Enns, Dr. Robert</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Erb, Dr. Siegfried</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Telford, Dr. Jennifer</td>
<td>Vancouver</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Whittaker, Dr. J.</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Chatur, Dr. Nazira</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Fishman, Dr. Martin</td>
<td>Richmond</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Lam, Dr. Eric</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Ramji, Dr. Alnoor</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Gill, Dr. Sharlene</td>
<td>BCCA</td>
</tr>
<tr>
<td>Associate Member</td>
<td>McManus, Dr. Bruce</td>
<td>SPH</td>
</tr>
<tr>
<td>Visiting Professor</td>
<td>Gomez-Munoz, Dr. Antonio</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Professor (Emeritus)</td>
<td>Chaun, Dr. Hugh</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Professor (Emeritus)</td>
<td>Stordy, Dr. Stanford</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Professor (Emeritus)</td>
<td>Anderson, Dr. Frank</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor (Emeritus)</td>
<td>MacDonald, Dr. Walter</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor (Emeritus)</td>
<td>Carr, Dr. Donald</td>
<td>VA</td>
</tr>
</tbody>
</table>

## Divisional Overview

The UBC Division of Gastroenterology consists of 5 UBC full-time faculty members, 14 clinical faculty members, 2 associate members, 5 emeritus professors, and one visiting professor. These
staff are based at St. Paul’s Hospital, Vancouver General Hospital, UBC Hospital, Vancouver Cancer Centre, B.C. Transplant Society, and Richmond General Hospital. There are active gastroenterology inpatient/consult services at Vancouver General Hospital and St. Paul’s Hospital as well as a liver transplant unit at Vancouver General Hospital and B.C. Transplant Society. The ambulatory care facilities include a hospital-based clinic at Vancouver General Hospital, as well as hospital-based or adjacent offices at St. Paul’s, UBC Hospital, and Richmond. The GI subspecialty training program currently has 5 trainees. The basic research focus of the division is on molecular and biochemical abnormalities, underlying GI cancer, and inflammatory bowel disease. The division is also engaged in an active and multifaceted clinical research and clinical trials program. As a result of recruitment initiatives over the past year, we have attracted three new academic clinicians to the division's faculty (Drs. Chatur, Ramji, and Telford). Dr. Chatur’s role will be in undergraduate and postgraduate medical education. Dr. Ramji will focus on clinical research in hepatology. Dr. Telford will focus on therapeutic endoscopy and clinical research in luminal gastroenterology.

Teaching

Undergraduate: The GI Division plays a key role in the enhancement and ongoing improvement of the GI block in phase II of the undergraduate curriculum. In addition to updates and revisions to the cases, lectures, and labs, priorities for 2005 are to plan for the expansion of the medical school class size over the next 4 years, to increase the quality, quantity, and accessibility of exhibits associated with the block cases, and to renew online resources for the block. Dr. Nazira Chatur was appointed Undergraduate Program Director for GI.

Postgraduate: Dr. Peter Kwan is Director of the GI training program and Dr. Chatur is co-Director. The division is proud of the excellent trainees currently enrolled in the program (Drs. Stacy Shapira and Jaber Al-Ali for 2003-5, and Dr. Henry Chung, Dr. Jin-Kee Ho and Dr. Nasser Al-Masri for 2004-2006).

Experimental Medicine: Dr. Bill Salh coordinates the GI components of the Experimental Medicine Program. There are currently 4 graduate students from the GI Division registered in Experimental Medicine. In addition, one international PhD student, two summer students, and two post-doctoral fellows are supervised by GI division members.

Continuing Medical Education: In 2004, the UBC GI Division organized several accredited CME courses, including the eighth Annual Digestive Disease Week Review Course for subspecialists, and an Update in Gastroenterology course. The St. Paul’s Division of Gastroenterology organized several additional CME courses for specialists. All were well-attended and highly-rated events.

Research

Division members generated more than 50 publications in peer-reviewed journals in 2004, and associate members added an additional 15 papers. Several division members including Drs. Salh, Steinbrecher, and Tai conduct active basic research programs supported by national and regional granting agencies (CIHR, HSFC, CCFC, and Canadian Society for Intestinal Research). The Division is expanding clinical research and clinical trials activities, and is involved in more
than 30 trials in a variety of clinical areas including viral hepatitis, liver transplantation, inflammatory bowel disease, esophageal reflux disease, peptic ulcer disease, and functional bowel disorders. Drs. Anderson, Enns, Yoshida, Gray, Kwan, and Whittaker have been particularly active in clinical trials. As a result of recruitment initiatives over the past year, we have attracted three new clinician-investigators to the division's faculty (Drs. Chatur, Ramji, and Telford) who will build on existing clinical research strengths in the division.

Administration and Future Directions

A search will be conducted in 2005 for a new UBC Division Head in Gastroenterology.

Special Honours and Awards

Several division members serve on or chair committees of professional organizations, editorial boards of medical and scientific publications, and on grant review committees of major peer-reviewed granting agencies. Of note, Dr. Hugh Chaun was elected Secretary-General, Bockus International Society of Gastroenterology and is Chair, Press and Congress News Committee, 2005 World Congress of Gastroenterology Canadian Organizing Committee, Governor of the American College of Gastroenterology representing the region of the Western Provinces, and Chair, Governing Board, Canadian Digestive Health Foundation. Dr. Rob Enns is Chair, Endoscopy Committee, Canadian Association of Gastroenterology, Member of the 2005 World Congress of Gastroenterology Scientific and Clinical Planning Committees, and a member of the Canadian Digestive Disease Health Foundation Committee. Dr. James Gray is President, B.C. Society of Gastroenterology. Dr. Eric Yoshida is Chair, Membership Committee, Canadian Association for the Study of the Liver and Head, B.C. Hepatitis Program. Dr. Urs Steinbrecher serves on the CIHR Metabolism Grant Panel, is Chair, Heart and Stroke Foundation of B.C. and Yukon Research Committee, and Chair, AHFMR Clinical Investigator Review Committee.
## GENERAL INTERNAL MEDICINE

### Dr. Iain Mackie  
**Clinical Professor & Acting Head**

**Faculty Members**

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Professor &amp; Acting Head</td>
<td>Mackie, Dr. Iain</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Page, Dr. Gordon</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Wright, Dr. James (Jim)</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Palepu, Dr. Anita</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Studney, Dr. Donald</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Hatala, Dr Rose</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Kassen, Dr. Barry</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Kennedy, Dr. James</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Onrot, Dr. John (Jake)</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Arseneau, Dr. Richard</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Ayotte, Dr. Brian</td>
<td>Sushwap Lake</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Baillie, Dr. Hector</td>
<td>Nanaimo</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Busser, Dr. James</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Dunne, Dr. James</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Magee, Dr. Laura</td>
<td>Women's Health Centre</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Ong-Lam, Dr. May</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Perry, Dr. Thomas</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Richmond, Dr. Allister</td>
<td>Chilliwack</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Wakefield, Dr. Robert</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Auersperg, Dr. Edward</td>
<td>Pitt Meadows</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Broder, Dr. Sarah</td>
<td>Penticton</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Caswell, Dr. Sherri</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Chan, Dr. Alex Chong Han</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Cunningham, Dr. Kenneth</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Deutscher, Dr. Timothy</td>
<td>Nanaimo</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Duke, Dr. Stephen</td>
<td>Victoria</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Ervin, Dr. Francis (Frank)</td>
<td>Maple Ridge</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Hawley, Dr. Philippa</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Holmes, Dr. Cheryl</td>
<td>Kelowna</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Kenyon, Dr. Michael</td>
<td>Nanaimo</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Khan, Dr. Nadia</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Kincade, Dr. David</td>
<td>Kamloops</td>
</tr>
</tbody>
</table>
Clinical Instructor | Lai, Dr. Kevin | Nanaimo  
Clinical Instructor | McKay, Dr. Rhonda | SPH  
Clinical Instructor | Purkiss, Dr. Susan | C&W Health Centre  
Clinical Instructor | Roberts, Dr. James | VA  
Clinical Instructor | Son, Dr. Wai Kon | Chilliwack  
Clinical Instructor | Sunderwood, Dr. Jennifer | VA  
Clinical Instructor | Winkler, Dr. Lawrence | Nanaimo  
Clinical Instructor | Wong, Dr. Steven | VA  
Associate Member | Birmingham, Dr. Carl Laird | SPH  
Associate Member | Zaidel, Dr. Patrick | Burnaby  
Professor (Emeritus) | Schulzer, Dr. Michael | VA  
Clinical Professor (Emeritus) | Johnson, Dr. Archibald |  
Clinical Professor (Emeritus) | McDonnell, Dr. C. Edward | SPH  
Clinical Professor (Emeritus) | Paige, Dr. Bruce | VA  
Clinical Associate Professor (Emeritus) | Rennie, Dr. Charles | VA  

The Division of General Internal Medicine forms an integral part of the UBC Department of Medicine, with faculty active in a variety of generalist and subspecialty areas. The main foci of the Division include teaching, research and administration. In 2004 the Division benefited from the recruitment of Dr. Irene Ma, who has subspecialty training in both general medicine and nephrology. Dr. Ma will have a major research commitment. Her area of research interest is ethnicity and its impact on disease.

Members of the Division were granted major research awards in 2004. Dr. Anita Palepu was awarded a CIHR research grant for work on the development of a quality of life instrument for homeless persons and street youth, as well as a major Michael Smith Foundation Award as a senior scholar in population urban health. Dr. Laura Magee continues to hold a Michael Smith Foundation Scholar Award until 2008. Dr. Magee holds numerous Michael Smith, CIHR and other grants related primarily to her research expertise in hypertension in pregnancy. Dr. Nadia Khan also won a CIHR award for her work on ethnicity and cardiovascular disease. Dr. Don Studney continues his research in diabetic neuropathy with major industry grants.

Drs. Rose Hatala, Barry Kassen, Mark Roberts and Iain Mackie were granted funds from the Royal College of Physicians and Surgeons to compare a brief, observed clinical examination (mini-CEX) with outcomes on the Royal College internal medicine examination. As a result of this work, a new series of observed mini-CEX examinations will be implemented as an evaluation tool within the core Internal Medicine residency training programme. Dr. Iain Mackie served as a member of the Drug Safety Monitoring Board for Tibotec Corporation for a new protease inhibitor for use in HIV positive patients.

Drs. Khan and Palepu, between them, had 17 publications and 2 book chapters in 2004. Dr. Palepu published her work in major HIV/AIDS journals. Dr. Khan and colleagues published new guidelines for hypertension on behalf of the Canadian Cardiovascular Society in the Canadian Journal of Cardiology. These guidelines will have significant impact on the care of patients with hypertension in Canada. Dr. Laura Magee published 14 journal articles and presented 12 abstracts on topics related to medical problems of pregnancy. Dr. Rose Hatala had 2 articles on evidence-based medicine published in 2004 in the Canadian Medical Association.
Journal. Dr. Pippa Hawley published a major survey on physicians’ attitudes and knowledge of cancer pain management in the journal Pain Research and Management. She has been instrumental in the development of a palliative care training programme at UBC.

Division members continue to play a major role in the administration of the Department of Medicine and its programmes. Dr. Mark Roberts was appointed Programme Director for the Internal Medicine Residency Training Programme, replacing Dr. Iain Mackie who stepped down after seven years. Drs. Barry Kassen (community programme development) and Dr. Rose Hatala (evaluations) were appointed as Associate Directors of the training programme. Dr. Anita Palepu was appointed as co-chair of the Clinical Investigator Programme for the Department of Medicine. Dr. Iain Mackie was appointed as Director of the Assessment of Competence Programme for the Department of Medicine. This new programme evaluates the clinical competence of international medical graduates. Dr. Barry Kassen was appointed to the Faculty of Medicine’s Faculty Development Committee.

Dr. Barry Kassen continues as Chair of the Internal Medicine Oral Examination Board at the Royal College of Physicians and Surgeons. Drs. Hatala, Mackie, Roberts and Dr. Jake Onrot continue as members of the Oral Examination Board of the Royal College of Physicians and Surgeons. Dr. Kassen sits on the Board of the Canadian Society of Internal Medicine. Dr. Nadia Khan is a member of the organizing committee for the Rocky Mountain Internal Medicine Conference. Dr. Palepu is a member of the organizing committee for the 3rd International Conference on Urban Health, and was the co-chair of the Epidemiology section of the Canadian Association of HIV Research.

At the annual meeting of the Canadian Society of Internal Medicine, Dr. Palepu was honoured with the “Young Investigator Award” for her work on HIV infection and injection drug users. Dr. Rose Hatala won the Dr. Shelly Naiman Award for Clinical Teacher of the Year at St. Paul’s Hospital.

On a lighter note, Dr. Tom Perry celebrated a “prime-number” birthday and celebrated this mid-life crisis by canoeing down the Turnagain River in northern BC. Both he, Dr. Bob Rangno and Dr. Jim Wright continue to play major roles in the Therapeutics Initiative and the Cochrane Collaborative.

Overall this has been a year of ongoing successes for the Division of General Internal Medicine. Division members continue to demonstrate excellence in research, teaching and administration, winning major local and national awards for their excellence in teaching and research.
GERIATRIC MEDICINE

Dr. Graydon S. Meneilly
Professor & Head
(January-June 30, 2004)

Dr. Larry Dian
Clinical Associate Professor &
Acting Head (July 1, 2004 - )

Faculty Members

Professor & Head, Dept. of Medicine
Meneilly, Dr. Graydon
Dian, Dr. Larry

Clinical Associate Professor &
Acting Head
Beattie, Dr. B

Professor
Madden, Dr. Kenneth

Assistant Professor
Adler, Dr. Reva

Clinical Associate Professor
Martini, Dr. Janet

Clinical Associate Professor
Chung, Dr. Maria

Clinical Assistant Professor
Hill, Dr. Amanda

Clinical Assistant Professor
O'Connor, Dr. Peter

Clinical Assistant Professor
Rauscher, Dr. Christopher

Clinical Assistant Professor
Wong, Dr. Roger

Clinical Instructor
Barnett, Dr. Kim

Clinical Instructor
Bater, Dr. Marilyn

Clinical Instructor
Bell, Dr. Kathryn

Clinical Instructor
Cook, Dr. Wendy

Clinical Instructor
King, Dr. Kim

Clinical Instructor
Kushner-Kow, Dr. Janet

Clinical Instructor
Lee, Dr. Philip

Clinical Instructor
Malone, Dr. Marilyn

Clinical Instructor
Menezes, Dr. Janice

Clinical Instructor
Ranchod, Dr. Hetesh

Clinical Instructor
Williams, Dr. Dorothy

VA
VA
VA
VA
SPH
VA
SPH
VA
VA
RCH
VA
VA
SPH
Royal Jubilee
VA
SPH
Nanaimo
Mount St. Joseph
SPH
VA
Mount St. Joseph
Victoria
Divisional Overview

The Division of Geriatric Medicine currently has 15 faculty at PHC and VA and 4 faculty in distributed sites. It delivers a wide range of clinical services spanning all sites of Providence Health Care and VA, including active geriatric consultation services, in-patient acute care for elders (ACE), geriatric activation and assessment beds, geriatric day hospitals and multiple outpatient clinics. Clinical services are provided in the community through outreach and through one faculty member who works primarily with community provider teams. Research by division members is in health service provision, diabetes, medical education, dementia, osteoporosis, falls prevention and cardiovascular disease.

Teaching

Undergraduate: Dr. Reva Adler coordinates Phase V for the Undergraduate Education Committee of the Department of Medicine and will coordinate this phase for the medical school expansion. Dr. Janet Kushner-Kow is the Undergraduate representative for the UBC Division of Geriatric Medicine and she is the chair for the dementia week block in Brain and Behaviour in PBL. Currently the division also organizes and teaches two sessions in Clinical Skills on assessment of confusion and function. Dr. Kushner-Kow is also the director for expansion for the Department of Medicine Undergraduate Program and is on the Undergraduate Education Committee.

Dr. Kushner-Kow and Dr. Hetesh Ranchod are participating in teaching International Medical Graduates at Mount St. Joseph Hospital.

Postgraduate: Dr. Janet Kushner-Kow is the new Program Director of the Geriatric Medicine Training Program. We presently have two trainees, one gulf state resident finishing his third year in geriatrics before returning to Saudi Arabia and one other resident. We have a new resident starting in July 2005. The internal review of the program will be conducted in Spring 2005. In addition, Division members teach Internal Medicine residents and fellows the principles of the care of the frail elderly by working on Clinical Teaching Units and teaching noon rounds and academic half days. Dr. Roger Wong has been appointed the Associate Program Director, Postgraduate Medical Education.

Continuing Medical Education: In 2004 the Division members were active participants in numerous CME events which included programs in osteoporosis, falls and fractures, dementia, diabetes and other topics. Dr. Janet Kushner-Kow organizes weekly division rounds which has local and international speakers. She is active in evaluating an interprofessional module series which teaches geriatrics to trainee and practicing health care professionals interested in the Care of the Elderly. This series has been used in Vancouver, the Fraser Health Region and three rural sites. The Division hosted a conference on Osteoporosis and Renal Disease that focused on the management and fracture risks in patients with end stage renal disease.

Research

Dr. Meneilly is a member of the board of the CIHR Institute for Aging and is also a member of the Steering Committee for the Canadian Longitudinal Study on Aging and he conducts several
research projects on diabetes in the elderly. Dr. Larry Dian is the Principal Investigator of a study of the prevalence of osteoporosis in nursing home patients. Dr. Roger Wong continues to conduct research in medical education. He is currently investigating the role of electronic academic detailing in teaching medical concepts to physicians. He is also involved in clinical outcomes research on the measurement and determinants of physical function in acutely ill seniors in ACE units. Dr. Janet Kushner-Kow is conducting research on optimal interactive multimedia education strategies for distance learning in the new distributed medical school curriculum. Dr. Beattie is involved in multiple research projects related to dementia, serves on the Clinical Research Ethical Board (CREB) committee, chairs the Research Policy Committee for the Alzheimer Society of Canada. She has been a member of a Michael Smith Foundation for Health Research Initiative to set up an Aging Network. Dr. Reva Adler has represented Canada at a number of international conferences on genocide in the past two years. She holds a grant from the Vancouver Foundation to research access to health services for older immigrants to Canada. Dr. Marilyn Malone is involved in collaboration with colleagues at SFU and UBC in developing a falls prevention program. Dr. Ken Madden has implemented his research program in cardiovascular physiology and pathophysiology in aging. He has two projects currently ongoing. The first study is an examination of the effects of hyperinsulinemic euglycemic clamps on cardiovascular and cerebrovascular control mechanisms (arterial baroreceptors, autonomic nervous system and cerebral autoregulation) that maintain blood flow to the brain during upright tilt. His second study is examination of the effects of a central alpha agonist (clonidine) on carotid sinus hypersensitivity in older adults that present to the emergency department with frequent falls. Dr. Janet Martini and her colleagues in Providence Health Care are developing a research focus in performance review and continuous quality improvement with ongoing evaluation of service delivery. Dr. Wendy Cook is working on an ongoing cohort study based in Toronto with nephrologist Dr. Vanita Jassal on the prevalence and incidence of falls in elderly dialysis patients. She is a co-investigator in a randomized study of exercise for fall prevention in elderly emergency department fallers. She has submitted a paper on the prevalence of falls. Dr. Philip Lee is doing research on behavioral neurology and dementia. He was recently awarded a CIHR Fellowship. Dr. Hill is collaborating with Dr. Thornton from Simon Fraser University and Dr. Shapiro from the Division of Nephrology, looking at cognition in predialysis patients.

Clinical Services

At both Providence Health Care and Vancouver Hospital clinical activities continue to increase. At the Vancouver Hospital the volume of in-patient consults has also increased. We have established a SAFE Geriatric assessment unit with a focus on regional and provincial needs which operates at the UBC hospital site. The Division is actively involved in patient assessment and management at the VGH STAT Centre and will participate in planning future community-based GEM services in Vancouver Community Health Services. Dr. Amanda Hill with Dr. Mark Roberts is developing a Congestive Heart Failure protocol. Dr. Chris Rauscher through self study and through his extensive involvement in planning and implementation of quality improvement initiatives related to chronic disease management and health system re-design is now a recognized expert in these areas. He was co-chair of the BC Congestive Heart Failure Collaborative and he is the physician lead for chronic disease management for Vancouver Coastal Health. He has been extensively involved in population health planning with the Ministry of Health Services and he is chairing working groups on Dementia and on the Frail Elderly. He is a member of the MOH/BCMA Guidelines and Protocols Committee and has
developed a number of guidelines for physicians related to chronic diseases. He has presented on his work in numerous local workshops and conferences. Dr. Philip Lee is attending physician for Geriatric Medicine and the CTU at SPH and an attending physician at the Alzheimer’s and related disorders clinic at UBC Hospital.

Administration

Dr. Larry Dian is Acting Head, UBC Division of Geriatric Medicine and Head, VGH Division Geriatric Medicine. Dr. B. Lynn Beattie is Acting Head, Division of Geriatric Medicine at Providence Health. Dr. Janice Menezes is the Physician Operations Leader at St. Paul’s. Dr. Meneilly is the Chairman of the UBC and VGH Department of Medicine. Dr. Reva Adler is the Medical Director of the VGH STAT Centre. Dr. Amanda Hill continues in her role as Medical Director, Community and Specialty Medicine. Dr. Roger Wong is the Medical Director, Geriatric Consultation Program and Medical Manager, ACE unit at VGH and the Associate Program Director, Postgraduate Medical Education, UBC Department of Medicine.

Special Honours and Awards

Dr. Reva Adler is doing Fulbright scholarship sponsored research in Rwanda on prevention of massacres.

Dr. Roger Wong was awarded an interdisciplinary research grant and the “In it for Life” research grant by the Vancouver Coastal Health Research Institute. He was also appointed the Associate Program Director, Postgraduate Medical Education, UBC Department of Medicine.

Dr. Wendy Cook has been a volunteer physician at the Manang Aid Post for the Himalayan Rescue Association, Nepal from September to December 2004.
HEMATOLOGY

Dr. Michael Barnett
Clinical Professor & Head

Faculty Members

Clinical Professor & Head  Barnett, Dr. Michael VA/BCCA
Professor                     Eaves, Dr. Allen BCCA
Professor                    Humphries, Dr. Richard Keith BCCA
Professor                   Schrader, Dr. John UBC
Associate Professor         Smith, Dr. Clayton VA/BCCA
Clinical Professor          Ballem, Dr. Penny C&W Health Centre
Clinical Professor          Buskard, Dr. Noel VA
Clinical Professor          Hogge, Dr. Donna VA/BCCA
Clinical Professor          Lansdorp, Dr. Peter BCCA
Clinical Associate Professor Benny, Dr. Barrett VA
Clinical Associate Professor Nantel, Dr. Stephen VA/BCCA
Clinical Associate Professor Nevill, Dr. Thomas VA/BCCA
Clinical Associate Professor Shepherd, Dr. John VA/BCCA
Clinical Associate Professor Sutherland, Dr. Heather VA/BCCA
Clinical Associate Professor Vickars, Dr. Linda SPH
Clinical Assistant Professor Forrest, Dr. Donna VA/BCCA
Clinical Assistant Professor Leitch, Dr. Heather SPH
Clinical Assistant Professor Li, Dr. Charles SPH
Clinical Assistant Professor Toze, Dr. Cynthia VA/BCCA
Clinical Instructor          Broady, Dr. Raewyn VA
Clinical Instructor          Galbraith, Dr. Paul SPH
Clinical Instructor          Lavoie, Dr. Julye VA/BCCA
Clinical Instructor          Leger, Dr. Chantal SPH
Clinical Instructor          Petraszko, Dr. Tanya VA
Clinical Instructor          Song, Dr. Kevin VA/BCCA
Clinical Instructor          Sreenivasan, Dr. Gayatri VA
Clinical Instructor          Tsang, Dr. Peter VA
Associate Member            Coupland, Dr. Robert VA
Associate Member            Eaves, Dr. Connie BCCA
Associate Member            Horsman, Dr. Douglas BCCA
Divisional Overview

The UBC Division of Hematology includes 27 staff and 3 associate staff members based at the Vancouver General Hospital (VGH), the Vancouver Cancer Centre (VCC) and the Terry Fox Laboratory (TFL) of the British Columbia Cancer Agency, St. Paul’s Hospital (SPH), BC Women’s & Children’s Hospital and UBC. In 2004, laboratory research programs at TFL and UBC brought in peer-reviewed operating support of $2.9 million and CFI equipment funds of $2.1 million and clinical research at VGH and SPH brought in $240,000. There was a total of 45 peer-reviewed publications. Training and patient care remained at the forefront of clinical activities. Trainees in the Division as a whole included 4 Hematology fellows, 5 Leukemia/BMT fellows, 19 laboratory post-doctoral fellows and 6 graduate students.

Teaching

Undergraduate: This was the 6th year of the Blood & Lymphatics Block in the Problem Based Learning course.

Postgraduate: A total of 32 Residents in the Internal Medicine Program took hematology-based electives during the past year. These were one or two month blocks spent on the Hematology Consultation Service at VGH or SPH.

Subspecialty Training: Four General Hematology fellows were based at VGH. Rotations included the General Hematology Consultation Service, Leukemia/BMT Service, Blood Transfusion Service, Cell Separator Unit, Out-patient Clinics and Hematopathology. Rotations were also taken at SPH, VCC, BC Women’s and Children’s Hospital. These positions were filled by Dr. Ahmad Al Saeed, Dr. Lynda Foltz, Dr. Yulia Lin and Dr. Carolyn Owen.

Leukemia/Bone Marrow Transplantation Fellowship: The Leukemia/BMT Program had five positions available for clinical training in the management of patients with leukemia and those undergoing hematopoietic stem cell transplantation. These positions were filled by Dr. Yasser Abou Mourad, Dr. Birgit Christ, Dr. Richard Doocey, Dr. Genevieve Gallagher and Dr. Sharif Khan.

Postdoctoral Training: Division Members conducting bench research at the TFL and UBC trained 19 postdoctoral fellows, of whom 7 were PhD’s and 12 were MD’s.

Experimental Medicine: In the TFL, the Experimental Medicine Program accommodated 9 graduate students, one of whom held a MSFHR studentship.

Continuing Medical Education: Division Members attended numerous national and international meetings both as attendees and speakers.

Research

Clinical research continued to be focused on hematological malignancies at VGH/VCC and thrombosis at SPH. As well as in-house studies, significant contributions were made to national and international trials. Laboratory research based at the TFL involved the regulation of normal
and malignant hematopoietic cell growth and differentiation with special emphasis on the myeloid leukemias, Hox genes and telomeres. The molecular characterization of regulatory pathways was the focus at UBC.

**Clinical Services**

The clinical services at VGH/VCC and SPH continued to cope with a high workload in terms of both inpatient and outpatient activities. At SPH, Dr. Heather Leitch was appointed as a staff hematologist and Dr. Leslie Zypchen provided locum coverage for a maternity leave.

**Administration**

Dr. Linda Vickars (Head of Hematology at SPH), Dr. Stephen Nantel (Director of the Clinical Practice Unit for Hematology/BMT at VGH), Dr. Barrett Benny (Director of the Cell Separator Unit at VGH), Dr. Peter Tsang (Director of the Hematology Training Program) and Dr. Charles Li (Coordinator of Undergraduate Teaching) continued in leadership positions.

**Future Directions**

The main research goals will be to enhance activity at the laboratory/clinical interface in hematological malignancy and to expand efforts in thrombosis. In addition, new initiatives, e.g., HIV-related lymphoma and collaborations, e.g., with the Centre for Blood Research at UBC will be pursued. In regard to clinical services, a priority will be to achieve a full complement of appropriately funded staff.

**Special Honours and Awards**

**Dr. Donna Hogge** – Served on the scientific review panel for the Leukemia Research Fund of Canada

**Dr. Keith Humphries** – 20 Year Service Award, Terry Fox Laboratory, BC Cancer Agency

**Dr. John Schrader** – Distinguished Scientists Distinction, awarded by the Canadian Society for Clinical Investigation

**Dr. Clayton Smith** – Named to “Celebrating Scholarships”, Academic Excellence at UBC

**Dr. Peter Tsang** – Professional Association of Residents – British Columbia Award for Excellence in Clinical Teaching

**Dr. Linda Vickars** – President, North Pacific Society of Internal Medicine
Professor & Head
Reiner, Dr. Neil
VA

Professor & Assistant Head
Stiver, Dr. H.
VA

Professor
Bowie, Dr. William
VA

Professor
Brunham, Dr. Robert
UBC/BCCDC

Professor
Chow, Dr. Anthony
VA

Professor
Montaner, Dr. Julio
SPH

Associate Professor
Av-Gay, Dr. Yossef
VA

Associate Professor
Phillips, Dr. Elizabeth
SPH

Associate Professor
Tyndall, Dr. Mark
SPH

Assistant Professor
Cherkasov, Dr. Artem
VA

*Assistant Professor
de Haan, Dr. Marie
VA

Assistant Professor
Grigg, Dr. Michael
VA

Assistant Professor
Hmama, Dr. Zakaria
VA

Assistant Professor
Steiner, Dr. Theodore
VA

Clinical Professor
Burdge, Dr. David
C&W Health Centre

Clinical Professor
Chan, Dr. Robert
SPH

Clinical Professor
Phillips, Dr. Peter
SPH

Clinical Professor
Rekart, Dr. Michael
BCCDC

Clinical Assistant Professor
Harrigan, Dr. Paul
SPH

Clinical Assistant Professor
Montessori, Dr. Valentina
SPH

Clinical Assistant Professor
Press, Dr. Natasha
SPH

Clinical Assistant Professor
Wood, Dr. Evan
SPH

Clinical Instructor
Reynolds, Dr. Robert
VA

Associate Member
Isaac-Renton, Dr. Judith
BCCDC

Associate Member
Jewesson, Dr. Peter
VA

Associate Member
Marra, Dr. Fawziah
BCCDC

Associate Member
McMaster, Dr. Robert
C&W Health Centre

Associate Member
Money, Dr. Deborah
C&W Health Centre

Associate Member
O'Shaughnessy, Dr. Michael
SPH

Associate Member
Patrick, Dr. David
BCCDC

Adjunct Professor
Sanghera, Dr. Jasbinder
Vancouver

Visiting Scientist
Lopez, Dr. Martin
VA
Visiting Scientist: Papavinahasundaram, Mr. Kadamvanasundaram
Visiting Scientist: Shamir-Elron, Dr. Yael

*Inactive Member

**Divisional Overview**

Growth and achievements in the Division of Infectious Diseases in the past year can be attributed to a highly industrious faculty which now includes 16 MD’s and 5 PhD’s who are located at Vancouver General, St. Paul’s and BC Children’s and Women’s Hospitals as well as at the BCCDC. Among the faculty are nationally and internationally recognized investigators with expertise and interests in areas including microbial pathogenesis, host defense, microbial genomics, HIV, clinical epidemiology, sexually transmitted diseases, respiratory, urinary tract, fungal infections, and vaccine studies.

The Division was pleased to welcome Dr. Elizabeth Phillips who was recruited from the University of Toronto/Sunnybrook Hospital to an Associate Professor position based at SPH. As Head of Clinical Pharmacology within the BC Centre for Excellence in HIV/AIDS, she is responsible for Clinical Pharmacology and Toxicology. Robert Chan, a longstanding faculty member, returned to private practice in downtown Vancouver after an extended period working in Hong Kong.

An External Review of the Division acknowledged significant developments and accomplishments that have taken place over the past ten years, particularly in research. The Review recommendations recognized and provided support for the challenges which lie ahead, including faculty recruitment, salary support, and replacement of research space.

**Teaching**

Teaching continues to be a major strength of the Division of Infectious Diseases. Members of the Division make substantial contributions to the education of undergraduate and postgraduate students, residents and fellows from the Faculty of Medicine. In addition, as many as 15 visiting undergraduate and postgraduate medical students and residents representing most Canadian medical programs received elective training in Infectious Diseases at Vancouver General Hospital and St. Paul’s Hospital this year.

**Undergraduate:** The Division’s significant commitment to undergraduate teaching includes the highly regarded Host Defense Infection Block in the Problem Based Learning course. Clinical Clerkship Half Days and inpatient rotations are also highly regarded by students. Dr. Grant Stiver continues his significant contribution to the Program as Director of Undergraduate Education for the Faculty of Medicine.

**Postgraduate:** Among the strengths of the Residency Training Program are the leadership of Dr. Valentina Montessori, Program Director, (shared with Dr. Grant Stiver during Dr. Montessori’s maternity leave this year), and the outstanding caliber of the Infectious Diseases Subspecialty trainees. The two year Royal College Subspecialty Training Program provides high
quality clinical and research training in order to equip fellows for an academic career in infectious diseases. Dr. Richard Lester won the Best Poster Prize at Residents Research Day (Staphylococcal heat shock protein 60 – responses in innate immune cells). Since completing his training he has begun a position in Kenya, in a University of Manitoba sponsored HIV Research Program. Senior ID Fellow, Dr. Mark Hull was joined in the Program by Drs. Ghassan Wali, and Abeer Alshukairi in July. Dr. Julie Stone, an OB/GYN specialist, began a year of Infectious Diseases training under the joint supervision of Drs. Valentina Montessori and Deborah Money. Training at the residency level included inpatient and outpatient rotations at St Paul’s Hospital and Vancouver General Hospital for 49 residents from Medicine, Dermatology, Neurology, Medical Microbiology, Anaesthesia and Pharmacy.

Graduate Students: Through Experimental Medicine as well as the Departments of Laboratory Medicine and Microbiology and Immunology, Infectious Diseases Faculty supervised 20 graduate students and 10 post doctoral research fellows at Vancouver General Hospital, BCCDC and St Paul’s Hospital. As well, Kenna Sleigh, an RN who has been active in clinical research with Grant Stiver for many years, received her PhD.

UBC MD/PhD Program: Dr Anthony Chow is a Director of the UBC MD/PhD Program jointly administered by the Faculty of Medicine and the Faculty of Graduate Studies. This integrated combined degree program prepares the students to pursue a research-intensive track of residency and postdoctoral training in a specialty or discipline of their choice, ultimately leading to an independent clinician-investigator career. The program enrolled 13 trainees this past year, engaged in a wide range of research including: cancer, cardiovascular disease, lipid metabolism, infectious disease pathogenesis, gene mutations and chromosomal abnormalities, host defense mechanisms, and social factors that determine access to health care. MD/PhD students have won prestigious awards such as the BC Cancer Research Centre Lloyd Skarsgard Research Excellence Prize, Canadian Society for Clinical Investigation’s Young Investigator Award, Western Society for Clinical Research Student Medical Research Forum Best Oral Presentation Award.

TRID Program: Dr. Anthony Chow is also Director of the CIHR-UBC Strategic Training Program for Translational Research in Infectious Diseases (TRID). Specific aims of this Program are: 1) To promote and strengthen the national capacity for translational research in infectious diseases through an integrative training program encompassing all 4 pillars of health research as defined by CIHR and MSFHR; 2) To raise the national standards in the training of health researchers, and 3) To cultivate and facilitate transdisciplinary and translational research in infectious diseases. Trainees include undergraduate co-op and summer research students, MD/PhD students, PhD students, and postdoctoral research fellows. In 2004 the Program administered 34 TRID studentships or fellowships involving 25 TRID faculty members. TRID trainees published 3 and submitted 7 papers, and presented 33 conference presentations. TRID held two thematic research symposia “Deciphering Global Host-Microbe Interactions”, and “Application of Basic and Clinical Research to Epidemiological Problems”. For details of TRID-supported students, their research supervisors, and research projects - http://cmdr.ubc.ca/trainingprogram.

Continuing Medical Education: Dr. Joshua Fierer, Professor of Medicine and Chief, Division of Infectious Diseases, University of California at San Diego, was a Visiting Professor sponsored
by the UBC TRID Program and the Division. He presented his research on *Coccidiomycosis* at a special seminar, and also met with faculty, students and fellows. A special presentation on *Prevention of fungal infections post-BMT* was given by another invited guest, Dr Kieren Marr, from the University of Washington, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center. The weekly Academic Rounds Plenary Presentations included visiting speakers Drs. George Zhanel and Daryl Hoban, Medical Microbiologists from the University of Manitoba.

**Research**

As noted in the External Review of the Division, “The Division has a strong record of achievement in research. The recruitment of five basic scientists to the Division makes this one of the strongest ID divisions in the country.” The total amount of research grant funding awarded to division faculty at all sites in Vancouver for the year was in the range of $5.5 M.

**Immunity and Infection Research:** The Division maintains an active basic research program in molecular microbial pathogenesis and host defense. Pathogens under study included *M. tuberculosis*, *Leishmania*, *Toxoplasma*, *E. coli*, *Staphylococci*, *Streptococci* and *Chlamydia*. In addition to addressing mechanisms of pathogenesis, ongoing research is concerned with both innate and acquired immune responses to infection including vaccine development. The Division’s research program has an important bioinformatics focus with additional state-of-the-art expertise in molecular modeling and computer-aided drug design.

**HIV/AIDS Research Program:** The AIDS Research Program, which involves seven faculty members at the St. Paul’s site, continues to study the role of antiretroviral therapy for the treatment of HIV infection. The main areas of research encompass epidemiology, clinical management and basic sciences. The epidemiology group has been actively developing and maintaining long-term analyses of drug treatment programs in Vancouver including harm reduction strategies. The group has been investigating the natural history of injection drug use including; study of HIV and Hepatitis C and other hazards related to injection drug use, scientific evaluation of North America’s first supervised injection site, examination of illicit opiate addiction, treatment and policy in Canada. The clinical science research focuses on issues important to the medical management of patients with HIV including multidrug-resistant virus, pharmacokinetics of antiretrovirals, and adherence to antiretroviral therapy regimens, drug toxicities, viral co-infections and primary care initiatives. The basic science program has a major focus on HIV resistance to antiretroviral therapy and mechanisms of toxicity. Other research within the Program includes pathophysiology and management of hypersensitivity reactions and adverse drug reactions associated with antiretroviral drugs; genetic screening and diagnostic testing for hypersensitivity reactions associated with antiretroviral therapy; mitochondrial toxicity of antiretrovirals, hepatitis C therapy in HIV/HCV co-infected patients; liver disease associated with HIV/HCV co-infected patients; and observational studies of HIV-related immune reconstitution syndromes.

**Epidemiological Research:** Dr. Bill Bowie is a co-investigator, along with Dr. Jerry Spiegel, for a CIDA operating grant of $5M for 7 years which is entitled *Sustainably managing environmental health risks*. He is also a co-applicant for a CIHR funded initiative – *The spread*
and evolution of SARS corona viruses through contact networks: prediction, recognition and control.

Clinical Research: Dr. Grant Stiver continues his timely research in respiratory tract infections, particularly influenza and Flulnsure vaccine efficacy. Other current trials include assessment of a new antibiotic Telavacin against MRSA skin and soft tissue infections and Gram positive nosocomial pneumonia, as well as further studies on oral gel formulations to treat C. difficile colitis.

Clinical Services

The Division maintains two highly active and intense consultation services, one located at SPH and one at VGH. In addition, an AIDS inpatient service based at SPH is also staffed by ID physicians. The consultation services see the usual full range of general ID cases. At the same time, there is a particular wealth of clinical material related to reconstructive orthopedics including spine, neurosurgery, bone marrow and solid organ transplant, tuberculosis, infections related to IVDU and infections in other marginalized populations.

Future Directions

- Development of recruitment plans is recognized as being critical, especially as the medical school expansion begins to increase the teaching component of activities.
- Development of a definite relocation plan for the VGH Division including research laboratory space.

Special Honours and Awards

Dr. Robert Brunham – Thomas Parran Award from The American Sexually Transmitted Diseases Association, and was a member of the National Advisory Committee for the Toronto Conference on Global Infectious Diseases

Dr. Anthony Chow – Canadian Infectious Disease Society Janssen-Ortho Distinguished Service Award

Dr. Julio Montaner – Distinguished Service Award, Department of Medicine, St. Paul’s Hospital

Dr. Mark Tyndall – Promoted to Clinical Associate Professor
MEDICAL ONCOLOGY

Dr. Susan E. O'Reilly
Clinical Professor & Head
(on sabbatical)

Dr. Joseph M. Connors
Clinical Professor & Acting Head
(June 2004 – February 2005)

Faculty Members

Clinical Professor & Head
O'Reilly, Dr. Susan
BCCA/Vancouver

Clinical Professor & Acting Head
Connors, Dr. Joseph
BCCA/Vancouver

Assistant Professor
Chi, Dr. Kim
BCCA/Vancouver

Assistant Professor
Chia, Dr. Stephen
BCCA/Vancouver

Assistant Professor
Gill, Dr. Sharlene
VA

Assistant Professor
Savage, Dr. Kerry
VA

Clinical Professor
Gelmon, Dr. Karen
BCCA/Vancouver

Clinical Professor
Hoskins, Dr. Paul
BCCA/Vancouver

Clinical Professor
MacLean, Dr. Grant
BCCA/Victoria

Clinical Professor
Murray, Dr. Robert Nevin
BCCA/Vancouver

Clinical Professor
Shah, Dr. Amil
BCCA/Vancouver

Clinical Professor
Swenerton, Dr. Kenneth
BCCA/Vancouver

Clinical Professor
Weinerman, Dr. Brian
BCCA/Victoria

Clinical Associate Professor
Coppin, Dr. Christopher
BCCA/ Fraser Valley

Clinical Associate Professor
Klasa, Dr. Richard
BCCA/Vancouver

Clinical Associate Professor
Klimo, Dr. Paul
Lion’s Gate Hospital

Clinical Associate Professor
Ragaz, Dr. Joseph
BCCA

Clinical Associate Professor
Wilson, Dr. Kenneth
BCCA/Victoria

Clinical Assistant Professor
Allan, Dr. Sharon
BCCA/Victoria

Clinical Assistant Professor
Anderson, Dr. Helen
Victoria

Clinical Assistant Professor
Bernstein, Dr. Vanessa
BCCA/Victoria

Clinical Assistant Professor
Bryce, Dr. Cicely
BCCA/Vancouver

Clinical Assistant Professor
Gill, Dr. Karamjit
Surrey
Clinical Assistant Professor  Khoo, Dr. Kong  BCCA/Kelowna
Clinical Assistant Professor  Knowling, Dr. Margaret (Meg)  BCCA/Fraser Valley
Clinical Assistant Professor  Laskin, Dr. Janessa  BCCA
Clinical Assistant Professor  Lee, Dr. Ursula  BCCA/Fraser Valley
Clinical Assistant Professor  MacPherson, Dr. Nicol  BCCA/Victoria
Clinical Assistant Professor  Melosky, Dr. Barbara  BCCA/Vancouver
Clinical Assistant Professor  Noble, Dr. R.  RCH
Clinical Assistant Professor  Norris, Dr. Brian  BCCA/Fraser Valley
Clinical Assistant Professor  Sawnhney, Dr. Ravinder  BCCA/Fraser Valley
Clinical Assistant Professor  Sehn, Dr. Laurie  BCCA/Vancouver
Clinical Assistant Professor  Shenkier, Dr. Tamara  BCCA/Vancouver
Clinical Assistant Professor  Stuart, Dr. David  Burnaby
Clinical Assistant Professor  Taylor, Dr. Marianne  BCCA/Victoria
Clinical Instructor  Bouttell, Dr. Elaine  Kelowna
Clinical Instructor  Ellard, Dr. Susan  VA
Clinical Instructor  Fenton, Dr. David  BCCA/Kelowna
Clinical Instructor  Fitzgerald, Dr. Catherine  BCCA/Victoria
Clinical Instructor  Lee, Dr. Christopher  BCCA/Fraser Valley
Clinical Instructor  MacNeil, Dr. Mary  BCCA/Victoria
Clinical Instructor  Martin, Dr. Lee Ann  BCCA/Fraser Valley
Clinical Instructor  Martins, Dr. Heidi  BCCA/Victoria
Clinical Instructor  Souliere, Dr. Sheila  Victoria
Clinical Instructor  Sutherland, Dr. Judith  BCCA/Kelowna
Honorary Professor  Bruchovsky, Dr. Nicholas  BCCA/Emeritus
Associate Member  Brigden, Dr. Malcolm  Victoria
Associate Member  Ling, Dr. Victor  BCCRC
Clinical Professor (Emeritus)  Goldie, Dr. James  BCCA/Emeritus
Clinical Professor (Emeritus)  Klaassen, Dr. David  BCCA/Emeritus
Clinical Professor (Emeritus)  Plenderleith, Dr. Ian  BCCA/Emeritus
Clinical Professor (Emeritus)  Silver, Dr. Hulbert  BCCA/Emeritus

Divisional Overview

The Division of Medical Oncology, UBC, comprises the Medical Oncology and scientific staff at the Vancouver Center, Fraser Valley Center, Surrey, Vancouver Island Center, Victoria and the Center for the Southern Interior, Kelowna, as well as community oncologists in Burnaby, North Vancouver, Nanaimo and the Royal Columbian Hospital, New Westminster.

In addition to the clinical division, there is a laboratory section (Advanced Therapeutics), which is located in the British Columbia Cancer Research Center. It comprises four senior scientists and six clinical investigators who have appointments at the Vancouver Cancer Center, Department of Medical Oncology.

Medical Oncology clinical services are organized as a Provincial Systemic Therapy Program reaching across the Province of British Columbia including the four cancer centers and outreach programs in more than ten additional community hospitals in smaller urban centers. Undergraduate and postgraduate teaching occurs primarily at the Vancouver Cancer Center with
additional elective opportunities available at all four cancer centers including Victoria, Fraser Valley and Kelowna. UBC clinical faculty at all centers participate in undergraduate teaching modules.

The next five years will pose some exciting challenges and opportunities. More medical oncologists and hematologists specializing in neoplastic diseases will be needed to address the rising incidence of cancer, related to the aging population and, even more importantly, the increasingly complex treatment programs incorporating new targeted small molecules and immunotherapeutic agents. Adding to the challenges of increased incidence and treatment complexity is the very high cost of new therapeutic agents. For example, the current standard of practice for metastatic colorectal cancer treatment has changed from simply administered single agent chemotherapy to complex multi-agent programs costing more than 100 times as much in just the last five years. Expanded opportunities for clinical and translational research is readily available based on the rapid emergence of new knowledge in cancer biology especially insights derived from genomic and gene expression studies.

The new $100,000,000 B.C. Cancer Research Center building opened in early 2005. This state-of-the-art research facility houses a wide range of laboratory research programs including molecular oncology, the Terry Fox Laboratory focusing on hematologic cellular biology and leukemias and core programs in genomic analysis, gene expression profiling, novel imaging and tumor modeling and population based epidemiology and biostatics. The BC Cancer Agency Genome Sciences Centre has moved into a large laboratory facility nearby but continues to forge collaborative projects with several tumor groups within Medical Oncology including breast cancer, gastrointestinal cancer and lymphoproliferative neoplasms.

Teaching

The Medical Oncology Undergraduate Training Committee, chaired by Dr. Amil Shah is active in providing and planning teaching modules and clinical bedside teaching in Internal Medicine. An elective in Medical Oncology is available to UBC and visiting medical students.

The Postgraduate Training Committee, chaired by Dr. Tamara Shenkier, offers popular two-month electives in Medical Oncology to internal medicine residents from UBC and other universities. Approximately 10-16 residents per year from these and other specialty disciplines spend elective periods at the Vancouver Cancer Center. Opportunities are available for electives at all of our regional cancer centers and some financial support for travel and accommodation is available for residents choosing one of these options.

The Postgraduate Training Committee also plans and supervises the two-year subspecialty-training program in Medical Oncology. This program is based at the Vancouver Cancer Center with elective opportunities at all other centers and in community oncology practice. The six-month elective period may also be applied to laboratory or clinical research. One or two month electives at centers elsewhere in Canada or in other countries may also be considered. This program, now one of the largest two such programs in Canada, has expanded to enroll four first year and four second year residents and is fully approved by the Royal College of Physicians and Surgeons of Canada and has consistently received excellent reviews. Additional training positions for overseas residents result in eight or nine trainees participating in this two-year
Residents are expected to conduct clinical research and have a number of publications and presentations to their credit. At least half of our residents from each year recently have competed successfully for post-residency academic subspecialty fellowships that have launched them on promising academic careers. Opportunities to pursue laboratory research projects are available.

**Continuing Medical Education:** All medical staff are active in continuing medical education courses organized by the British Columbia Cancer Agency, other provincial, national and international bodies. Several of our faculty members have emerged as international leaders in their field and are actively sought out to provide leadership within the major international societies including the American Society of Clinical Oncology, the American Society of Hematology and the American Association for Cancer Research in addition to their contributions to the National Cancer Institute of Canada and its Clinical Trials Group.

**Research**

Members of the Division are involved in a wide variety of phase I, II, III and IV clinical trials. These include the development of new anti-cancer drugs, the evaluation of new doses schedules and combinations of drugs in the phase II setting and the participation in multi-institutional phase III studies and post marketing phase IV trials evaluating effective new treatments on specific categories of malignancy.

Our phase I investigational new drug program has grown rapidly as a reflection of the energy and enthusiasm of the scientists and physicians in the Advanced Therapeutics section of Medical Oncology and in response to the increasing availability of new agents for testing in North America.

Our Advanced Therapeutics Section is able to evaluate new biological response modifiers, gene therapy and pharmaceutical agents through all stages from in-vitro testing in the laboratory to evaluation in human volunteers. The Vancouver Cancer Center has the only Clean Room in an academic center in Canada that is equipped and licensed for the packaging and formulation of pharmaceutical agents in small quantities for clinical testing.

At the pre-clinical level, studies are being carried out in evaluating anti-angiogenesis agents, gene modifiers, enzyme inhibitors, experimental drug modulators, pre-clinical drug toxicities and molecularly targeted agents such as the new tyrosine kinase inhibitors, immunotherapeutic agents targeted against breast cancer, colorectal cancer, lung cancer and lymphomas. Currently, the BCCA manages its own grants and these are not listed in this report.

**Clinical Services**

The four B.C. Cancer Centers now provide medical oncology consultations for 7,000 new patients annually with more than 50,000 ambulatory care visits to these centers. The Provincial Systemic Therapy Program, headed by Dr. Susan O’Reilly manages the $80,000,000 oncology drug budget, which supports the care of more than 24,000 patients annually, both within BCCA centers and in community hospitals. Opportunities for health services research projects are
available and linkages with the Provincial Tumour Registry and Vital Statistics are readily available. We are uniquely positioned to further develop province-wide population-based research in health outcomes for cancer patients and regularly take advantage of this special opportunity.

**Future Directions**

The major academic goal of the Division is to continue to build an outstanding translational research unit that combines the excellent basic science research at the British Columbia Research Center, the input from the Genome Science Centre, the resources of our academic medical oncologists and the participation of our large patient population.

British Columbia has consistently shown the best cancer survival statistics in Canada and we are in a unique position to carry out province-wide treatment programs in both clinical and translational research. We are continuously expanding our research agenda in these areas and in those of health outcomes and economic analyses.
NEPHROLOGY

Dr. Paul A. Keown
Professor & Head

Faculty Members

Professor & Head  Keown, Dr. Paul  VA
Professor       Quamme, Dr. Gary  VA
Professor       Wong, Dr. Norman  VA
Assistant Professor  Gill, Dr. John  SPH
Clinical Professor  Chan-Yan, Dr. Clifford  SPH
Clinical Professor  Levin, Dr. Adeera  SPH
Clinical Professor  Werb, Dr. Ronald  SPH
Clinical Associate Professor  Chan, Dr. Victor  RCH
Clinical Associate Professor  Landsberg, Dr. David  SPH
Clinical Associate Professor  Shapiro, Dr. Jean  VA
Clinical Associate Professor  Taylor, Dr. Paul  SPH
Clinical Associate Professor  Yeung, Dr. Choi Kit  VA
Clinical Assistant Professor  Chiu, Dr. Anthony  SPH
Clinical Assistant Professor  De Luca, Dr. Linda  SPH
Clinical Assistant Professor  Duncan, Dr. John  VA
Clinical Assistant Professor  Jastrzebski, Dr. Jacek  VA
Clinical Assistant Professor  Kiaii, Dr. Mercedeh  SPH
Clinical Assistant Professor  Singh, Dr. Rajinder  VA
Clinical Instructor  Copland, Dr. Michael  VA
Clinical Instructor  Jamal, Dr. Abeed  SPH
Clinical Instructor  Jung, Dr. Beverly  SPH
Professor (Emeritus)  Cameron, Dr. Eugene  VA
Professor (Emeritus)  Price, Dr. John  VA
Professor (Emeritus)  Sutton, Dr. Roger  VA
Clinical Professor (Emeritus)  Rae, Dr. Angus  SPH

Divisional Overview

The Division of Nephrology includes 21 members based at three principal sites: St. Paul’s Hospital, Vancouver General Hospital, and the UBC Campus, who provide provincial leadership in research, education, and clinical care within the field of renal medicine. The Division has a strong clinical base and provides integrated and decentralized nephrology care throughout
Vancouver Coastal Health including Richmond, North Vancouver and coastal areas. The Division has an important role in the UBC undergraduate medical curriculum, and has one of the largest nephrology postgraduate training programs in Canada. Research activities range from genetic and molecular sciences to innovative trials in renal disease and transplantation, with novel measures of health status and economic outcomes. Members of the Division assume leadership roles in the advancement of nephrology at provincial, national and international levels through their positions in the BC Provincial Renal Agency, BC Transplant Society, the Kidney Foundation of Canada, the Canadian and International Societies of Nephrology, the International Transplantation Society, and US National Kidney Foundation.

Teaching

Undergraduate: Division of Nephrology members have contributed significantly in developing and implementing the medical school’s distributed curriculum in 2004/5. From first year to fourth year clinical exams, they have been involved in all areas of undergraduate education.

In the first phase (P2P1), Dr. Suneet Singh and Dr. Mike Copland give physiology lectures laying the groundwork for the curriculum blocks to follow. In the second phase (P2P2), Dr. Suneet Singh is the key person in the development and delivery of five week FERGU block. She is the week 4 chair and week 5 co-chair. She works with Dr. Colin White (block chair) in the design and coordination of the block. Teachers in the block include Dr. Mike Copland, Dr. Mercedeh Kiaii, Dr. Adeera Levin, Dr. Clifford Chan-Yan and Dr. Abeed Jamal. The Nephrology subspecialty residents are also involved in the clinical case sessions.

In the clinical years, members of the Division contribute to the academic half days, bedside teaching and oral examinations for the medical students. Dr. Ron Werb, Dr. Anthony Chiu, Dr. John Duncan, Dr. Abeed Jamal, Dr. Paul Taylor, Dr. Mercedeh Kiaii, Dr. Beverly Jung and Dr. Suneet Singh are prominent clinicians in these areas.

Dr. Singh was a member of the Medical School Admissions Committee in 2004. Dr. Abeed Jamal participated in the newly formed 4th Year Curriculum Committee. Dr. Singh and Dr. Levin coordinate medical student rotations through Nephrology at the VGH and SPH sites respectively, with Dr. Jamal being the students’ contact, along with administration staff at both sites, for electives and selectives. These rotations receive excellent evaluations and many students return as residents.

Postgraduate: After several years successfully crafting an outstanding training program, Dr. A. Levin handed the reins over to Dr. J. Duncan who took over the role of Director of the Postgraduate Training Program in Nephrology in July 2004. The Division is proud of the excellent trainees currently enrolled in the first year (four) and the second year (one) of core nephrology training and one in the UBC American Society of Transplantation Renal Transplant Fellowship Program. We look forward to welcoming three more outstanding trainees to our program in 2005. There are also three trainees continuing post-fellowship research training at UBC, Harvard and Oxford Universities.

Residents and fellows remain active in clinical research with submission and presentation of abstracts at meetings of the American Society of Nephrology, the Canadian Society of
Nephrology, the American Society of Transplant Physicians, the Canadian Transplant Society, and the UBC Resident Research Day. Current fellows continuing training hold funding from the Clinician Investigator Program of the University of British Columbia (Debbie Rosenbaum, and Nadia Zalunardo), the Kidney Foundation of Canada (Jennifer Macrae) and competitive applications have been submitted for continued funding from the Michael Smith Foundation, the Kidney Foundation of Canada, and the KRESCENT program.

**Experimental Medicine:** Dr. Norman Wong stepped down in June 2004 after serving 10 years as the Director of the Experimental Medicine Program. His successor is Dr. Vincent Duronio (see separate report). This Program had 117 trainees including those supervised by Dr. Paul A. Keown.

**Continuing Medical Education:** The annual BC Nephrology Day was held in October 2004. This was a highly successful multidisciplinary meeting attracting over 300 participants from all renal care dialysis centers in British Columbia.

Members of the Division participated in Continuing Medical Education activities at the local, provincial, national and international levels. Drs. Duncan, Copland, Landsberg and Gill were involved in a number of CME activities for both general practitioners, internists and subspecialists within and outside the Vancouver area. In addition, CME activities organized for patients and caregivers, by both the Kidney Foundation and other groups, highlighted divisional members in culturally sensitive environments.

Included in CME activities are those activities created by and for the division: divisional rounds have been re-organized to ensure twice-monthly scheduling of visiting and divisional speakers. All divisional members participate in Fellow’s rounds for the division, and have been asked to speak at various subspecialty rounds (Internal Medicine, Cardiology).

Drs. A. Levin and P. Keown maintained active speaking schedules in national and international meetings, presenting both reviews of key topics and original research.

**Research**

**Clinical Research:** The clinical research in the Division of Nephrology emphasized outcomes research and clinical trials. The Division was actively involved in both industry-sponsored and peer-reviewed research in the areas of chronic kidney disease, dialysis and transplantation. Division members held grants from the Kidney Foundation grants, BC Research, BC Transplant Foundation, Michael Smith Foundation for Health Research, and other operating grants.

The scope of clinical research included patient care prior to dialysis, cardiovascular disease in patients with kidney disease - determinants of outcomes and severity, vascular access monitoring and tracking programs, the relationship of monitoring systems to patient outcomes, mineral metabolism and patient outcomes, the evaluation of new medications on patient parameters, the evaluation of new immunosuppressive medications on transplant outcome, gender studies in renal disease, and ethics studies related to genetic identification of polycystic renal disease.
**Basic Research:** The laboratory of Dr. N. Wong studies the role of vasoactive peptide in regulating the expression of vasopressin V2 receptor expression in the inner medullary collecting duct of the kidney. Dr. G. Quamme’s laboratory continues research on the magnesium response element that controls magnesium transport. Dr. P. Keown’s research projects funded by the Michael Smith Foundation for Health Research and Genome Canada include the genetic control of immune response in transplantation and arthritis, analysis of immune response gene polymorphisms, genomic and proteomic analysis in organ transplantation, and immunopharmacokinetics and dynamics.

**Administration**

Dr. Eugene C. Cameron stepped down in 2004 after serving 10 years as Head of the Division of Nephrology. His successor is Dr. Paul A. Keown. Dr. Keown is Professor of Medicine, Director of Immunology, and Director, VCH Regional Renal Program, Departments of Medicine, Pathology and Laboratory Medicine. Dr. Keown graduated in Medicine from the University of Manchester, and pursued postgraduate training in England, France, and Canada. He holds research Doctorates in both Medicine and in Science from the University of Manchester, and an MBA from Simon Fraser University in British Columbia. Dr. Keown's research focuses particularly on the immune response in transplantation and autoimmune disease, and ranges from molecular genetics to healthcare economics.

**Future Directions**

The Division will continue to build on its strengths to ensure the highest quality of academic and clinical activity for the University, the health system, and the community. It is anticipated that the Division will take a major role in Renal & Fluid and Electrolyte teaching in the expanded Medical School, continue leadership in nephrology postgraduate education, pursue integration of laboratory and clinical research in nephrology, and introduce innovative initiatives in the delivery of care to patients with renal disease.

**Special Honors and Awards**

- Dr. Gary Quamme: The Martin M. Hoffman Award for Excellence in Research in 2004, Department of Medicine, UBC
- Dr. Clifford Chan-Yan: The Master Teacher Award for 2004, Department of Medicine, UBC
- Dr. Paul A. Keown: Bringing Clinical Renown to VA Award
- Dr. Paul A. Keown: 2004 Genome Canada Award
- Dr. John Gill: Michael Smith Clinical Investigator Award
NEUROLOGY

Dr. Howard Feldman
Professor & Head

Faculty Members

Professor & Head  
Feldman, Dr. Howard  
VA

Professor  
Barton, Dr. Jason  
VA

Professor  
Doudet, Dr. Doris  
VA

Professor  
Oger, Dr. Joel  
VA

Professor  
Pelech, Dr. Steven  
VA

Professor  
Stoessl, Dr. A  
VA

Professor  
Tsui, Dr. Joseph  
VA

Professor  
Wang, Dr. Yu Tian  
VA

Associate Professor  
Kastrukoff, Dr. Lorne  
VA

Associate Professor  
McKeown, Dr. Martin  
VA

Assistant Professor  
Hsiung, Dr. Robin  
SPH

Assistant Professor  
Lee, Dr. Chong  
VA

Assistant Professor  
Spacey, Dr. Sian  
VA

Assistant Professor  
Tremlett, Dr. Helen  
VA

Clinical Associate Professor  
Hooge, Dr. John  
SPH

Clinical Associate Professor  
Javidan, Dr. Manouchehr  
VA

Clinical Associate Professor  
Jones, Dr. Michael  
VA

Clinical Associate Professor  
Krieger, Dr. Charles  
VA

Clinical Associate Professor  
Robinson, Dr. Gordon  
VA

Clinical Assistant Professor  
Beckman, Dr. Jeff  
VA

Clinical Assistant Professor  
Briemberg, Dr. Hannah  
VA

Clinical Assistant Professor  
Clarke, Dr. Stephen  
SPH

Clinical Assistant Professor  
Foti, Dr. Dean  
VA

Clinical Assistant Professor  
Gibson, Dr. Gillian  
VA

Clinical Assistant Professor  
Johnston, Dr. Dean  
SPH

Clinical Assistant Professor  
Keyes, Dr. Robert  
SPH

Clinical Assistant Professor  
Martzke, Dr. Jeffrey  
VA

Clinical Assistant Professor  
Mezei, Dr. Michelle  
VA

Clinical Assistant Professor  
Prout, Dr. Alister  
SPH

Clinical Assistant Professor  
Teal, Dr. Phillip  
VA

Clinical Assistant Professor  
Thiessen, Dr. Brian  
VA

Clinical Assistant Professor  
Traboulsee, Dr. Anthony  
VA
Clinical Instructor Chapman, Dr. Kristine SPH
Clinical Instructor Costantino, Dr. Anthony VA
Clinical Instructor Devonshire, Dr. Virginia VA
Clinical Instructor Hallam, Dr. Bradley VA
Clinical Instructor Murphy, Dr. Colleen VA
Clinical Instructor Smyth, Dr. Penelope VA
Clinical Instructor Tai, Dr. Charles SPH
Clinical Instructor Tessler, Dr. Barry RCH
Clinical Instructor Varelas, Dr. Michael VA
Clinical Instructor Woolfenden, Dr. Andrew VA
Associate Member Anderson, Dr. Duncan VA
Associate Member Forwell, Dr. Susan VA
Associate Member Graeb, Dr. Douglas VA
Associate Member Hurwitz, Dr. Trevor VA
Associate Member Leavitt, Dr. Blair VA
Associate Member Li, Dr. David VA
Associate Member Moore, Dr. Wayne VA
Associate Member Raymond, Dr. Lynn UBC
Associate Member Sadovnick, Dr. Adele VA
Associate Member Stowe, Dr. Robert VA
Associate Member Wilkinson, Dr. Rosemary VA
Adjunct Professor Bub, Dr. Daniel U Victoria
Adjunct Professor Ruth, Dr. Thomas VA
Adjunct Professor Sossi, Dr. Vesna VA
Visiting Assistant Professor Al-Araji, Dr. Adnan
Professor (Emeritus) Calne, Dr. Donald VA
Professor (Emeritus) Eisen, Dr. Andrew VA
Professor (Emeritus) Kim, Dr. Seung VA
Professor (Emeritus) Pate, Dr. Brian VA
Professor (Emeritus) Sweeney, Dr. Vincent VA
Clinical Professor (Emeritus) Anzarut, Dr. Andre SPH
Clinical Professor (Emeritus) Bratty, Dr. Paul VA
Clinical Professor (Emeritus) Hashimoto, Dr. Stanley VA
Clinical Associate Professor (Emeritus) Jones, Dr. David VA
Clinical Associate Professor (Emeritus) Wong, Dr. Milton SPH

Divisional Overview

The Division of Neurology is the largest division within the Department of Medicine. It has its major teaching, research and clinical activities at Vancouver General Hospital, UBC Hospital and St. Paul’s Hospital. There are 40 Neurology faculty members whose primary appointment is in the Division, with another 11 appointed as associate members, 2 as adjunct professors and 10 as emeritae.

The Division is nationally and internationally recognized for its clinical and research programs in neurodegenerative, demyelinating, neuromuscular and cerebrovascular diseases. It has been consistently very productive in obtaining peer reviewed grant funding, and makes important
contributions to both basic neuroscience and clinical neurological literature. This past year divisional members published more than 115 papers in peer-reviewed journals. The Division provides neurological care province wide including tertiary and quaternary care for a variety of neurological disorders. The division has clinical outreach to many communities around the province. Faculty are actively involved in teaching and supervising all levels of students and trainees from undergraduate to post doctoral fellows.

Amongst the highlights for the Division in the past year has been the recruitment and arrival of a number of full-time faculty who will be adding their clinical, teaching and research expertise to the division. Dr. Jason Barton was recruited from Harvard to UBC in September 2004 to take up a position as Tier II Canada Research Chair and Michael Smith Scholar, as well as Section head of the division of Neuro-ophthalmology. His research activities will center on cognitive neuroscience with collaborations within the Brain Research Center and with a number of divisions and departments across the university. Dr. Robin Hsiung, has been recruited to the Division to work at the interface of neurogenetics and neurodegenerative diseases particularly the dementias. He has completed a Michael Smith post-doctoral fellowship prior to taking up this junior faculty appointment in the Division. He will be contributing clinically within the SPH division and will be attending at the UBCH Alzheimer Clinic. Dr. Hannah Briemberg was recruited from Harvard to UBC to take up a clinical faculty appointment in the Neuromuscular Disease Unit. She completed her clinical fellowship training in neuromuscular diseases at the Brigham Hospital where she had been appointed as junior faculty member. She will add expertise within neuromuscular diseases and will be developing a research program in muscle diseases.

The Division was deeply moved by the passing of Dr. Donald Paty at the end of 2004. Dr. Paty had been Division Head from 1980-1996. He was an outstanding clinician scientist, educator and administrator who created the academic tradition of the division both by his own example and by his leadership. An Endowment Fund in his name is in place within the Division to honour his accomplishments. It will provide funding to aspiring academic neurologists in the early years of their career with the goal of building the academic mission of the Division.

Teaching

Undergraduate: Division members continue to be involved as PBL facilitators and teachers in the Brain and Behaviour block during 2nd year, providing lectures and bedside sessions in clinical skills. As in previous years student evaluations for the clinical skills sessions give neuroscience tutors outstanding reviews. The Division is particularly grateful to the community neurologists who have faithfully supported this teaching activity.

Seminars and bedside sessions are provided in 3rd year and a 4th year clerkship is available as an elective/selective. The clerkship is based on an inpatient and outpatient experience allowing students to take advantage of all of the resources within the Division. As well as UBC students the clerkship attracts students from other medical schools in Canada and other countries.

Divisional members are an integral part of Phase VI providing curricula designed to encourage critical evidence-based management of clinical problems.
Postgraduate: The Post Graduate Residency Training in Neurology is fully accredited with the Royal College of Physicians and Surgeons. It currently has 16 residents at various levels of training from PGY1 to PGY5. In the first two years of the program, the residents rotate through various subspecialties in Internal Medicine, ICU, Emergency, as well as doing their first Neurology rotations. The PGY3-5 years are core Neurology training years. Residents do their inpatient training at Vancouver General Hospital and St. Paul's Hospital. Many outpatient subspecialty clinics are done at UBC Hospital. During their training the residents in Neurology are actively involved in various research projects. In 2004 there were 6 resident poster presentations at various international meetings and 4 papers published in peer-reviewed journals. Dr. Brian Buck, the chief resident in Neurology was awarded a Resident Scholarship Award for the American Academy of Neurology Annual Meeting in 2004. A number of residents also presented at the BC Neuroscience Day held in March 2004.

Dr. Colleen Murphy undertook a new teaching initiative within the Division in 2004, developing a 32-hour course, which she presented to the residents from September 2003 to February 2004, on Neuroanatomy and its applications within Neurology. This course was extremely highly rated by the residents.

Fellowship Training and Awards: The Division of Neurology appointed the following individuals to fellowship and post-doctoral fellowship training in 2004:

Multiple Sclerosis Program: Dr. Helen Tremlett (post doctoral fellow of the MS Society), Dr. Penny Smyth and Dr. Cavit Boz (clinical fellow).

Alzheimer’s Disease and Related Disorders: Dr Claudia Jacova (CIHR and Michael Smith Training Award) post-doctoral fellowship.

Parkinson’s Disease and Movement Disorders (Pacific Parkinson’s Research Center): Dr. John Adams, Dr. Andre Troiano and Dr. Wing Lok Au (clinical fellows).

Basic Neuroscience Research: Dr. Nadege Chery, Dr. Tara Gaertner and Dr. Changiz Taghibiglou (postdoctoral fellows).

Neuropsychology: Dr. Jane Kucera was appointed clinical fellow in Neuropsychology under the supervision of Dr. Jeff Martzke.

Vancouver General Hospital Neurology Service (Clinical Teaching Unit)

The in-patient service at VGH consists of a 14 bed unit located on T5-B of the Pattison Pavilion. This unit is the only dedicated in-patient Neurology clinical teaching unit (CTU) in the province and has within its mandate the provision of tertiary care for complex neurological disorders. The inpatient program features a specialized epilepsy monitoring unit (2 beds), a stroke service (6 beds) and an allotted 6 beds for general neurology. Life and Limb policies are in place for accepting acute stroke patients, as well as neuromuscular disorders requiring plasmapheresis.

Over the last year substantial improvements to stroke care have been made within VGH. A very large percentage of all stroke patients presenting or referred to VGH are now admitted to the
Neurology service for acute management during the first 5-7 days of their post stroke care. From there the stroke pathway includes transfer to the UBCH Subacute Stroke Unit before moving on to appropriate rehabilitation facilities or home. This has resulted in an increase in the number of stroke patients cared for on neurology with a reduction in patients requiring a prolonged stay on the unit.

The VGH and UBCH neurologists provide important consultation services within Vancouver Acute. Neurological diagnostic services at VGH include electroencephalography (EEG), intraoperative monitoring (IOM) and electromyography (EMG) are based at VGH.

Ambulatory services provided include subspecialty clinics for Movement Disorders, Multiple Sclerosis, Alzheimer’s Disease and dementias, Stroke, Neuromuscular Disease, Amyotrophic Lateral Sclerosis, Epilepsy and Neuro-oncology. These clinics integrate with a strong research environment for each of these programs, which in turn forms the core of the academic mission of the Division. The clinics also provide important post-graduate educational activities for trainees within the Division. There are subspecialist clinical neurologists within the division dedicated to care of patients with headache (Dr. Gordon Robinson), pregnancy complications (Dr. Robert Keyes) and HIV (SPH).

St. Paul's Hospital Division of Neurology

The St. Paul’s Hospital Division of Neurology is an important part of the clinical and teaching program of the UBC Division of Neurology. Dr. Robert Keyes is the division head of SPH. This division provides tertiary referral care for the Providence Health Care network as well as to the province more widely. The SPH division participates in an important and extensive outreach program to communities in northern BC and the Yukon territory. It is additionally involved in providing inpatient consultation services to the Mount St. Joseph’s Hospital site and Women’s Hospital. The division has opened an outpatient neurology clinic at the Mount St. Joseph’s Hospital Site to meet the needs of the patient population it serves. At SPH there is a Rapid Access Neurology Clinic where patients requiring urgent but not emergent care are seen and provide clinical service especially to the patient population arising from the downtown core.

The members of the Division of Neurology at SPH includes a wide cross section of subspecialty interests including clinical neurophysiology, neuromuscular disease, multiple sclerosis, neurological diseases in pregnancy, cerebrovascular disease and neurological diseases in HIV and AIDS. A close link between the Division of Neurology at SPH and the Department of Pediatrics and the Department of Obstetrics continues by virtue of the subspecialty interests of Dr. Keyes. The appointment of Dr. Robin Hsiung has added expertise in neurogenetics especially in neurodegenerative disease. Dr. Hsiung will conduct lab research in collaboration with the I-Capture Center at SPH.

Research

Alzheimer’s Disease and Related Dementias

Clinical Activities: The UBCH Alzheimer Clinic evaluated about 1000 patients in 2004 making it one of the largest clinics of its kind in Canada. It is the main tertiary care referral center in BC
for dementia assessment. New referrals include a range of multidisciplinary assessments including Genetics, Social Work, Neuropsychology, Geriatric Psychiatry and Neurological/Medical.

The UBC Alzheimer’s Clinical Trials Program has been active in applications for peer-reviewed grants in 2004. Success in CIHR funding for projects on Frontotemporal Dementia (3 years) and Primary Prevention of dementia (1 year) has just been announced. The research unit will also participate in an NIH project developing biomarkers for AD and related dementias (ADNI). This 50 million dollar initiative is one of the largest grants ever provided through NIH and continues a line of collaborative research with the US Alzheimer research community reflecting the international recognition of the unit.

Divisional faculty participating include: Dr. Howard Feldman (Director), Dr. Dean Foti, Dr. Jeff Beckman, and Dr. Robin Hsiung. The research group includes: Dr. Lynn Beattie, Dr. Philip Lee, Dr. Kiran Rabheru, Dr. Brad Hallam, Dr. Ian Mackenzie, Dr. Claudia Jacova (post-doctoral fellow), Ms. Sandra Tam (data management core), Jacob Grand (graduate student) and Dr. Alan Donald (statistician), and a dedicated group of research assistants and research coordinators.

The ACCORD study, a longitudinal multicenter cohort study of subjects referred with cognitive symptoms received funding to complete final visit data on all subjects. This national study has been led by the coordinating center at UBC. Dr. Howard Feldman is the National Principal Investigator for this study.

Peer reviewed research funding from CIHR/Alzheimer Society of Canada has been ongoing for a longitudinal study of novel MRI techniques in mild cognitive impairment (2002-4).

Clinical trials have continued to focus in the past year on studies of mild cognitive impairment as a precursor state to AD, with completion of a series of large clinical trials investigating the potential for delay of time to the diagnosis of AD. A core group of very experienced nurse coordinators and research assistants are critical to the success of the clinical trials program.

Teaching and Education: The Clinic has been very active in providing teaching to trainees of multiple disciplines at many levels. A formal one-day preceptorship training program for family physicians and specialists is in place. Clinic members participated extensively in CME activities, and on expert national international working groups and advisory committees. The Clinic is very active in public education.

**Stroke and Cerebrovascular Program**

The VGH serves as the tertiary referral centre for stroke and cerebrovascular diseases in B.C. To support this clinical role the VGH Stroke Program maintains a dedicated on-call system with the commitment of six neurologists. A “Stroke Hot Line” pager system is available 24/7 to triage patients from around the lower mainland and southern British Columbia. The VGH Stroke Team consists of stroke neurologists, diagnostic and interventional neuroradiologists, neurointerventional/neurovascular neurosurgeons, and vascular surgeons. The program provides state-of-the-art care to cerebrovascular patients. Neuroradiology provides superb diagnostic and interventional services. In cooperation with the BC Bedline the program has successfully
developed an acute stroke referral system for the provision of thrombolytic and interventional stroke care.

The VGH Stroke Unit provides intensive care nursing for the treatment of acute stroke patients who are critically ill or who have received interventional therapies. Organized delivery of stroke care at the VGH and the development of a regional stroke care strategy will permit patients to flow from the Acute Stroke Unit to the Subacute Stroke Unit to Rehab and reintegration into the community. Efforts are now underway to develop a British Columbia Stroke Strategy in collaboration with the Heart and Stroke Foundation.

The Stroke Prevention Clinic is busy two days a week and provides same day clinical and diagnostic services to patients. This clinic provides a critical resource for patients at risk of stroke and to emergency departments and physicians. Prompt and expert care reduces the need for hospitalization through the rapid evaluation of patients.

The VGH Stroke Program has had an extremely busy year in educational activities. Vancouver served as the host city for the 5th World Stroke Congress which attracted 2500 international delegates. The 8th International Thrombolysis and Acute Stroke Meeting was held at Whistler as a satellite meeting to the World Stroke Congress. Both meetings were widely acknowledged the most successful held to date. The Annual Western Canada Stroke Conference was again highly successful in its mission to provide stroke education to neurologists from B.C. and western Canada. Weekly stroke rounds are held to provide education to residents and medical students. Residents and students spend time in the Stroke Prevention Clinic evaluating and making decisions on urgent cases. The Stroke neurologists continue to give Grand Rounds, medical rounds and talks at CME events to educate physicians around the province. Public forums have been held by the Heart and Stroke Foundation with the participation of stroke neurologists and others. On an international level, members of the Stroke Program delivered posters and platform presentations at the American Stroke Association meeting, the Canadian Congress of Neurological Sciences, the American Academy of Neurology, and the European Stroke Conference.

Multiple Sclerosis

The 2004 census of Clinic activity included 4517 active charts with 3239 patient visits during the year and with 285 new patients confirmed to have Multiple Sclerosis.

There were several new faculty appointed to the Division with special expertise in MS. Dr. Penelope Smyth completed her fellowship and was recruited to the division as clinical faculty to assist in building the clinic core while Dr. Helen Tremlett (Ph.D PharmD) was appointed to the division as Assistant Professor with a 5 year grant support from the Multiple Sclerosis Society of Canada. Dr. Tremlett will be focusing her research on the side-effects of the immune modulatory drugs and, in collaboration with Dr. V. Devonshire, has initiated a research program on the natural history of multiple sclerosis using the COSTAR database created by Drs. Paty and Studney. These appointments bring the Clinic to a faculty of 7 consultant neurologists (Drs. V. Devonshire, S. Hashimoto, J. Hooge, L. Kastrukoff, J. Oger, P. Smyth and (A) T. Traboulsee. There is an active recruitment process underway to fill an Endowed Chair in MS-MRI as well as to replace Dr. Don Paty in providing academic leadership to the program.
Dr. Adnan Al-Araji completed his MS clinic fellowship (Dupré Fellowship from the International Federation of Multiple Sclerosis London UK) and has taken up an appointment as a Consultant Neurologist at the University Hospital of North Staffordshire in Stoke on Trent (UK).

The Clinic continues to maintain important interdepartmental collaborations to provide best care to affected patients. In particular the close collaboration of Dr. A. Jiwa (psychiatric care), Dr. S. Elliot (sexual medicine care), Drs. J. Barton and D. Anderson (for neuroophthalmologic care) and neuro-urology.

The clinic has provided outreach to 3 satellite clinics in Victoria (800 patients registered), Kelowna (600 patients), and Prince George (250 patients), as well as providing outreach through clinic activities in Comox. Each clinic is organized in the local hospital under the umbrella of the local health board around a full time coordinating nurse. The UBC consultants and local neurologists work together in providing the highest quality MS care within a multidisciplinary setting that includes critical contributions from Physiotherapy, Occupational Therapy and Social work. The genetic counseling team provides an important resource to patients with their activities that are centered at the UBC MS clinic office.

In collaboration with Pharmacare and with educational funding from the pharmaceutical industry it has been possible to continue the valuable “MS Special Therapy” program to help educate patients in the choice and management of adverse effects of Disease Modifying Therapies (DMT). We are now following over 1500 treated patients.

Under the leadership of Sandra Burnham (PT) the Clinic has produced an educational videotape for “newly diagnosed patients” which has already received international recognition.

The MS clinical trial group: Through this research program of the Clinic MS clinic patients can participate in innovative clinical trials that have resulted in major advances in therapy. In 2004 clinical trials included a study of _high dose interferon versus copaxone®_, _studies of new oral immunosuppressors and modulators and vaccines to induce tolerance to myelin proteins._

Rehabilitation Programs: Our rehabilitation team has been very active in setting-up the website of the International Consortium of MS Centers (T. Jiwa), as well as representing us on the Editorial Board of the Journal of MS Care (S. Forwell). S. Forwell is now doing her PhD in OT at UCSF (J.O. member of Committee) after focusing on MS fatigue (paper submitted). S. Burnham (PT) has presented at the Consortium of MS Centers meeting. Sandy Burnham has received the Silver Quill Award of the PT Association of Canada. Drs. Oger and Tremlett are recipients of a research grant from the MS Society of Canada. This grant will permit Dr. Tremlett to work on the World database on MS at the Sylvia Lowry Centre in Munich (Germany) where she will collaborate in 2005.

Neuro-immunology Laboratories: The lab has added new assays on antibodies to interferons fulfilling a need identified by the Canadian Network of MS clinics to have this testing available for clinical use in Canada.

Genetics of MS: Dr. Sadovnick, a Michael Smith Distinguished Scholar, has received a 3 million dollar grant from the MS Foundation of Canada to pursue further studies on the genetic
susceptibility to MS. She has also initiated a North American pregnancy registry under the auspices of the Consortium.

MS/MRI: The MS/MRI Research Group, directed by Drs. Li and Traboulsee, continues to provide internationally recognized high quality MRI analyses for multicentre research as well as developing a 4-terabyte database for future natural history studies. Innovative analytic techniques have been developed that allow semi-automated lesion load and brain volumetric measures. In collaboration with the Consortium of MS Centres, Drs. Li and Traboulsee have developed international guidelines for clinical MR imaging in the diagnosis and management of Multiple Sclerosis. The MS/MRI Research Group has fostered translational research in MS by supporting basic physics research (Alex MacKay) and pathological correlation studies (Drs. Moore and Dorovini-Zis).

Neurogenetics

The initiatives in Neurogenetics have brought together a group of researchers including Dr. Sian Spacey, Dr. Michelle Mezei, Dr. Blair Leavitt, Dr. Robin Hsiung, Dr. Dessa Sadovnick, Dr. Lynn Raymond and a group of genetic counselors.

At the UBCH the Neurogenetics clinic is a referral center for British Columbia providing over 300 outpatient visits in 2004. The patients seen have a wide range of inherited peripheral and central CNS disorders. The most common include the ataxias, channelopathies, hereditary spastic paraparesis, the phakomatoses, myotonic dystrophy, CMT, ALS, and mitochondrial disease. Many of these patients are participants in genetic research run through the UBC Neurogenetics Unit and have donated DNA to the clinic DNA bank. As well there are Neurogenetic arms of the Alzheimer and MS Clinics which provide genetic counseling to patients and families with these disorders.

The research focus of the program overall spans both translational and basic science research. Dr. Blair Leavitt has been involved in ongoing clinical research on the hereditary movement disorders, specifically the various forms of ataxias, hyperkinetic syndromes, and chorea-form disorders, as well as being involved in post-mortem studies of HD, SCA and FTD. His lab has directed attention at identifying novel forms of CAG repeat disorders and he has been involved in ongoing clinical trials looking for novel Biomarkers or testing new therapeutic agents.

Dr. Spacey’s primary clinical interests are the hereditary CNS disorders, in particular the ataxias and the channelopathies. Dr. Spacey runs a translational research program through the Neurogenetics clinic. The clinic is the point of contact between the patients and her basic science activity. The main focus of Dr. Spacey’s research is the molecular genetics of the channelopathies and ataxia. Dr. Spacey was recently awarded an operating grant from the CIHR to investigate the genetics and pathogenic mechanism of the paroxysmal dyskinesias. Additionally she holds operating grants from the National Ataxia Foundation (USA) and the Vancouver Costal Health Authority for investigation into the pathogenesis of the hereditary ataxias.

Dr. Mezei’s primary interest is in the hereditary neuromuscular diseases with a special interest in mitochondrial disease and ALS. She is currently involved in a number of research projects
ranging from Predictive Testing in SOD-1 familial ALS, to Comparison of brain MR spectoscopy with measurement of brain myelin content in individuals with cognitive deficits related to phenylketonuria.

**Neuromuscular Diseases Program**

The Neuromuscular Diseases Unit at VGH has a variety of specialized programs which attract patients from around the province for their care.

1. **Peripheral Neuropathy Program** – Drs. Chapman and Gibson continue to be active in the development of the Peripheral Neuropathy Clinic. They have several ongoing diabetic neuropathy and CIDP trials. The recruitment of Dr. Hannah Briemberg has added her expertise in nerve and muscle biopsy to the program.

2. **Myasthenia Gravis Program** – This program includes the MG Clinic at VGH which has expanded with the involvement of Drs. Oger, Gibson, Mezei, Chapman and Briemberg. Its current projects include a formal review of the clinical course of antibody negative myasthenia gravis and an epidemiological study of the incidence and course of myasthenia gravis in the Asian BC population.

3. **Muscle Diseases Program** – Dr. Briemberg additionally brings a new expertise to muscle diseases. Clinical muscle pathology Rounds are scheduled monthly and the NDU at VGH has strengthened its association with the pediatric neuromuscular program with Dr. Briemberg attending the weekly pediatric neuromuscular clinic at BCCH.

4. **ALS Program** – Drs. Gibson and Eisen have continued their successful activities in fundraising in support of the merged VGH-GF Strong ALS Clinic. These efforts have added to those of UBC, the Vancouver Hospital Foundation and the ALS Society of BC. The new Vancouver Coastal ALS Centre will open at the G.F. Strong site in March 2005. This clinic will stand as a legacy to the many contributions that Dr. Andrew Eisen made in the diagnosis and treatment of ALS patients throughout his career. Dr. Eisen formally retired as the Director of the ALS Clinic in December 2004 with Dr. Charles Krieger assuming the role of Interim Director. In addition to his active involvement in the ALS Clinic, Dr. Charles Krieger continues with his research in the murine mouse model of ALS and examining the role of protein kinases in the disease.

The Neuromuscular Diseases Unit and the UBC Division of Neurology will welcome Dr. Neil Cashman as the new Director of the Vancouver Coastal ALS Centre in July 2005.

Dr. Michelle Mezei has been active in her role as the Director of Residency Training in the Neuromuscular Program and electromyography. In addition to supervising weekly Neurophysiology Rounds, she is actively involved in the monthly Muscle Pathology Rounds and Clinical Neuromuscular Rounds. Dr. Mezei is further developing her focus in the metabolic myopathies and genetic neuromuscular diseases, attending clinics in the Adult Metabolic Diseases Unit and the Adult Neurogenetics Clinic at UBC.
Neuro-Oncology Program

The Neuro-Oncology program is a multidisciplinary program involving members of the Divisions of Neurology, Radiation Oncology, Neurosurgery and Medical Oncology. Its goal is to provide comprehensive care for patients with CNS malignancies and establish both clinical and translational research programs in Neuro-Oncology.

In the realm of patient care, the program has continued to supply patients with advanced surgical and radiotherapeutic management of brain tumors including a well-established linear accelerator based stereotactic radiation program. Molecular diagnostic technology has advanced our understanding of oligodendrogliomas and improved our management and chemotherapeutic strategies for these tumors.

Over the 2004 year, grant supported research into ILK inhibition in gliomas has completed with publication of results in peer-reviewed literature. Research into molecular genetic changes in oligodendroglioma and other gliomas is ongoing with grant support from the Brain Tumour Foundation of Canada.

New clinical research trials include a phase II trial of a novel tyrosine kinase inhibitor GW572016 for relapsed glioblastoma multiforme. A phase I trial using the oncolytic virus Reolysin in glioblastoma multiforme may open in 2005.

Neuro-Ophthalmology

The UBC Neuro-ophthalmology Division provides neuro-ophthalmic clinical, teaching, and research services at St. Paul’s Hospital Eye Clinic, Vancouver Hospital Eye Care Centre, UBC Hospital MS Clinic, and consulting services at VH, SPH, GF Strong and BC Children’s Hospital and outreach programs. There are 10 neuro-ophthalmology clinics per week. Medical students, ophthalmology and neurology residents and fellows rotate through the neuro-ophthalmology service and we supply approximately 60 hours of clinical teaching per week. During the year 2,150 patients were seen at SPH site, 640 at UBC site, 1,400 at Eye Care Centre site.

The neuro-ophthalmology members have all been involved with presentations both locally and nationally. The neuro-ophthalmology clinics continue to attract consultations from all over the province and provide an excellent database for ongoing research studies, as well as for teaching purposes. The program had 2 international clinical fellows and provided a remarkable teaching dossier of 1536 hours of instruction of fellows, 588 hours for residents and 688 for medical students.

Pacific Parkinson’s Research Centre

Teaching

The Movement Disorders Clinic provides ambulatory teaching to medical students and to residents in neurology, geriatrics, psychiatry and family medicine.
Faculty members of the Pacific Parkinson’s Research Centre participate in the Brain & Behaviour course and provide training to trainees at the MSc. and PhD. levels in the Experimental Medicine and Graduate Neuroscience programs. Dr. McKeown took over as co-director of the Motor Systems module of the Systems Neuroscience (Neuroscience 501) core course in the Graduate Neuroscience program. Faculty members within the Centre serve as mentors in the CIHR-funded Neuroscience Training Initiative. One of the first group of training award recipients has joined our program as a PhD student this past year.

Research

During the past year, successful CIHR grant applications included The Natural History of Sporadic and Inherited Parkinson’s (Stoessl/Lee et al.), Neural Mechanisms Underlying Response Changes to Levodopa in PD (Lee/Phillips et al.), and Development of Radiotracers based on Oligonucleotide Labeling (Ruth et al.). Additionally, both Drs. Sossi and Ruth obtained NSERC funding, for Quantitative High Resolution PET Imaging and Gas Targetry, respectively. The Centre was awarded one of only a few National Parkinson Foundation Center of Excellence awards. This award provides support for clinical services and outreach, as well as a research award to Dr. McKeown for Spatial & Temporal Aspects of Compensatory Mechanisms in PD. Finally, Dr. McKeown is co-PI on a successful CFI application for development of a Biomedical Signal and Image Computing Laboratory.

One of the major collaborations of our Centre is with the neurogenetics program at the Mayo Clinic, Jacksonville. During the past year, this collaboration resulted in identification of a novel gene mutation underlying dominantly inherited Parkinson’s. The paper describing this mutation appeared in Neuron. Imaging studies helped identify preclinical disease in some members of the pedigrees that were studied.

The backbone of the Centre’s research program continues to be the close partnership with the UBC-TRIUMF PET program. During the past year, development work and preliminary experiments were conducted on the new small animal PET tomograph, as well as the high-resolution, high sensitivity human research tomograph. Dr. Doudet has continued work on understanding the mechanisms underlying benefit from retinal pigmented epithelial cell implants and electroconvulsive therapy in PD.

In addition to our basic and imaging research program, a number of clinical trials continued.

Clinical

The Movement Disorders Clinic provided more than 3,500 outpatient visits in 2004. The majority of these are for patients with Parkinson’s disease or focal dystonia. This reflects on the increasing emphasis on outpatient care with the extremely restricted access to in patient beds. The program is heavily supported by nurse coordinators, who provide education and counseling to patients, families and other health care professionals.
Epilepsy

The comprehensive Epilepsy Program was established almost 20 years ago by Dr. Sherrill Purves and Dr. Barry Woodhurst, with assistance from hospital administration, and with funding from the B.C. Government to recognize the uniqueness of this program. Dr. Michael Jones is currently the program director.

This multidisciplinary program is the only one in the province that evaluates patients for surgical epilepsy management. The Epilepsy Program team includes Dr. W. Barry Woodhurst (Neurosurgery), Dr. David Katz (Neuropsychologist), and Dr. Mano Javidan (Epilepsy Neurologist). The program benefits from an excellent nurse clinician in Janice Henrikson, plus the unique expertise and support of the EEG technology service. There is capable administrative support from Jean A’Bear.

Epilepsy Education is a very important and active part of the program. Both Dr. Jones and Javidan provide CME around the province and country. Dr. Woodhurst is currently doing a large in-depth analysis of program’s surgical results.

Over the past year a new state of the art digital telemetry system has been implemented.

The program also assists patients with “fits, faints, and funny turns”, and specifically the topic of non-epileptic seizures, a spectrum of problems that are costly and labour intensive to reconcile diagnostically. In its clinical research the program participates in multicenter drug trials of emerging therapeutics for epilepsy.

SPH Research

A number of clinical research projects are ongoing at SPH including neuroprotective studies in cerebrovascular disease, and carnitine use in HIV and AIDS related peripheral neuropathy.

Basic Neurosciences

The lab of Dr. Yu Tian Wang has continued to receive international accolades with outstanding academic productivity. Dr. Wang’s research focuses on understanding the molecular mechanisms responsible for regulating the function and intracellular trafficking of neurotransmitter receptors critical for brain functions such as learning, memory and cognition. He is investigating the manner by which these mechanisms may be altered in central nervous disease processes. His goal is to be able to treat central nervous disorders such as stroke, epilepsy and drug addiction by designing new therapeutics which specifically target these receptors and their pathways. Amongst his current lab projects is a study of the molecular mechanisms mediating neuronal death following stroke. A major research focus of this project is to develop new therapeutic agents that will interfere with cell-death inducing glutamate receptor signaling pathways by disrupting interactions of the glutamate receptors, particularly the NMDA subtype (NMDAR), with scaffolding and signaling proteins. His lab has been a strong training environment with 3 post doctoral fellows appointed in 2004.
Appointments and Promotions

Dr. Anthony Traboulsee was promoted from the rank Clinical Instructor to Clinical Assistant Professor with effect from July 1, 2004.

Dr. Jason Barton was appointed to the rank of Associate Professor with effect from September 1, 2004.

Dr. Hannah Briemberg was appointed to the rank of Clinical Assistant Professor with effect from October 1, 2004.

Dr. Robin Hsiung was appointed to the rank of Assistant Professor with effect from September 1, 2004.

Dr. Helen Tremlett was appointed to the rank of Assistant Professor with effect from October 1, 2004.

Dr. Bradley Hallam was appointed to the rank of Clinical Instructor with effect from July 1, 2004.

Dr. Penelope Smyth was appointed to the rank of Clinical Instructor with effect from September 1, 2004.

Special Honours and Awards

Dr. Doris Doudet served as External Reviewer, National Institute of Health (NIH) - Center for Scientific Research as well as serving as an External Reviewer, CIHR, BSB in October 2004.

Dr. Philip Teal was awarded the Donald M. Whitelaw Award for Outstanding Grand Rounds Presentation in the UBC Department of Medicine in 2004.

Dr. Gillian Gibson was awarded the Master Teacher Award in the UBC Department of Medicine for 2004.

Dr. Lynn Raymond was promoted to the rank of Full Professor and was awarded the Killam Research Prize, Senior Science Category in the amount of $5000 in 2004.

Dr. Charles Krieger won the Vancouver Hospital and Health Science Centre and University of British Columbia Scholarship Award in 2004.

Dr. Gordon Robinson was the chair and convener at the 2004 Annual Forefronts in Neurology meeting for the neurologists of BC.

Dr. Howard Feldman convened a national conference on regulatory guidelines for the development of antidementia drugs in Canada. This conference received peer reviewed funds from Canadian Institutes of Health Research (CIHR) Institute on Aging. He was invited to deliver plenary lectures at the 9th International Conference on Alzheimer’s Disease and Related
Disorders as well as the 7th International Springfield Montreal Conference on Therapy in Alzheimer’s Disease.

Dr. Helen Tremlett was awarded a travel grant for young investigators (Euro400) by the ECTRIMS Scientific Committee to attend the annual conference in Vienna 2004.

Dr. Y.T. Wang was awarded the J.A.F. Stevenson Professor of the Canadian Physiological Society and the UBC Killam Research Prize in 2004.

Dr. Donald W. Paty was awarded the Meritorious Service Decorations (civil division) by the Governor General of Canada in 2004.

Dr. Colleen Murphy became a diplomate of the American Board of Psychiatry and Neurology.

Dr. Mano Javidan holds the positions of Examiner, Canadian Society of Clinical Neurophysiology-EEG and Evoked Potentials, Secretary Treasure Canadian Society of Clinical Neurophysiology, Member of Executive Board, Canadian Congress of Neurological Sciences, Member, Liaison Committee, Canadian Congress of Neurological Sciences and Vice Chair, Diagnostic Accreditation Program (Neurodiagnostics), British Columbia, 2004.

Dr. Martin McKeown was awarded a large peer reviewed grant from the Canadian Foundation of Innovation New Opportunities Fund and the BCKDF with contributions, cash and in kind, from the Department of Electrical and Computer Engineering, the Brain Research Center (Facility of Medicine/UBC Hospital), ICICS, and equipment vendors. This funding will be used to equip the Biomedical Signal and Image Computing Lab (BiSICL). He was also awarded the Vancouver Coastal Health Research Institute Interdisciplinary Award for a project on the novel assessments of motor performance in patient populations.
Dr. Theo van Rijn
Clinical Assistant Professor & Head

Faculty Members

Clinical Assistant Professor & Head: van Rijn, Dr. Theo
Clinical Associate Professor: Anton, Dr. Hubert
Clinical Associate Professor: Hahn, Dr. George
Clinical Associate Professor: Schamberger, Dr. Wolfgang
Clinical Associate Professor: Travlos, Dr. Andrew
Clinical Assistant Professor: Dhawan, Dr. Pankaj
Clinical Assistant Professor: Hirsch, Dr. Gabriel
Clinical Assistant Professor: Jung, Dr. Susan
Clinical Assistant Professor: Mortifee, Dr. Peter
Clinical Assistant Professor: Townson, Dr. Andrea
Clinical Assistant Professor: Vondette, Dr. Michael
Clinical Assistant Professor: Weeks, Dr. Claire
Clinical Instructor: Adrian, Dr. Mark
Clinical Instructor: Crossman, Dr. Mark
Clinical Instructor: Dawson, Dr. Andrew
Clinical Instructor: Hughes, Dr. Barbara
Clinical Instructor: Koo, Dr. David
Clinical Instructor: Lau, Dr. Herman
Clinical Instructor: O'Connor, Dr. Russell
Clinical Instructor: Reebye, Dr. Nittin
Clinical Instructor: Underwood, Dr. Heather
Clinical Instructor: Weiss, Dr. Elliott
Clinical Instructor: Willms, Dr. Rhonda
Clinical Instructor: Yao, Dr. Jennifer
Honorary Professor: Kaplan, Dr. Paul
Associate Member: Eng, Dr. Janice
Associate Member: Miller, Mr. William
Associate Member: Yassi, Dr. Annalee
Professor (Emeritus): Murray, Dr. Duncan
Clinical Professor (Emeritus): Robinson, Dr. Cecil
Clinical Associate Professor (Emeritus): Pinkerton, Dr. Alexander
Divisional Overview

The UBC Division of Physical Medicine & Rehabilitation currently has twenty-four active faculty members who are involved with patient care, teaching and research. Our members consult and provide rehabilitation services to persons ranging from the very young to the very old. We manage inpatient and outpatient programs for persons who have suffered spinal cord injury, acquired brain injury, neuromuscular abnormalities and cardio/pulmonary dysfunction. Inpatient services are provided at several sites, including Vancouver Acute/GF Strong Rehab Center, St. Paul’s Hospital, Holy Family Hospital, Eagle Ridge Hospital, Sunny Hill Health Center, as well as consultation services to the Vancouver teaching hospitals, BC Children’s Hospital, Royal Columbian Hospital and Burnaby General Hospital. Our staff is actively involved in teaching of residents and undergraduate students, as well as undergraduate students in related disciplines. Research activity deals with disease specific issues related to our patient population, as well as disability issues for the population at large.

Undergraduate

Dr. David Koo has continued to serve as the Undergraduate Coordinator. Nine members of our Division participated in the Undergraduate curriculum including half-day lectures on disability, impairment and handicap, problem-based learning, MSK clinical skills sessions, mentorship and specialty-specific discussions on impairment and disability. Our Division continues to be actively involved in teaching elective medical students who have an interest in our specialty.

Postgraduate

There were seven residents in the program at the end of 2004. All residents from PGY2 onwards now have a formal half day of research experience throughout their academic years. Resident teaching is done at the bedside and in ambulatory clinics. Formalized seminars are undertaken during weekly Academic Half Days. Residents continue to participate in a scheduled monthly Journal Club supervised by members of the Division, in order to learn critical assessment of journal articles.

Four of our Physiatry residents were active at the Annual Department of Medicine Research Day. Dr. Andrei Krassioukov won an award for ‘Best Resident Presentation – PGY3/4.’ Our residents also participated in the Canadian Association of Physical Medicine & Rehabilitation Annual Meeting on a yearly basis.

Continuing Medical Education

Dr. Theo van Rijn served as a coordinator for CPD activities for the Division in the academic year. Our Division continues to enjoy a vibrant CPD schedule attended by Division and non-Division members who have an interest in topics presented. The CPD Committee meets bi-annually to review upcoming CPD activities and to formulate ways to enrich ongoing education of our membership. The CPD committee continues to encourage members to develop innovative teaching methods, as well as utilizing panel discussions and experts from other sub-specialties for broader educational experience.
Research

Dr. Hugh Anton served as the Research Coordinator and Chair of the UBC/PM&R Divisional Research Committee and helped organize monthly Committee meetings for the Division. Collectively the Division has embarked on several projects that share common interest to our members.

Caroline Abramson and Catherine Tadey served as Research Coordinators for Divisional Research and Research activities during the year.

Dr. Drew Dawson was the principal investigator of 1 research project dealing with cardiovascular fitness following stroke and co-investigator of 2 research projects at GF.

Dr. David Koo was principal investigator of one study involving spinal epidural abscess.

Dr. Andrew Travlos was principal investigator of two studies: one dealing with spasticity and another with care issues regarding ALS patients.

Dr. Andrea Townson was co-investigator of 2 research projects dealing with issues regarding spinal cord dysfunction.

Dr. Andrei Krassioukov, PGY4, was the primary investigator of six research projects dealing with neurological dysfunction following brain and/or spinal cord injury, as well as co-investigator in one other spinal cord related project.

Clinical Services

Many members of our Division continue to provide consultation services to Vancouver Acute, St. Paul’s Hospital, as well as other hospitals in the Fraser Health Authority. Dr. Elliot Weiss is the leader for rehabilitation of Providence Health Care. Dr. Travlos and team members continue to provide clinical services and direction to the rehabilitation programs for persons suffering from ALS. While Drs. Rhonda Willms and Heather Underwood took maternity leave absences this year, they have actively supported and will continue to participate in services for persons requiring orthotics and/or prosthetics. Dr. George Hahn continues to provide consultation services for the BC Children’s Hospital, Vancouver Acute, and Sunnyhill Health Center.

Administration

Dr. Andrew Travlos served as a Chair of Specialty Committee in Physical Medicine & Rehabilitation of the Royal College of Physicians and Surgeons of Canada.

Dr. Pankaj Dhawan served as examiner for the Specialty of PM&R at the Royal College.

Dr. Gabriel Hirsch served as Chair of the Section of PM&R for the BC Medical Association.

Dr. Theo van Rijn served as the Medical Director of GF Strong Rehab Center, as well as Head, Division of PM&R.
Drs. Andrea Townson, Andrew Travlos, and Rida Baruni served as medical managers assisting in program related issues at G.F. Strong Rehabilitation Center.

**Special Honours and Awards**

Drs. Theo van Rijn and Pankaj Dhawan were invited speakers at the Annual Canadian Association of PM&R Conference in Prince Edward Island in June 2004.

Drs. Janice Eng, Bill Miller and Annalee Yassi were appointed Associate Members of the Division Physical Medicine & Rehabilitation. Drs. Eng and Miller, both faculty of the School of Rehabilitation Sciences, are actively involved with mentoring and collaborating in research with many of our members. Dr. Annalee Yassi, has a specialty in Community & Occupational Medicine. She will be teaching our residents and joining us in some collaborative research projects in years to come.

**Future Directions**

Following a successful retreat in December 2004, the Division will be undertaking a new initiative in Undergraduate Education. Selected second year medical students will be given the opportunity to answer physical exam skills by participating in a collaborative staff/resident teaching project undertaken by Division members in a pilot project.

The Division also is undertaking a longer term initiative to foster a post-graduate education/teaching initiative which will be part of a larger national endeavor to promote academic excellence in our specialty.
### RESPIRATORY MEDICINE

**Dr. John Fleetham**  
**Professor & Head**

**Faculty Members**

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor &amp; Head</td>
<td>Fleetham, Dr John</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Bai, Dr. Tony</td>
<td>SPH</td>
</tr>
<tr>
<td>Professor</td>
<td>Duronio, Dr. Vincent</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Fitzgerald, Dr. J. Mark</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Lam, Dr. Stephen</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Man, Dr. Paul S F</td>
<td>SPH</td>
</tr>
<tr>
<td>Professor</td>
<td>Ostrow, Dr. David</td>
<td>VA</td>
</tr>
<tr>
<td>Professor</td>
<td>Pare, Dr. Peter</td>
<td>SPH</td>
</tr>
<tr>
<td>Professor</td>
<td>Road, Dr. Jeremy</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Khalil, Dr. Nasreen</td>
<td>BCCDC</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Levy, Dr. Robert</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Ryan, Dr. Francis (Frank)</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Sin, Dr. Donald</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Van Eeden, Dr. Stephan</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Ward, Dr. Helen</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Wilcox, Dr. Pearce</td>
<td>SPH</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Ayas, Dr. Najib</td>
<td>VA</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Cook, Dr. Victoria</td>
<td>VA</td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Sandford, Dr. Andrew</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Professor</td>
<td>Champion, Dr. Paul</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Professor</td>
<td>Lawson, Dr. Lindsay</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Elwood, Dr. Richard</td>
<td>BCCDC</td>
</tr>
<tr>
<td>Clinical Associate Professor</td>
<td>Nakielna, Dr. Barbara Edina</td>
<td>SPH</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Fera, Dr. Tharwat</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Assistant Professor</td>
<td>Turner, Dr. Mark</td>
<td>VA</td>
</tr>
<tr>
<td>Clinical Instructor</td>
<td>Wilson, Dr. Jennifer</td>
<td>VA</td>
</tr>
<tr>
<td>Honorary Professor</td>
<td>Lertzman, Dr. Morley</td>
<td>VA</td>
</tr>
<tr>
<td>Honorary Professor</td>
<td>Tan-Hogg, Dr. Wan</td>
<td>SPH</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Brauer, Dr. Michael</td>
<td>Vancouver</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Lowe, Dr. Alan</td>
<td>Vancouver</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Muller, Dr. Nestor</td>
<td>VA</td>
</tr>
<tr>
<td>Associate Member</td>
<td>Roberts, Dr. Clive</td>
<td>Vancouver</td>
</tr>
</tbody>
</table>
Visiting Scientist: De Jong, Dr. Pieter Arie (Pim)
Professor (Emeritus): Abboud, Dr. Raja VA
Professor (Emeritus): Bates, Dr. David
Professor (Emeritus): Yeung, Dr. Moira VA
Clinical Professor (Emeritus): Allen, Dr. Edward

Divisional Overview

The UBC Respiratory Division consists of 31 faculty members who are located at Vancouver Acute (Vancouver General Hospital, UBC Hospital), Providence Health Care (St. Paul’s Hospital, Mt. St. Joseph Hospital) Vancouver Cancer Centre, BC Centre for Disease Control and BC Transplant Society. There are active respiratory medicine in-patient and ambulatory care programs at Vancouver General Hospital and St. Paul’s Hospital. The two year subspecialty respiratory medicine training program accepts one provincially funded trainee per year. Respiratory Medicine is considered a centre of research excellence at both Providence Health Care and Vancouver Acute. Respiratory Medicine is a major component in the iCapture Centre primarily based at St. Paul’s Hospital. Respiratory Medicine is the primary component of the Lung and Critical Care Research Program at Vancouver Coastal Health Institute. The UBC Respiratory Division is developing a strategic plan for clinical care, research and teaching of Respiratory Medicine within the Vancouver Coastal Health Authority, which incorporates an academic funding contract for all divisional members. Dr. Paul Man was appointed Head of Medicine, Providence Health Care March 1st 2004, and is also a member of the UBC Respiratory Division. Dr. Victoria Cook joined the UBC Respiratory Division July 1st 2004 and performs research and clinical work with the Division of TB Control, BC Centre for Disease Control and is also based at VGH.

Teaching

Undergraduate: The UBC Respiratory Division continues to have a major responsibility for the five week pulmonary block in the undergraduate curriculum. Dr. F. Ryan continues as chair of the pulmonary block. Division members participate in undergraduate teaching either as tutors or clinical skills instructors.

Postgraduate: The UBC Respiratory Medicine Training Program, directed by Dr. P. Wilcox, continues to attract a large number of highly qualified applicants from across Canada. The program has full approval from the Royal College. This two year clinical program is based at both Vancouver General Hospital and St. Paul's Hospital. There are elective opportunities at community based centres throughout BC and the program offers an optional third year of research training. Our current trainees are Dr. M. Al Ajmi (Kuwait), Dr. T. Shaipanich (Thailand), Dr. J. Swiston (Vancouver), Dr. M. Molavi (Omaha, NE). The UBC Respiratory Division proposes to expand the number of trainees from one to two per year and to offer a three year combined fellowship program in Respiratory Medicine/ICU.

Experimental Medicine: The UBC Respiratory Division continues to make significant contributions to the Departmental Experimental Medicine program with MSc. and PhD students being trained in both the Jack Bell Research Laboratory at Vancouver General Hospital and the iCapture Centre at St. Paul's Hospital.
**Continuing Medical Education:** Dr. Mark FitzGerald is primarily responsible for continuing medical education within the UBC Respiratory Division and organizes a three day annual international CME course on critical care and respiratory medicine in spring at Whistler. A weekly research seminar series for the UBC respiratory community is held between September-May. Division members are very active in CME in a large variety of provincial, national and international forums.

**Research**

Respiratory Medicine is considered a centre of research excellence at both Providence Health Care and Vancouver Acute. Respiratory Medicine is a major component in the iCapture Centre primarily based at St. Paul’s Hospital. Respiratory Medicine is the primary component of the Lung and Critical Care Research Program at Vancouver Coastal Health Institute (VCHI). The iCapture Centre was created with CFI funds to examine how abnormal genes change the structure and function of cells, tissues and organs to cause lung disease. The major respiratory medicine research interests at the VCHI Lung and Critical Care Research Program are respiratory sleep and neuromuscular disease, environmental and occupational lung disease and emphysema. The prevention and early diagnosis of lung cancer is the primary research focus at the Vancouver Cancer Centre and research into tuberculosis and mycobacterial disease is the major interest at the BC Centre for Disease Control. Research in lung transplantation takes place at both Vancouver Acute and the BC Transplant Society.

**Clinical Services**

Active respiratory medicine in-patient and ambulatory care programs continue at both Vancouver General Hospital and St. Paul's Hospital. Ambulatory care space has been developed within St. Paul’s Hospital for the members of the St. Paul’s Hospital Respiratory Division.

**Administration**

Dr. John Fleetham is the Head of the UBC Respiratory Division. Dr. Robert Levy is Head of the Providence Health Care Respiratory Division. Dr. Mark FitzGerald took over leadership of the Vancouver Acute Respiratory Division effective July 1, 2004. Bernice Robillard continues to work to support the administrative activities of the UBC Respiratory Division with major responsibilities for the postgraduate program. An external review of the UBC Respiratory Division was performed in November by Dr. Denis O’Donnell and Dr. Paul Keown.

**Future Directions**

The UBC Respiratory Division proposes to develop a strategic plan for clinical care, research and teaching of Respiratory Medicine within the Vancouver Coastal Health Authority, which incorporates an academic funding contract for all divisional members.

**Special Honours And Awards**

Dr. Najib Ayas was the recipient of a Michael Smith Health Research Foundation Scholar award. Dr. Victoria Cook was awarded a VCHRI In-It-For-Life Mentored Clinician Scientist award. Dr.
Mark FitzGerald was awarded a Michael Smith Health Research Foundation Distinguished Scholar Award. Dr. John Fleetham headed a group of UBC Respiratory Medicine members and was awarded a Michael Smith Health Research Foundation Research Unit award for Respiratory Sleep Disorders. Dr. Peter Pare was awarded the 2004 UBC Killam Research Prize. Dr. Jennifer Wilson was the recipient of a Department of Medicine Academic Enhancement Fund award. Dr. Stephan van Eeden was awarded the Martin M. Hoffman Award for Excellence in Research.
RHEUMATOLOGY

Dr. John M. Esdaile
Professor & Head

Faculty Members

Professor & Head
Professor & Head Esdaile, Dr. John VA

Professor
Professor Chalmers, Dr. Andrew VA

Assistant Professor
Assistant Professor Cibere, Dr. Jolanda VA

Assistant Professor
Assistant Professor Lacaille, Dr. Diane VA

Clinical Professor
Clinical Professor Blocka, Dr. Kenneth VA

Clinical Professor
Clinical Professor Koehler, Dr. Barry Richmond General

Clinical Associate Professor
Clinical Associate Professor Huang, Dr. Simon SPH

Clinical Associate Professor
Clinical Associate Professor Patterson, Dr. A. Caroline VA

Clinical Associate Professor
Clinical Associate Professor Reid, Dr. Graham VA

Clinical Associate Professor
Clinical Associate Professor Shojania, Dr. Kamran VA

Clinical Associate Professor
Clinical Associate Professor Wade, Dr. John VA

Clinical Assistant Professor
Clinical Assistant Professor Ensworth, Dr. Stephanie VA

Clinical Assistant Professor
Clinical Assistant Professor Kelsall, Dr. John SPH

Clinical Assistant Professor
Clinical Assistant Professor Klinkhoff, Dr. Alice VA

Clinical Assistant Professor
Clinical Assistant Professor Shuckett, Dr. Rhonda SPH

Clinical Instructor
Clinical Instructor Fenton, Dr. Stanley RCH

Clinical Instructor
Clinical Instructor Gillies, Dr. Jean SPH

Clinical Instructor
Clinical Instructor Watterson, Dr. John VA

Honorary Professor
Honorary Professor Stein, Dr. Howard

Visiting Professor
Visiting Professor Pouchot, Dr. Jacques

Associate Member
Associate Member Kopec, Dr. Jacek

Professor (Emeritus)
Professor (Emeritus) Ford, Dr. Denys

Clinical Professor (Emeritus)
Clinical Professor (Emeritus) Robinson, Dr. Harold

Clinical Professor (Emeritus)
Clinical Professor (Emeritus) Tsang, Dr. Ian

Divisional Overview

The UBC Division of Rheumatology has 18 active faculty members, one associate member, 3 emeritus members, and one honorary member. Rheumatology consultation services are offered at Vancouver Acute, St. Paul’s Hospital, BC Women’s Hospital & Health Centre, and G.F. Strong Rehabilitation Centre. Ambulatory care services are available at the Mary Pack Arthritis Centre, St. Paul’s Hospital, BC Women’s Hospital & Health Centre, and in private practices throughout
Vancouver. The Arthritis Society (BC & Yukon Division) provides excellent patient education and resources available through the Learning Centre based at the Mary Pack Arthritis Centre.

Many divisional faculty are members of the Arthritis Research Centre of Canada (ARC), a multidisciplinary clinical research and clinical trials facility affiliated with both the University of British Columbia and the Vancouver Coastal Health Research Institute. ARC is based at the Mary Pack Arthritis Centre. It includes faculty from Rheumatology, Orthopaedics, Epidemiology & Health Care, Pharmaceutical Sciences and the School of Rehabilitation Sciences. ARC focuses on "Practical Research for Everyday Living" for people with arthritis.

The two-year Postgraduate Training Program in Rheumatology continues to be the second-largest clinical rheumatology training centre in Canada. The program accepts one Ministry-funded trainee every year and two trainees funded by The Arthritis Society of Canada as well as one to two internationally-funded trainees. Active in-patient, ambulatory care and research training is done at Vancouver Acute, St. Paul’s Hospital, G.F. Strong, BC Women’s Hospital & Health Centre, the Arthritis Research Centre of Canada, and in private practices throughout the Lower Mainland and elsewhere in the province.

In recognition of his many contributions, Dr. Ian Tsang was honoured with an appointment as a Clinical Professor Emeritus at the University of British Columbia. Dr. Andrew Chalmers was promoted to full Professor of Medicine (see “Distinctions and Awards” for further details). Dr. Jolanda Cibere was newly appointed in 2004 as an Assistant Professor of Medicine upon completing her PhD in Health Care & Epidemiology on the topic of the effectiveness of glucosamine sulfate in osteoarthritis of the knee. She has also joined the active staff at Vancouver Acute. As well, Dr. Kam Shojania was promoted to Clinical Associate Professor. Dr. Jacques Pouchot, a Visiting Professor to the Division from August 2003 to August 2004, completed his sabbatical and returned to Paris. His interaction with the Division members and the mentorship he provided to the trainees will be greatly missed.

Teaching

Dr. Simon Huang continues to direct undergraduate rheumatology program with several members of faculty teaching in the Musculoskeletal Block each year. In 2004, the Vancouver Acute training program adopted the Patient Partners Program, an arthritis consumer-led seminar designed to teach medical students and residents the basics of musculoskeletal examination early in their rotation. Dr. Kenneth Blocka has led this program for several years and has been using it with great success in the St. Paul’s Hospital training program. The Vancouver Acute group found it similarly beneficial and has noted improved musculoskeletal examination skills in residents rotating through the service.

Dr. John Esdaile continues as the Program Director for the Postgraduate Training Program and the hospital programs continue to be led by Drs. Kenneth Blocka and John Esdaile at SPH and VHHSC, respectively. This year, Dr. John Watterson took on the role of hospital program director at G.F. Strong. We would like to thank Dr. Graham Reid for many years of dedicated service in this capacity. He continues to be a valued teacher in many other areas of the postgraduate program.
The postgraduate program is currently comprised of three first-year residents, two second-year residents, and two doctoral candidates. We expect three new residents to commence in July 2005. The clinical trainees continue to be involved in outreach clinics in Trail, Cranbrook, Fort St. John and other rural communities throughout B.C. Both UBC and The Arthritis Society (BC & Yukon Division) provided support for travel and accommodation for these outreach clinics. The residents also participate in mandatory rotations at Vancouver Acute, St. Paul’s Hospital, G.F. Strong, BC Children’s Hospital, Allan McGavin Sports Medicine Centre, and in numerous drug/disease monitoring clinics and community rheumatology practices throughout their training.

For the fourth year, a basic skills course for rheumatology fellows was given in the first week of July to provide detailed instruction on the clinical examination of the musculoskeletal exam, as well as the essentials of emergency arthritis care. The course was organized by Dr. Kam Shojania and involved the majority of the divisional faculty.

Dr. Janet Pope from the University of Western Ontario visited in May 2004 to perform mock oral examinations for the clinical fellows. This two-day event, which included a physical examination seminar, mock oral examinations, noon rounds and academic half-day teaching, was extremely helpful and much appreciated. Dr. Howard Stein acted as the Co-Examiner.

Dr. Raheem Kherani, a second-year rheumatology clinical fellow, developed a website for the rheumatology program to facilitate teaching and communication between trainees. This has received high praise both from the other trainees and from the Postgraduate Medical Education Office. Similar designs are being considered for other programs. The trainees and the faculty have now completed the development of new comprehensive learning objectives for all the rotations.

Dr. Howard Stein continues to volunteer his time teaching the clinical fellows every week at the weekly Academic Half-Day. The clinical fellows have also benefited from weekly guest speakers from many other divisions at their Academic Half-Day. As well, both the Division and the postgraduate program have benefited from a number of visiting professors including Drs. Nancy Lane (University of California, San Francisco), Walter Maksymowych (University of Alberta), Hyon Choi (Harvard University), Art Lipman (University of Utah), Janet Pope (University of Western Ontario), Sasha Bernatsky (McGill University), Eric Sasso (formerly University of Washington), and Rick Adachi (McMaster University).

Research

Members of the Division continue to be active in the Arthritis Research Centre of Canada (ARC). ARC includes faculty from the Division of Rheumatology, the Department of Orthopedics, the Department of Epidemiology and Health Care, the Department of Pharmaceutical Sciences and the School of Rehabilitation Sciences, as well as from the Centre for Health Evaluation and Outcome Studies at St. Paul’s Hospital and the Centre for Clinical Epidemiology and Evaluation at Vancouver Acute.

Current research includes a large team grant involving researchers from across Canada evaluating the development and treatment of early osteoarthritis.
Dr. John Esdaile, Dr. Jolanda Cibere and others received a grant from the Canadian Institutes of Health Research to study prevention of knee injuries in young soccer players. Dr. Esdaile and others also received funding from the Lupus Research Institute to develop a virtual network between lupus researchers around North America.

The Canadian Foundation for Innovation funded a $5.2 million infrastructure grant to build the Centre for Hip Health at the Vancouver Acute site (PI: Dr. Thomas Oxland), and all the members of the Arthritis Research Centre of Canada were participants. A secondary hospital competition later in the year was also successful bringing the total award to $10.8 million.

Dr. Jolanda Cibere received funding from The Arthritis Society of Canada to continue her study of MRI and value of biomarkers in assessing progress in knee osteoarthritis. She, Dr. Ian Tsang and Dr. John Esdaile received funding from the Lotte & John Hecht Foundation to study the effect of the Chinese herb, *Tripterygium wilfordii*, in rheumatoid arthritis in collaboration with researchers at the Guangdong University of Traditional Chinese Medicine in Guangzhou, China. Finally, Dr. Cibere was awarded a Clinician Scientist Phase II Award from the Canadian Institutes for Health Research as well as a Department Scholar Award from the UBC Department of Medicine.

Dr. Jacek Kopec, a clinical epidemiologist and Associate Member of the Division of Rheumatology, received funding from the Canadian Institutes of Health Research to study physical activity and joint health using an adaptive web-based tool that he has developed. He also received funding from the Workers’ Compensation Board to measure quality of life in patients suffering from back pain.

Dr. Antonio Avina-Zubieta, a rheumatologist from Mexico, began doctoral studies in the Department of Experimental Medicine and will be working closely with Dr. Diane Lacaille.

This year, the Canadian Arthritis Network went through the grueling process of applying for renewal of funding from the Networks of Centres of Excellence. Dr. John Esdaile formed part of a small team that was responsible for this application, which was successfully renewed for a second seven-year term.

Drs. Maziar Badii, Ken Blocka, Andrew Chalmers, Jan Dutz, John Kelsall, Alice Klinkhoff, Graham Reid, and Kam Shojania continue to study novel modalities for persons with arthritis in BC. There are over 50 new biologic therapies that are currently either in the development or testing phase and our clinical trials group is participating in the testing of several of these for use in rheumatoid arthritis and other inflammatory conditions such as psoriatic arthritis, ankylosing spondylitis and systemic lupus erythematosus. They are also involved in trials of treatments for osteoarthritis and chronic pain.

**Clinical Services**

The Mary Pack Arthritis Centre (operated by Vancouver Coastal Health) is the largest centre for ambulatory care in the province headed up by Dr. Alice Klinkhoff. Many faculty members from both Vancouver Acute and St. Paul’s Hospital participate in the programs offered here. Extensive drug monitoring and disease monitoring clinics have been established, several of
which have developed international reputations. Dr. Andrew Chalmers is the Director of the world’s largest Cyclosporine Monitoring Program and Dr. Alice Klinkhoff is pursuing innovative methods of treatment in the Gold Clinic. Dr. Stephanie Ensworth is the Director of the Provincial Lupus Program, one of 9 such programs across Canada participating in coordinated lupus research. In addition, arthritis-specific treatment services offered in physiotherapy, occupational therapy, social work, patient education and vocational counseling are valuable resources for the members of the Division and their patients. This program also coordinates the travels of divisional faculty to 28 rural locations throughout the province to provide consultation and treatment services.

Several ambulatory care clinics are also offered at St. Paul’s Hospital for scleroderma (run by Dr. James Dunne) and low back pain (run by Dr. Jean Gillies) as well as a rapid-access program (run by Dr. John Kelsall). Dr. Stephanie Ensworth runs the Reproductive Rheumatology Clinic (one of only two such clinics in Canada) and the Rheumatic Diseases in Pregnancy Program at BC Women’s Hospital & Health Centre.

The Arthritis Unit at G.F. Strong Rehabilitation Hospital offers post-operative and rehabilitative services to rheumatology patients along with specialized physiotherapy, occupational therapy and vocational counseling. In-patient services are offered at Vancouver Acute, St. Paul’s Hospital, and BC Women’s Hospital & Health Centre.

Administration

Dr. John Esdaile is Head of the UBC Division of Rheumatology, the Vancouver Acute Division of Rheumatology, and the UBC Postgraduate Training Program in Adult Rheumatology. Dr. Ken Blocka is the Head of the St. Paul’s Hospital Division of Rheumatology and also oversees the hospital training program there. Dr. John Watterson oversees the hospital training program at G.F. Strong Hospital. Dr. Alice Klinkhoff is Director of the Mary Pack Arthritis Centre. Dr. John Esdaile is also the Scientific Director of the Arthritis Research Centre of Canada.

Future Directions

In 2005, the Division will continue to pursue excellence in research, teaching and clinical care. A rapid-access clinic for rheumatoid arthritis patients is under consideration. We expect the Mary Pack Chair in Rheumatology Research (endowed by The Arthritis Society, BC & Yukon Division) to be filled this year. In addition to an academic appointment in the UBC Division of Rheumatology, the Chair will also be appointed to the Vancouver Acute and the Arthritis Research Centre of Canada. The Arthritis Research Centre of Canada is looking forward to breaking ground for the new Centre for Hip Health in the summer of 2005.

Distinctions and Awards

Dr. Maziar Badii completed his Masters of Health Sciences degree in the Department of Health Care and Epidemiology in November 2004. He will be appointed as Clinical Assistant Professor in the Division of Rheumatology in the coming year. He will continue his research on low back pain.
In recognition of his many contributions to both the UBC Division of Rheumatology as Past Head and the UBC Medical School as Past Associate Dean of Undergraduate Medicine, Dr. Andrew Chalmers was promoted to full Professor of Medicine. Dr. Chalmers was key in the development of the new Undergraduate Medicine curriculum for the UBC Medical School and has played a major role in the continued excellence of the UBC Rheumatology Training Program.

Dr. Jolanda Cibere was awarded the Vancouver Coastal Health Research Institute’s Prize for Graduating Doctoral Students for her work on the efficacy of glucosamine sulfate. Dr. Cibere was also honored with a Young Innovator Award from the Networks of Centres of Excellence. She was one of only three young Canadian scientists to receive this award and was presented with this award in Ottawa in early December.

Dr. John Esdaile is chairing the American College of Rheumatology’s Committee on Practice Guidelines.

Dr. Diane Lacaille was one of three to be appointed to the new Young Investigators Subcommittee of the American College of Rheumatology. This committee will function as a liaison between young research scientists and the larger American College of Rheumatology Committee on Research identifying their research needs.
EDUCATIONAL PROGRAMS
The Clinical Investigator Program (CIP) program is an integral component of the Department of Medicine. Its main goals are to integrate promising medical students, residents and fellows into an academic environment that sustains and nurtures academic interests. This year, Drs. Palepu and Levin, were selected as co-directors of this program, after Dr. Peter Pare stepped down from the position. The CIP program is a resource which permits divisions within the DOM to leverage funding opportunities in order to support the academic endeavors of those divisions.

The Faculty Clinical Investigator Program is a 2-year program, which has the potential to fund at least 4 individuals each year. Current CIP young investigators enrolled in the DOM CIP program from 2004 include: Dr. Warren Davidson (2nd year), Respirology, Dr. Nadia Zalunardo (1st year) Nephrology, and Dr. Debbie Rosenbaum (1st year) Nephrology.

Accomplishments of those individuals are listed in the appendix below.

Given the importance of the CIP program to the growth and sustainability of research programs, the co-directors have been more formally integrated into key activities of the DOM. This has included presentations to the DOM business meetings at both PHC and VGH sites, and ongoing interaction with Division Heads at the UBC DOM Division Heads meeting held monthly.

There is currently a dedicated office administrative assistant, who works in conjunction with the other staff in the DOM administrative offices at both sites, to facilitate communication and serve as a resource for the enrollees.

The CIP directors are currently surveying program and department heads to estimate the number of research fellows who are currently in the Faculty of Medicine. The intent is to learn of existing educational curricula and develop an abbreviated curriculum that would be useful to junior clinician researchers in training.
APPENDIX

**Dr. Warren Davidson (Year 2)**
Division of Respirology  
Supervisor: Dr. Tony Bai

*Abstracts*
A Comparison of the Leicester Cough Questionnaire with the St. George’s Respiratory Questionnaire in the Evaluation of Treatment Response in Patients with Chronic Cough. ATS Meeting, May 2005.

*Publications*


*Presentations*


*Degree Programs currently enrolled*
Master of Health Science Degree  
Department of Health Care & Epidemiology, UBC

**Dr. Nadia Zalunardo (Year 1)**
Division of Nephrology  
Supervisor: Dr. Adeera Levin

*Abstracts*

Publications


Degree Programs currently enrolled
Masters in Science, Epidemiology
Harvard School of Public Health
Expected completion June 2006

Grants applied for 2005-6
Kidney Foundation Fellowship Grant
Michael Smith Fellowship Grant
KRESCENT Program Fellowship Grant

Dr. Debbie Rosenbaum (Year 1)
Division of Nephrology
Supervisor: Drs. Adeera Levin and Paul Keown

Abstracts

Publications

CIP Research Project
A strategy for reducing erythropoetin therapy in patients with erythropoetin resistance. Study timeline: To commence in May/June.

Grants Applied for 2005-6
Kidney Foundation Fellowship

Currently on maternity leave
CONTINUING MEDICAL EDUCATION PROGRAM

Dr. G.B. John Mancini
Professor & Director

New Initiatives/Developments

In 2004 Dr. G.B. John Mancini accepted the position of Director of the Program. The Department was involved in several initiatives through the year. In February we co-sponsored, with the Cardiovascular Society of Arizona, the “Southwestern Cardiology Symposium” held in Phoenix. This was an excellent event and involved the participation of both Canadian and American speakers.

Our “Medicine in the 21st Century” Conference was held June 10th – 12th at the Sutton Place Hotel. Twenty-one UBC Faculty participated in the course which was presented to 105 attendees primarily from Canada and the United States. As in past years, we were pleased with the attendance and quality of the course. The speakers were evaluated highly as was the course content. It is our hope and intention to continue to offer this course on an annual basis and to maintain the high quality as well as to continue increasing attendance. This annual event was followed this year by a post-CME event in the form of an Alaskan Cruise on June 13 – 20. The faculty consisted of Drs. Jerry Tenenbaum, Lucretia van den Berg, Najib Ayas and Hector Baillie. The program and speakers were also highly evaluated by the attendees. We are currently in the process of coordinating our 2005 program which is scheduled to be held June 2 – 4, 2005 at the Fairmont Hotel Vancouver.

In December 2004 we were involved with the Canadian Vascular Biology Working Group and coordinated a meeting held in Whistler December 9 – 12. This meeting involved 20 participants and the proceedings will again be published in the Canadian Journal of Cardiology.

In 2004 we began meeting with CME Divisional Program Directors/Division heads to begin to work on development of further divisional events. We are also looking at development of a Saturday morning series directed towards Family Practitioners and General Internists in the community.

We would like to take this opportunity to thank the Faculty Members who have contributed to the conferences in the past years and continue to work with the Department to help ensure excellent ongoing CME programs.
GRADUATE STUDIES PROGRAM IN EXPERIMENTAL MEDICINE

Dr. Vincent Duronio
Professor & Director

Divisional Overview

Experimental Medicine is the UBC graduate studies program, within the Department of Medicine, which was developed to train individuals seeking a career in biomedical research. Students are enrolled in both MSc and PhD degree programs. Subspecialties within the Experimental Medicine Program include Cancer Biology, Cardiology, Dermatology, Gastroenterology, Haematology/Oncology, Immunology, Infectious Diseases, Molecular Biology, Nephrology, Neurology, Pediatrics, Physiotherapy and Respiratory Medicine. A substantial number of students in the program are under the supervision of faculty members outside of the department. In 2004, 30 new students were admitted to the program. At the end of 2004, there were 117 students registered in the program, 53 for MSc degrees and 64 for PhD degrees.

During 2004, a total of sixteen students graduated, seven at the May 2004 Convocation and nine at the November 2004 Convocation. Student names and thesis titles are listed below (research supervisor in parenthesis):

PhD Graduates

1. Svetlana Dmitrienko, *Gene Polymorphisms in Renal Transplantation*, (Dr. Paul Keown)
2. Ryan Hung, *The Regulation of Apoptosis by Toxic Shock Syndrome Toxin-1 and Associated Mutants*, (Dr. Anthony Chow)
3. Xiaomei Li, *Selective Inhibition of Signal Transduction Pathways in Human CD4+ T Lymphocyte*, (Dr. Paul Keown)
4. Muhammad Marwali, *Role of Lipid Rafts in the Regulation of LFA-1*, (Dr. Fumio Takei)
5. Christopher Miller, *The Antibacterial Role of Exogenous Nitrous Oxide Gas*, (Dr. Jeremy Road)
6. Kenna Sleigh, *Relations between Illness Perceptions, Coping, Social Support, and Outcomes in the Chronic Fatigue Syndrome*, (Dr. Grant Stiver)
MSc Graduates

1. Kadria Alasaly, *The Maternal Predisposition to the Syndrome of Pre-eclampsia*, (Dr. Keith Walley and Dr. Peter von Dadelszen)

2. Mei Yieng Chin, *Molecular Functions of the Tumour Suppressor p33ING2*, (Dr. Gang Li)

3. Clare Gardiner, *The Role of STAT-3 in Androgen-Dependent Prostate Cancer*, (Dr. Michael Cox)


5. Mohammed Khan, *Mechanisms of Enteroaggregative Escherichia Coli flagellin-induced IL-8 secretion from epithelial cells*, (Dr. Theodore Steiner)

6. Maryam Moussavi, *Insight into the mechanisms by which apigenin, curcumin and sulfasalazine induce apoptosis in colon cancer cells*, (Dr. Bill Salh)

7. Kuldip Ken Parhar, *Interleukin 1B signaling in Intestinal Epithelial Cells*, (Dr. Bill Salh)

8. Amanda Rooyackers, *Absence of complement receptor 3 results in reduced binding and ingestion of mycobacterium tuberculosis but has no significant effect on the induction of reactive oxygen and nitrogen intermediates or on the survival of the bacteria in resident and interferon-gamma activated macrophages*, (Dr. Richard Stokes)


10. Troy Sutton, *Interventions for Prevention of Respiratory Syncytial Bronchiolitis and Sequelae in Guinea Pigs*, (Dr. Richard Hegele)

In 2004, 86 Experimental Medicine students received a total of $1,792,816 in funding, an average of $20,847 per student. Research Supervisors provided $956,700 in Graduate Research Assistantships. Other funding sources included CIHR ($299,700), the Michael Smith Foundation ($162,800), NSERC ($72,300), the Heart and Stroke Foundation ($41,000), and the UBC Graduate Entrance Scholarship ($12,296).

There are 111 faculty members currently registered as Research Supervisors in the program. Faculty members from other departments also participate as course lecturers, thesis committee members, in research seminars and as examiners for internal examinations and theses defenses.

In the academic year 2004, the Experimental Medicine Program offered nine graduate courses. These included: MEDI 501 (Molecular & Cellular Biology), MEDI 502 (Methodology), MEDI 530 (Gastroenterology) MEDI 535 (Journal Club), MEDI 548 (Directed Studies in Experimental
Medicine), MEDI 560 (Pulmonary Pathophysiology), MEDI 570 (Cardiology), MEDI 580 (Infectious Diseases) and MEDI 590 (Molecular Medicine).

The overall administration of the program is under the guidance of the Experimental Medicine Committee. The committee is composed of representatives from each subspecialty and one student representative. This committee meets four times per year to discuss policy and procedures. Current members of the committee are: Dr. Anthony Chow (Infectious Diseases), Dr. Vincent Duronio (Respiratory Medicine and Director), Dr. R. Keith Humphries (Haematology/Oncology), Dr. Gang Li (Dermatology), Dr. Steve Pelech (Molecular Medicine), Dr. Bill Sali (Gastroenterology), Dr. Andrew Sandford (Respiratory Medicine, iCapture Centre), Dr. Yu Tian Wang (Neurology, Brain Research Centre), Ms. Alison Wallace (Student Representative), Dr. Keith Walley (Critical Care), and Dr. Graydon Meneilly (ex-officio). The Experimental Medicine Program’s daily administration is through the director and one secretary. The Experimental Medicine Program continues to sponsor an annual Student Research Day. The 2004 event was held on November 12, at the Holiday Inn on Broadway. 16 students gave oral presentations and 60 students participated in poster presentations. A total of $900 in cash prizes was presented this year. The prizes this year went to:

- Michael Rauh (MD/PhD, Supervisor: Dr. Gerry Krystal) - $300 Best Overall Presentation
- Zabrina Brumme (PhD, Supervisor: Dr. Richard Harrigan) - $100 Best Oral Presentation
- Poh Tan (PhD, Supervisor: Dr. Kelly McNagny) - $100 Best Oral Presentation
- Sima Allahverdian (PhD, Supervisor: Dr. Delbert Dorscheid) - $100 Best Poster Presentation
- Kyle Niessen (PhD, Supervisor: Dr. Aly Karsan) - $100 Best Poster Presentation
- Benjamin Patchell (PhD, Supervisor: Dr. Delbert Dorscheid) - $100 Best Poster Presentation
- Gina Rossi (PhD, Supervisor: Dr. Michael Cox) - $100 Best Poster Presentation

Financial support for Student Research Day was provided by GlaxoSmithKline Inc., Merck Frosst Canada Inc., the Vancouver Hospital and Health Sciences Centre, Altana Pharma Inc., the Canadian Society of Biochemistry, Molecular and Cellular Biology, AstraZeneca Canada Inc., Hoffman La-Roche, and Janssen-Ortho Inc.

The Experimental Medicine Program continued to offer travel grants to students who had already used the travel grant provided by the Faculty of Graduate Studies.

The Experimental Medicine Office is located in Room S125, Koerner Pavilion, 2211 Wesbrook Mall, UBC Campus. The office telephone number is 604-822-7215, the fax number is 604-822-7897 and e-mail address is exptlmed@interchange.ubc.ca.
HIV/AIDS RESEARCH PROGRAM

Dr. Julio Montaner
Professor & Director

Overview

The AIDS Research Program continues to refine the role of antiretroviral therapy for the treatment of HIV infection. The main areas of research continue to be epidemiology, basic science and clinical science. In the following report we summarize the program's activities and areas of concern for the year 2004.

Epidemiological Research

The epidemiology group has again been very productive and continues to benefit from long-term analyses emerging from the VanGuard Project, the VIDUS and CEDAR cohorts under the leadership of Drs. Lampinen, Wood and Spittal, respectively. The Drug Treatment Program, under the leadership of Dr. Robert Hogg, has emerged as a key contributor to our understanding of the dynamics of the HIV epidemic as well as the effect of treatment. Several key papers, some of them in highly respected international journals, were published demonstrating the efficacy of antiretroviral therapy in terms of decreasing morbidity, mortality, and improving the quality of life in HIV-infected individuals. Members of our team have received funding from the Michael Smith Health Research Foundation and the Canadian Institutes of Health Research for doctoral and post-doctoral training. These include Paula Braitstein, Tom Lampinen, Cari Miller, Magda Piacenza, Amy Weber, Melanie Rusch and Laura Kuyper. Grant funding has also been obtained by members of our group from the Michael Smith Health Research Foundation, Canadian Institutes of Health Research, the Ontario HIV Treatment Network, and a number of pharmaceutical companies.

Basic Science

The research laboratory based at the B.C. Centre for Excellence in HIV/AIDS has established itself not only as a leading force in Canada, but also as a centre with considerable international influence. During the year, the laboratory provided clinical services to the province of B.C. in the areas of HIV drug resistance testing and pharmacokinetic measurement. The clinical implications and predictors of HIV drug resistance continue to be investigated, both at the B.C. Centre for Excellence and as part of international collaborations. The research laboratory continues to develop new tools with clinical applications that may be employed in the near future. These include tools for monitoring the side-effects and degree of adherence to
medications, as well as tracking variations in the HIV and human genomes which are associated with response to HIV therapy, and virus pathogenicity. In addition to providing HIV drug resistance testing as a clinical service to most of Canada and investigator driven trials, the research lab has also received peer-reviewed funding for several studies from the Canadian Institutes of Health Research, Michael Smith Health Research Foundation, and the Ontario HIV Treatment Network. Finally, the novel testing applications in the laboratory have lead to the Research Lab being used to provide testing support for three Phase III clinical trials from a major pharmaceutical company.

In 2004, members of the lab published more than a dozen important research papers in peer-reviewed journals including The Journal of Infectious Disease and AIDS.

Clinical Science

Members of the clinical science group are actively researching a range of issues essential to the medical management of patients with HIV. Among the areas of focus are treatment of patients with multidrug-resistant virus, pharmacokinetics of antiretrovirals, optimizing adherence to antiretroviral therapy regimens, recognition and management of drug toxicities, management of viral co-infections, and primary care initiatives.

Therapeutic strategies continue to evolve for patients who have experienced treatment failure on a number of previous antiretroviral regimens. During 2004, a number of new agents with promise for the treatment of multidrug-resistant HIV became available. These include enfuvirtide (the first approved HIV fusion inhibitor, administered by subcutaneous injection) and the investigational agents TMC125 and tipranavir. Enfuvirtide in particular has enabled the design of effective salvage regimens which are more streamlined than the previous multiple drug salvage regimens. The clinical group is evaluating novel mechanisms to optimize enfuvirtide administration with the aim of maximizing patient acceptance and tolerance of this very useful agent. Other strategies for optimizing salvage therapy, including simplifying complex salvage regimens, are also being explored.

A number of studies being done by the clinical group in association with the B.C. Centre for Excellence laboratory have focused on plasma concentrations of antiretroviral drugs, which are increasingly being recognized as a critical factor in their effectiveness and toxicity. Complex pharmacokinetic interactions between protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and other co-administered drugs can have clinically relevant effects on plasma drug levels in HIV patients and are being studied by our group as well as others worldwide. For example, intensive studies are underway at our centre examining pharmacokinetic interactions between the investigational agents TMC125 and tipranavir, and other drugs with which they are likely to be combined in salvage therapy regimens. In addition, drug level measurements performed by our clinical and laboratory groups have identified that plasma levels are often low for atazanavir, a new protease inhibitor that was approved for clinical use in 2004. Ongoing studies are evaluating strategies for manipulating regimens to improve atazanavir levels and thus optimize its effectiveness. The group’s capacity to conduct meaningful research into the pharmacology and toxicology of antiretroviral drugs was greatly enhanced in September 2004 with the addition of Dr. Elizabeth Phillips to the clinical research team.
The issues surrounding adherence to antiretroviral drug regimens are a topic of active study by two clinical psychologists on the team. A number of studies have been completed while others are underway to systematically evaluate the factors associated with adherence, and to develop effective intervention techniques with the goal of optimizing patients’ ability to take their antiretrovirals.

Adverse effects of antiretroviral therapy continue to be a key focus of the clinical research team’s efforts. Metabolic disorders such as dyslipidemia and mitochondrial toxicity of various antiretroviral regimens are being intensively evaluated in two international, randomized clinical trials spearheaded by the B.C. clinical research team, the SPRINT study (completed in 2004) and the NRTI-sparing study (which is ongoing). Collaborative efforts with the Healthy Heart Program are evaluating risk factors for cardiovascular disease in patients taking antiretrovirals and developing novel strategies for preventing these complications of HIV therapy. Previous work by our group which established an association between kidney toxicity and tenofovir, now a widely-used antiretroviral agent, has been expanded with the identification of reduced glomerular filtration rate (a measure of kidney function) as a factor which can be used to identify patients at risk for this complication. As one strategy for reducing duration of exposure to antiretrovirals and thereby deferring cumulative toxicities, as well as decreasing associated health care costs, supervised treatment interruptions continue to be evaluated in terms of their effects on short- and long-term outcomes. The clinical research team’s findings in all of these areas were presented at major national and international conferences during 2004.

Co-infection with hepatitis B and C continues to have a major effect on the HIV-infected clinic population. Ongoing research in this area is examining the effect of tenofovir on hepatitis B viral load in individuals with HIV/hepatitis B co-infection, and mitochondrial toxicity in the liver caused by HIV and hepatitis C treatment. In addition, a study is planned which will examine the issue of suboptimal adherence to anti-hepatitis C treatment in HIV-positive patients.

In 2004, the John Ruedy Immunodeficiency Clinic (IDC) entered its second year as a primary and specialty clinic for HIV infected patients. The clinical team includes individuals with expertise in all areas of HIV care with specific emphasis on primary care, infectious diseases, lipid disorders, anal dysplasia, neurology, dermatology, counseling and psychology, nephrology, and clinical trial operations.

In the IDC, a large number of HIV-positive patients are monitored regularly. The clinic operates 5 days a week with after-hours on call coverage. A comprehensive team of family physicians, nurses, social workers, nutritionist, pharmacist, and a substance use counselor is available to all patients. A large database has been generated with information on primary care initiatives, allowing a comprehensive assessment of the patient’s health status as well as immunizations, co-morbidities, medications, substance use, and other factors of interest.

The clinic, in partnership with the Vancouver Coastal Health Authority and the UBC skill enhancement program for Family Physicians, offers a 3-month post-graduate program for family doctors. The aim of the program is to enhance skills in the care and treatment of patients with HIV/AIDS. An Antiretroviral Outreach Program (ARV-ORO) was also established to help inform, support and evaluate activities in Vancouver's Downtown Eastside.
Current Areas of Active Clinical Research

- First-line antiretroviral therapy
- Salvage therapy for patients with previous treatment failure and multiple drug-resistant HIV
- Strategies for optimizing the use of investigational and newly available antiretroviral agents
- Complications of antiretroviral therapy, including lipodystrophy, dyslipidemias, cardiovascular disease, mitochondrial toxicity, peripheral neuropathy, hepatotoxicity, nephrotoxicity, osteopenia/osteoporosis
- Effect of treatment interruptions on long-term outcomes of HIV disease
- Assessing and optimizing adherence to antiretroviral regimens and hepatitis C therapy
- Pharmacokinetics of antiretroviral drugs, achieving optimal therapeutic drug levels, and drug interactions
- Treatment and complications of hepatitis B and C co-infections
- Prevention and treatment of opportunistic infections
<table>
<thead>
<tr>
<th>Student Name</th>
<th>Program Type</th>
<th>Dates</th>
<th>Supervisor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braitstein, Paula</td>
<td>PhD, UBC</td>
<td>1999-2005</td>
<td>R. Hogg</td>
</tr>
<tr>
<td>Craib, Kevin</td>
<td>PhD, UBC</td>
<td>1997-2004</td>
<td>M. Schechter</td>
</tr>
<tr>
<td>Cuscheri, A.</td>
<td>PhD, UBC</td>
<td>2002-Present</td>
<td>M. Tyndall, R. Hogg</td>
</tr>
<tr>
<td>Rusch, Melanie</td>
<td>PhD, UBC</td>
<td>2002-Present</td>
<td>M. Tyndall</td>
</tr>
<tr>
<td>Miller, Cari</td>
<td>PhD, UBC</td>
<td>2001-Present</td>
<td>J Frankish et al.</td>
</tr>
<tr>
<td>Brumme, Zabrina</td>
<td>PhD, MSHRF, CIHR</td>
<td>2001-Present</td>
<td>R Harrigan, R. Hogg, J. Montaner</td>
</tr>
<tr>
<td>Lampinen, Tom</td>
<td>Post-Doc</td>
<td>2002-Present</td>
<td>R. Hogg</td>
</tr>
<tr>
<td>Edwards, J.</td>
<td>Environmental Health</td>
<td>2002-2004</td>
<td>Dr. Heacock, E Wood, MW Tyndall</td>
</tr>
<tr>
<td>Kulkarni, S.</td>
<td>Infectious Diseases Resident</td>
<td>2003-2004</td>
<td>V. Montessori</td>
</tr>
<tr>
<td>O’Connell, Jacqueline</td>
<td>Medical Student</td>
<td>2003-2004</td>
<td>E. Wood</td>
</tr>
<tr>
<td>Christie, Timothy</td>
<td>MSc</td>
<td>2003-Present</td>
<td>R. Hogg, J. Montaner</td>
</tr>
<tr>
<td>Ramirez Moreno, Saby</td>
<td>Postdoctoral Research Fellow-</td>
<td>2004-Present</td>
<td>J. Montaner</td>
</tr>
<tr>
<td>Kretz, Patricia</td>
<td>CIHR Translational Research</td>
<td>2004</td>
<td>R. Hogg, E. Wood</td>
</tr>
<tr>
<td>Lloyd-Smith, Elisa</td>
<td>Epidemiology</td>
<td>2004</td>
<td>E. Wood, M. Tyndall</td>
</tr>
<tr>
<td>Collins, C.</td>
<td>CIHR Translational Research</td>
<td>2004</td>
<td>E. Wood</td>
</tr>
<tr>
<td>Kuypers, Laura</td>
<td>Medical Student</td>
<td>2004</td>
<td>E. Wood, R. Hogg, J. Montaner</td>
</tr>
<tr>
<td>Buchcar, Anna</td>
<td>Postdoctoral Research Fellow-</td>
<td>2004</td>
<td>J. Montaner</td>
</tr>
<tr>
<td>Lester, Richard</td>
<td>Postdoctoral Research Fellow-</td>
<td>2004</td>
<td>J. Montaner</td>
</tr>
<tr>
<td>Kristen Chen, Samir</td>
<td>Residency</td>
<td>2004</td>
<td>J. Montaner</td>
</tr>
<tr>
<td>Malhotra</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ryan Cooper</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osama Al Enezi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jenny Su</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Hull</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eliana Castillo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erin Pepper</td>
<td>David Shu</td>
<td>Al Abdali</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Elena Koundour</td>
<td>Gurpreet Hans</td>
<td>Abeer Al Shukairy</td>
<td></td>
</tr>
<tr>
<td>Florian Muller</td>
<td>Ibrahim Momenkhan</td>
<td>Ghassan Wali</td>
<td></td>
</tr>
<tr>
<td>Ana Luiza</td>
<td>Julie Stone</td>
<td>Melody Monro</td>
<td></td>
</tr>
<tr>
<td>Michael Buyliss</td>
<td>Harinder Dhaliwal</td>
<td>Gil Kimel</td>
<td></td>
</tr>
<tr>
<td>Roberta Halpenny</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dr. Mike Burns</th>
<th>Preceptorship</th>
<th>2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Daphne Hart</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Susan Ackland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Dave Forrest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Nikki Shaw</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Danielle Rouleau</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Tracey Morris</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Claudia Vanzulli</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>J. Montaner</th>
<th>S. Guillemi</th>
<th></th>
</tr>
</thead>
</table>
New Initiatives/Developments

2004 proved to be an exciting year for the Internal Medical Residency Training Program. In March 2004 the Chief Residents coordinated the “Resident Whistler Conference” over a two day period. It is through the hard work and diligence of Chief Residents Carolyn Taylor, David Wood, Monica Beaulieu and Andrew Robinson that this event was, for the second year, very successful and well-attended.

In March 2004 the Chief Residents organized and hosted the Canadian Chief Medical Resident Conference held at the Sutton Place Hotel in Vancouver. Over 35 Chief Residents from across the country attended this 3-day event.

In April 2004 Vancouver was the host city for the Joint Canadian Internal Medicine Program Directors (CAIMPD) & Canadian Internal Medicine Program Administrators (CAIMPA) Meeting. Hazel Wilcox chaired the CAIMPA meeting.

In May 2004 we held the 20th Annual Resident Research Day where, once again, the calibre of research presentations was superb. We welcomed adjudicators Dr. Kathryn Myers, Program Director at Queen’s University; Dr. Frank Ervin, a community respirologist in Maple Ridge and Dr. John Conly, Head of Medicine at the University of Calgary. Dr. Anita Palepu did an excellent job as moderator for this event.

With respect to our resident numbers we received 3 additional PGY-1 positions from the MOH bringing our currently MOH funding PGY-1 positions to 21. In 2004 several of our first year residents transferred into other programs/disciplines leaving the Program with a shortage in
second year residents for the 2004/2005 academic year. We will receive 2 additional positions for the 2005/2006 year and 1 PGY-2 position.

In September the program welcomed Sue Wong to the Postgraduate Administrative Team. Sue is located in the Department of Medicine offices at St. Paul’s Hospital and liaises with the Vancouver Hospital site.

In October 2004, Dr. Iain Mackie, Program Director for 7 years stepped down and the position was restructured with the appointment of four New Program Directors. Dr. Mark Roberts, Program Director, Dr. Roger Wong, Associate Program Director responsible for Curriculum Development, Dr. Rose Hatala, Associate Program Director responsible for Evaluations & Remediation, & Dr. Barry Kassen, Associate Program Director responsible for Community and expansion into the distributed sites.

In November we received 296 Canadian PGY-1 applications for the upcoming academic year. The interview process was reviewed and restructured and 130 interviews will be held on 3 different days in January rather than on each day throughout the month as in previous years. Interviews will involve tours by our PGY-1 resident, question & answer session with the Program Directors and Administrator and lunch to be followed by the actual interview. This will allow for all applicants to get a better overview of our program as well as interact with many of the Program Directors. This new process would not be possible without recruitment of many faculty not directly associated with the Program as well as several senior residents. We would like to take this opportunity to thank the faculty and residents who have given their time to help with this process.

Challenges for the upcoming 2005 year will involve an Internal Review to be held in September 2005. Implementation of the Mini Clinical Examinations (Mini-CEX) during each resident rotation. We also are looking forward to further development of the distributed sites during expansion of the medical school. We look towards building a strong postgraduate team during the next academic year with the aim to continue to develop and strengthen this program.
UNDERGRADUATE EDUCATION PROGRAM

Dr. H. Grant Stiver  
Professor & Director

In the 2003-04 semester, the Undergraduate Program continues to be actively involved in the bedside training of Second Year medical students prior to entering the Clinical Clerkship. In the Third Year Clerkship, the National Board of Medical Examiners (NBME) Shelf Examination in Medicine continues to be the written examination administered to Third Year clerks at the end of their eight-week Clinical Teaching Unit (CTU) rotation in Internal Medicine. We are also in the process of preparing pilot clerkship rotations in support of the Medical School Expansion and researching ways in which academic materials can be delivered to distributed sites.

Second Year Bedside Clinical Skills: In the 2003-04 academic year, the Second year bedside teaching sessions were again well received by both faculty and students. These sessions continue to be one of the highest rated courses in the undergraduate curriculum. We have continued with these sessions this current academic year where students are assigned a patient and perform a complete and focused history and physical examination, reviewed at the bedside by a clinician preceptor who also critiques the student’s write-up of the case. The duration of the course this academic year remains the same as last, January to May, 2005.

Third Year Clerkship:

Evaluation of Academic Half-Day sessions: In September 2004, our Program will use the WebEval on-line evaluation system for the evaluation of our academic half-day sessions and Neurology Bedside Teaching sessions. This system sends electronic evaluation forms to students to obtain feedback on their academic sessions. These reports will be made available to faculty at the end of each academic year.

Written Examination at the End of the Third year Clerkship in Medicine: The National Board of Medical Examiners Shelf Examination in Medicine continues to be administered to all clinical clerks at the end of the 8-week Medicine clerkship. Advantages are the consistent quality of the clinical case scenarios requiring not only a knowledge base but also some clinical problem solving skills, as well as the opportunity to compare the performances of our students with students at a similar stage of training across North America and assess deficiencies and strengths of our curriculum. Our students are at or above the mean for North American 8-week clerkships on the NBME exams. The performance of UBC first-time examinees of the NBME shelf examination in Medicine (all clerkship rotations) during the 2003-04 academic year resulted in a mean subject exam test score of 74.4 which is a bit higher than the mean for North
American medical schools who have an 8 week clerkship (73.9). The performance of students beginning the clerkship at the end of Third Year generally increased compared with the performance of the students beginning in September, reflecting the increased clinical experience acquired throughout the year.

**Medical School Expansion:** In July 2004, the Undergraduate Program welcomed Dr. Janet Kushner Kow as the Associate Director of Expansion and New Programs in the UBC Department of Medicine. Dr. Kushner Kow is involved in planning pilot clerkship rotations in Medicine in support of the Medical School Expansion. The Medical School Expansion Office will run an integrated pilot clerkship rotation in Chilliwack, involving six Third Year UBC medical students, from September 2004 to August 2005. Dr. Kushner Kow and members of the Undergraduate Education Committee are also actively involved in researching ways in which academic materials can be delivered to distributed sites.
ALLERGY/IMMUNOLOGY

Kanani, Dr. Amin S

Schellenberg, Dr. Robert R

Wong, Dr. HC George

CARDIOLOGY

Aymong, Dr. Eve D
Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. JACC. 2004 Sept 15;44(6):1215-23.


Buller, Dr. Christopher E


Cairns, Dr. John A

Carere, Dr. Ronald G

Chan, Dr. Sammy
**Fung, Dr. Anthony**


**Gin, Dr. Kenneth G**


**Hamburger, Dr. Jaap N**

stenting with Taxus stents seems to be as safe and effective as with predilation: a posthoc analysis of TAXUS II. Herz; 2004; 29: 171-180.

**Heilbron, Dr. Brett G**


**Humphries, Dr. Karin**


**Ignaszewski, Dr. Andrew P**


**Jue, Dr. John**

**Kerr, Dr. Charles R**

**Mancini, Dr. GB John**

**Munt, Dr. Bradley I**

**Rabkin, Dr. Simon**

**Ricci, Dr. Donald R**

**Saw, Dr. Jacqueline W**

**Straatman, Dr. Lynn P**
Thompson, Dr. Christopher R


Tung, Dr. Kei Kwong (Stanley)


Webb, Dr. John G


Yeung-Lai-Wah, Dr. John A

CRITICAL CARE
Dodek, Dr. Peter M
• Dodek P. Diabetes and other comorbidities were associated with a poor outcome in the severe acute respiratory syndrome [Comment]. ACPJ Club. 2004 Jan-Feb; 140:19.
Dorscheid, Dr. Delbert R

Keenan, Dr. Sean P

Ronco, Dr. Juan J

Russell, Dr. James A
Walley, Dr. Keith R


DERMATOLOGY

Cowan, Dr. Bryce J


Dutz, Dr. Jan P


Ho, Dr. Vincent

Li, Dr. Gang

Lui, Dr. Harvey

McLean, Dr. David I

Rivers, Dr. Jason K
- Rivers JK. Is there more than one road to melanoma? Lancet 2004;363:728-730.

Shapiro, Dr. Jerry

ENDOCRINOLOGY

Fung, Dr. Michelle A


Prior, Dr. Jerilynn C

• Hitchcock CL and Prior JC. Evidence about extending the duration of oral contraceptive use to suppress menstruation. Women's Health Issues. 2004 Vol 14/6 pp201-211.

Tildesley, Dr. Hugh D

• Tildesley H. Long-Term Experience in Out-Patient Treatment of Type 1 Diabetes: Results of 934 Patients Up To 10 Years. (Accepted for Publication - Canadian Journal of Diabetes) 2004.

GASTROENTEROLOGY

Byrne, Dr. Michael F


**Chatur, Dr. Nazira**


**Enns, Dr. Robert A**

- Enns R. Less acid + less bleeding = better outcomes and more money! Can J Gastroenterol. 2004;18:747-748; discussion 748.

**Fishman, Dr. Martin J**

**Freeman, Dr. Hugh J**

**Halparin, Dr. Lawrence**
Kwan, Dr. Peter W

Ramji, Dr. Alnoor

Salh, Dr. Baljinder Singh

Steinbrecher, Dr. Urs P

Telford, Dr. Jennifer J

Yoshida, Dr. Eric M
- Warburton DE, Sheel AW, Hodges AN, Stewart IB, Yoshida EM, Levy RD, McKenzie DC. Effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients after...


GENERAL INTERNAL MEDICINE

Hatala, Dr. Rose


Holmes, Dr. Cheryl L


Khan, Dr. Nadia A

- Wardman D, Khan N. Antidepressant medication use among First Nations people within British Columbia 2004 (accepted).

Magee, Dr. Laura A

- Caetano M, Ornstein M, von Dadelszen P, Hannah ME, Logan AG, Gruslin A, Willan A, Magee LA. A survey of Canadian practitioners regarding the diagnosis and evaluation of the


Palepu, Dr. Anita


Wright, Dr. James (Jim) M


GERIATRIC MEDICINE

Beattie, Dr. Lynn


Lee, Dr. Philip E


Madden, Dr. Kenneth M


Menezes, Dr. Janice A


Wong, Dr. Roger Y

HEMATOLOGY

Ballem, Dr. Penny J


Barnett, Dr. Michael J


Benny, Dr. Barrett W


Eaves, Dr. Allen C


Forrest, Dr. Donna L


**Galbraith, Dr. Paul**

**Hogge, Dr. Donna**

**Humphries, Dr. Richard Keith**
- Rawat VPS, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK, Bohlander SK, Feuring-Buske M & Buske C. Ectopic expression of the homeobox gene Cdx2 is


Lansdorp, Dr. Peter M


Lavoie, Dr. Julye C


Leger, Dr. Chantal S


Leitch, Dr. Heather A


Li, Dr. Charles H


Nantel, Dr. Stephen H


Nevill, Dr. Thomas J


Petraszko, Dr. Tanya R

Schrader, Dr. John W

Shepherd, Dr. John D

Smith, Dr. Clayton A
Song, Dr. Kevin W


Sutherland, Dr. Heather J


Toze, Dr. Cynthia L


Tsang, Dr. Peter W

Vickars, Dr. Linda M

INFECTIONIOUS DISEASES

Av-Gay, Dr. Yossef Y

Bowie, Dr. William R

Brunham, Dr. Robert C


Cherkasov, Dr. Artem

Chow, Dr. Anthony W

Grigg, Dr. Michael

Hmama, Dr. Zakaria


Montaner, Dr. Julio S


Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. CD4+ T-Cell gain with nonnucleoside or protease inhibitors: Convenience may not always be the most convenient. JAIDS 2004;36(2):760-761.


Montessori, Dr. Valentina C


Phillips, Dr. Elizabeth J


Phillips, Dr. Peter


Press, Dr. Natasha M


**Reiner, Dr. Neil E**


**Rekart, Dr. Michael L**


**Steiner, Dr. Theodore S**

• Khan MA, Kang J, Steiner TS. Enteropathogenic Escherichia coli flagellin-induced interleukin-8 secretion requires Toll-like receptor 5-dependent p38 MAP kinase activation. Immunology. 2004 Aug;112 (4):651-60.

**Stiver, Dr. H Grant**


**Tyndall, Dr. Mark W**


Wood, Dr. Evan


Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active therapy and continuation of HIV care: The impact of incarceration and prison release on adherence


**MEDICAL ONCOLOGY**

**Chi, Dr. Kim N**


**Connors, Dr. Joseph M**


- Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: A clinical, pathological and cytogenetic study of 87


Gill, Dr. Sharlene

- Sinicrope FA, Gill S. Role of Cyclooxygenase-2 in Colorectal Cancer, Cancer and Metastasis Reviews, 2004 Jan; 23:63-75


Hoskins, Dr. Paul J


Melosky, Dr. Barbara L

Murray, Dr. Robert Nevin C

Savage, Dr. Kerry J

Shenkier, Dr. Tamara N

Swenerton, Dr. Kenneth D

NEPHROLOGY

Duncan, Dr. John A

Gill, Dr. John S


Keown, Dr. Paul A


Levin, Dr. Adeera


Wong, Dr. Norman L


NEUROLOGY

Barton, Dr. Jason J


Briemberg, Dr. Hannah


Chapman, Dr. Kristine M


Devonshire, Dr. Virginia A


Doudet, Dr. Doris J

Neto P, Doudet DJ, Cumming P. "Gradients of dopamine D1 and D2/3 binding sites in the basal ganglia of pig and monkey measured by PET" NeuroImage 22:1076-1083 (2004).


Feldman, Dr. Howard H


Hallam, Dr. Bradley J

Hsiung, Dr. Ging-Yuek R

Johnston, Dr. Dean C

Keyes, Dr. Robert D

Krieger, Dr. Charles
Lee, Dr. Chong S

McKeown, Dr. Martin J

Oger, Dr. Joel
- Tremlett HL, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) Neurology 2004;63 1142-1143.

Pelech, Dr. Steven


Prout, Dr. Alister


Spacey, Dr. Sian


Stoessl, Dr. A Jon


Teal, Dr. Phillip A

Thiessen, Dr. Brian A

Traboulsee, Dr. Anthony

Tremlett, Dr. Helen L
● Tremlett HL, Yoshida E, Oger J: Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im); Neurology 2004;62:628-631.
● Tremlett HL, Oger J: Elevated aminotransferases during treatment with Beta-Interferon for Multiple Sclerosis: actions and outcomes; Multiple Sclerosis 2004; 10: 298-301.


● Tremlett HL, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) Neurology 2004;63 1142-1143.

Tsui, Dr. Joseph K


Wang, Dr. Yu Tian


Woolfenden, Dr. Andrew R


PHYSICAL MEDICINE & REHABILITATION

Anton, Dr. Hubert A


Dawson, Dr. Andrew S


Eng, Dr. Janice J


Underwood, Dr. Heather A


Yassi, Dr. Annalee


RESPIRATORY MEDICINE

Ayas, Dr. Najib T


Bai, Dr. Tony R

- Bai TR. Role of airway smooth muscle dysfunction in asthma. Journal of Asthma, Allergy and Clinical Immunology 2004. 24 [Suppl II]: S82-97.
Cook, Dr. Victoria J


Elwood, Dr. Richard K


FitzGerald, Dr. J Mark

- Baker RG, Norton PG, Flinton V, et al (Member of the study group). The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Can Med
Assoc J 2004;170:1678-86.


Fleetham, Dr. John A


Levy, Dr. Robert D


Man, Dr. SF Paul

- Sin DD and Man SFP. Inhaled Corticosteriods in the Long-Term Management of Patients with Chronic Obstructive Pulmonary Disease. Drugs and Aging 2003;20(12):867-880.


Pare, Dr. Peter D


Road, Dr. Jeremy


Ryan, Dr. Francis (Frank) C


Sandford, Dr. Andrew J


Tebbutt, Dr. Scott J

Van Eeden, Dr. Stephan F

Ward, Dr. Helen

Wilson, Dr. Jennifer M

RHEUMATOLOGY

Chalmers, Dr. Andrew


Cibere, Dr. Jolanda


Ensworth, Dr. Stephanie G


Esdaile, Dr. John M


Gillies, Dr. Jean H


Klinkhoff, Dr. Alice V


• Klinkhoff A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs 2004;64:1267-83.

Koehler, Dr. Barry


Lacaille, Dr. Diane


Shojania, Dr. Kamran


Wade, Dr. John P

GRANTS AND RESEARCH AWARDS
<table>
<thead>
<tr>
<th>Division</th>
<th>Researcher</th>
<th>Type</th>
<th>SPONSOR</th>
<th>04/05</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy/Immunology</td>
<td>Stark</td>
<td>Clinical Trial</td>
<td>Aventis Behring Canada Inc.</td>
<td>$7,813.00</td>
<td>A phase 2/3 open-label, prospective, randomized, actively-controlled, multicentre study of the pharmacokinetics, efficacy, safety and tolerability of immune globulin subcutaneous (human), CE1200 in subjects with primary immune deficiency</td>
</tr>
<tr>
<td>Allergy/Immunology</td>
<td>Stark</td>
<td>Clinical Trial</td>
<td>Bayer Inc.</td>
<td>$5,172.00</td>
<td>IVIG-C %10 Rapid Infusion Trial in Primary Immune Deficient Patients</td>
</tr>
<tr>
<td>Allergy/Immunology</td>
<td>Wong</td>
<td>Grant</td>
<td>VCHRI: Interdisciplinary Grant</td>
<td>$9,550.00</td>
<td>Measurement Properties of a Novel Walk Test in a Frail Elderly Population</td>
</tr>
<tr>
<td>Allergy/Immunology</td>
<td>Wong</td>
<td>Grant</td>
<td>VCHRI: VGH &amp; UBC Hospital Fdn In it for Life (Operating)</td>
<td>$35,376.00</td>
<td>Functional Performance in the Frail Elderly Population</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Aymong</td>
<td>Clinical Trial</td>
<td>The Medicines Company</td>
<td>$7,699.00</td>
<td>The ACUTITY Trial: A randomized comparison of Angiomas(bivalirudin) versus Lovenox/Clexane(enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Sanofi-Synthelabo Canada Inc.</td>
<td>$2,118.00</td>
<td>AMADEUS 64720: Multicenter Randomized Open-Label Assessor-Blind Non-Inferiority Study Comparing the Efficacy &amp; Safety of Once-Weekly Subcutaneous Idraparinux (SanOrg34006) with Adjusted-Dose Oral Vitamin-K Antagonists in the Prevention of…</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Pfizer Canada Inc.</td>
<td>$1,309.00</td>
<td>A2581087 (ACTFAST): Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Multicentre 12 Wk Treatment Single Step Titration Open-Label Study Assessing the % of Dyslipidemic High-Risk Patients Achieving Low Density Lipo…</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Grant</td>
<td>Various pharmaceutical companies</td>
<td>$71,911.00</td>
<td>Cardiology Research</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>CIHR: Health Research Institutes</td>
<td>$1,000.00</td>
<td>AF-CHF: Atrial Fibrillation and congestive Heart Failure</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Vasogen Inc.</td>
<td>$3,780.00</td>
<td>Protocol 0202 (ACCLAIM): Multicenter Randomized Double-Blind Parallel Placebo-Controlled Study to Assess the Effects of Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Vasogen Inc.</td>
<td>$12,820.00</td>
<td>Protocol 0101: Multicenter Randomized Double-Blind Parallel Placebo Controlled Study of Efficacy &amp; Safety of Immune Modulation Therapy in Improving Walking Distance in Patients with Intermittent Claudication Secondary to PAD</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Hamilton Health Sciences Corporation</td>
<td>$11,154.00</td>
<td>ONTARGET: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>MRC: Clinical Trials</td>
<td>$9,466.00</td>
<td>Heart Outcomes Prevention Trial (HOPE)</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>National Institutes of Health</td>
<td>$39,877.00</td>
<td>STICH: Surgical Treatment for Ischemic Heart Failure</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Eli Lilly Canada Inc.</td>
<td>$30,991.00</td>
<td>Ruth Study, Raloxifene Hydrochloride or placebo in postmenopausal women at risk for major cardiovascular events</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Pfizer Canada Inc.</td>
<td>$35,593.00</td>
<td>Magnesium use in the prevention of atrial arrhythmias after cardiac surgery</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Grant</td>
<td>VCHRI: Interdisciplinary Grant</td>
<td>$60,000.00</td>
<td>IMAGINE - Ischemia Management with Accupril post bypass graft via inhibition of converting enzyme (IMAGINE): An evaluation of the effect of 12 to approximately 24 months treatment with Quinapril 40 mg QD post CABG surgery Isometric events</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Knoll Pharmaceuticals</td>
<td>$10,159.00</td>
<td>PEACE - Prevention of Events with Angiotensin Converting Enzyme Inhibition</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Bernstein</td>
<td>Clinical Trial</td>
<td>Merck Frost Canada Inc.</td>
<td>$9,600.00</td>
<td>804-00: Randomized Double-Blind Placebo-Controlled Multicentre Study to Evaluate Efficacy Safety &amp; Tolerability of Ezetimibe 10mg or Placebo Co-administered with Existing Atorvastatin 10mg or 20mg in Attaining LDL Cholesterol Target Levels…</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Buller</td>
<td>Clinical Trial</td>
<td>Canadian Vigour Centre</td>
<td>$3,900.00</td>
<td>Protocol CVC1002: The WEST Study: Which Early ST Elevation Myocardial Infarction Therapy</td>
</tr>
<tr>
<td>Division</td>
<td>Sponsor</td>
<td>Project Description</td>
<td>Amount</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiology</td>
<td>Buller</td>
<td>Clinical Trial Takeda Global Research and Development</td>
<td>$12,577.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial Arginox Pharmaceuticals, Inc.</td>
<td>$13,801.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial evYsio Medical Devices ULC</td>
<td>$1,500.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial Canadian Heart Research Centre</td>
<td>$1,500.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial NIH (US): Research Grant</td>
<td>$5,051.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial Organon Canada Ltd.</td>
<td>$3,150.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial Heart and Stroke Foundation of Ontario</td>
<td>$43,200.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buller</td>
<td>Clinical Trial National Heart, Lung and Blood Institute</td>
<td>$3,002.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carere</td>
<td>Agreement MRC: Clinical Trials</td>
<td>$3,383.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carere</td>
<td>Grant St Lukes-Roosevelt Institute For Health Sciences</td>
<td>$34,050.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chan</td>
<td>Grant H&amp;SFBC: Research</td>
<td>$60,000.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chan</td>
<td>Clinical Trial PPD Development</td>
<td>$64,584.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Grant Vancouver Coastal Health Authority</td>
<td>$233,897.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Clinical Trial Genentech Canada Inc.</td>
<td>$1,110.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Clinical Trial Canadian Heart Research Centre</td>
<td>$1,445.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Clinical Trial Sanofi-Synthelabo Canada Inc.</td>
<td>$6,700.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Clinical Trial Aventis Pharma Inc.</td>
<td>$150,000.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Clinical Trial Velocimed, Inc.</td>
<td>$27,812.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fung</td>
<td>Clinical Trial Amersham Life Sciences Inc.</td>
<td>$6,686.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

UBC DEPARTMENT OF MEDICINE
AWARDS BY DIVISION FOR 2004-2005

UBC Department of Medicine
Page 188
Annual Report 2004
<table>
<thead>
<tr>
<th>Division</th>
<th>Name</th>
<th>Type</th>
<th>Grantor</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiology</td>
<td>Gin</td>
<td>Clinical Trial</td>
<td>Sanofi-Synthelabo Canada Inc.</td>
<td>$10,181.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Gin</td>
<td>Clinical Trial</td>
<td>AstraZeneca Canada Inc</td>
<td>$1,203.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Gin</td>
<td>Clinical Trial</td>
<td>Procter &amp; Gamble, Canada</td>
<td>$46,350.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Gin</td>
<td>Clinical Trial</td>
<td>Atherogenics, Inc.</td>
<td>$8,739.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Hamburger</td>
<td>Clinical Trial</td>
<td>Atherogenics, Inc.</td>
<td>$29,638.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Hamburger</td>
<td>Clinical Trial</td>
<td>Boston Scientific Corporation</td>
<td>$30,174.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Hamburger</td>
<td>Clinical Trial</td>
<td>Kerberos Proximal Solutions, Inc</td>
<td>$29,502.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Humphries</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP 57884</td>
<td>$25,356.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Humphries</td>
<td>Grant</td>
<td>MSFHR: Career Investigator Program C1-SCH-67(01-2)</td>
<td>$80,000.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Humphries</td>
<td>Grant</td>
<td>H&amp;SFBC: Research</td>
<td>$190,859.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Humphries</td>
<td>Grant</td>
<td>MSFHR: Institutional Infrastructure Support Program INS002031</td>
<td>$3,600.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Humphries</td>
<td>Grant</td>
<td>NCE/Stem Cell Network: Research</td>
<td>$396,846.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Humphries</td>
<td>Grant</td>
<td>NCE/Stem Cell Network: Research Student Award</td>
<td>$20,000.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Ignaszewski</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$1,500.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Ignaszewski</td>
<td>Clinical Trial</td>
<td>Amgen, Inc.</td>
<td>$7,550.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Ignaszewski</td>
<td>Clinical Trial</td>
<td>Parke-Davis Pharmaceuticals</td>
<td>$94,146.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Jue</td>
<td>Clinical Trial</td>
<td>Pfizer Canada Inc.</td>
<td>$1,934.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Jue</td>
<td>Contract</td>
<td>Various Sources</td>
<td>$26,045.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Jue</td>
<td>Clinical Trial</td>
<td>Canadian Heart Research Centre</td>
<td>$375.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Jue</td>
<td>Clinical Trial</td>
<td>Aventis Pharmaceuticals Inc.</td>
<td>$26,210.00</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Jue</td>
<td>Grant</td>
<td>Canadian Institutes of Health Research</td>
<td>$15,779.00</td>
</tr>
</tbody>
</table>
Cardiology  Jue  Clinical Trial  Guidant Corporation  $1,600.00  CAFÉ: Canadian Atrial Fibrillation Evaluation Study
Cardiology  Kerr  Clinical Trial  Various US Companies  $137.00  SHOCK - Should we emergently revascularize occluded coronaries for cardiogenis shock: an international randomized trial of emergently PTCA/CABG
Cardiology  Kerr  Clinical Trial  Guidant Corporation  $800.00  Insignia I ULTRA SR Pacemaker Trial
Cardiology  Kerr  Grant  Montreal Heart Institute  $1,200.00  Atrial Fibrillation and Congestive Heart Failure (AF-CHF) - A multicentre study evaluating the value of a therapeutic strategy to restore and maintain sinus rhythm in patients with atrial fibrillation and congestive heart failure versus...
Cardiology  Kerr  Clinical Trial  Procter & Gamble, Canada  $5,456.00  A multi-centre, six-month, double-blind, placebo-controlled, parallel-group design clinical study to assess the efficacy and safety of a daily oral dose of 125mg of Azimilide Dihydrochloride for the prophylactic treatment of atrial fibrillation...
Cardiology  Kiess  Grant  King Pharma  $4,218.00  (VISION 304) Vasodilator Induced Stress in Concordance with Adenosine
Cardiology  Mancini  Grant  Various Sources  $397,816.00  Carotid studies
Cardiology  Mancini  Contract  Canadian Vigour Centre, University of Alberta  $26,000.00  The WEST Study: Which Early ST Evaluation Myocardial Infarction Therapy?
Cardiology  Mancini  Grant  VCHRI: Scholar Award (Fellow: Lacaille, Diane)  $10,000.00  Preventing work loss from inflammatory arthritis: program development and pilot testing
Cardiology  Penn  Grant  MSFHR: Institutional Infrastructure Support Program INS002031  $3,600.00  Study to assess associated risk factors for premature atherosclerosis and coronary artery disease in people of South Asian descent (STAAR)
Cardiology  Rabkin  Clinical Trial  Various Pharmaceutical Companies  $280.00  Clinical Trials
Cardiology  Ricci  Clinical Trial  Eli Lilly Canada Inc.  $38,388.00  Protocol H7T-MC-TAAH (JUMBO-TIMI 26): Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared with Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention - Joint Utilization of Medications to Block Plate...
Cardiology  Straatman  Clinical Trial  Novartis Pharmaceuticals Canada Inc  $8,499.00  A 12-month, multicentre, randomized, adaptive design, open-label study to evaluate the benefit of C-2 hour monitoring of Neoral(R) on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction in a multiple injection regimen, in the treatment of pregnant women with...
Cardiology  Thompson  Clinical Trial  Novo-Nordisk  $3,979.00  A randomized, parallel-group, open-label, multinational trial comparing the safety and efficacy of insulin aspart (NovoRapid) versus human insulin (Actrapid) used in a multiple injection regimen, in the treatment of pregnant women with...
Cardiology  Thompson  Grant  CIHR: Health Research Institutes  $58,513.00  To reduce IDDM in type 1 diabetes in the genetically at risk TRIGR
Cardiology  Tung  Clinical Trial  Medtronic (USA)  $2,300.00  SAVE PACe - Search AV Extension for Promoting Atrioventricular Conduction
Cardiology  Tung  Clinical Trial  St. Jude Medical Inc.  $3,668.00  Sensitivity and Specificity of Morphology Discrimination: A Prospective Study
Cardiology  Webb  Grant  Various Sources  $6,300.00  various sources
Cardiology  Webb  Clinical Trial  Hoffmann-La Roche Ltd (Canada)  $51,325.00  WEST: Which Early ST Elevation Myocardial Infarction Therapy?
Cardiology  Webb  Clinical Trial  Sanofi-Synthelabo Recherche  $11,000.00  An international randomized double-blind study evaluating the efficacy and safety of Fondaparinux versus Enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes (OASIS - 5)
Cardiology  Webb  Clinical Trial  PercuSurge Inc.  $61,988.00  Enhanced myocardial efficacy and recovery by aspiration of liberalized debris (EMERALD) P02-0040
Cardiology  Webb  Clinical Trial  Sanofi-Synthelabo Canada Inc.  $6,000.00  An international, randomized study evaluating the efficacy and safety of fondaparinux sodium versus control therapy and glucose insulin-potassium infusion versus control in a broad range of patients with ST segment elevation acute myocardial...
Cardiology  Webb  Clinical Trial  Boston Scientific Corporation  $19,226.00  SYMBIOT III: A prospective randomized trial evaluating the Symbiot III covered stent system in saphenous vein grafts
Cardiology  Webb  Clinical Trial  Boston Scientific Corporation  $4,268.00  TAXUS II: A double-blind, controlled, study of the safety and performance of the NIRx(TM) Paclitaxel-coated conformer coronary stent
<table>
<thead>
<tr>
<th>Division</th>
<th>Investigator</th>
<th>Grant Type</th>
<th>Sponsor</th>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>Cardiva Medical, Inc</td>
<td>$2,968.00</td>
<td>Clinical study of the VasoStasis Vascular Closure System (VCS)</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>Arginox Pharmaceuticals, Inc.</td>
<td>$24,543.00</td>
<td>SHOCK-2 Trial - A randomised, double-blind, placebo-controlled, dose-ranging study of Nitrous Oxide Synthase inhibition with Ng-Monomethyl L-Arginine (L-NMMA) in patients with cardiogenic shock complicating acute myocardial infarction...</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>VELOCIMED, INC</td>
<td>$20,921.00</td>
<td>Proximal Protection during Saphenous Vein Graft Intervention using the Proxis TM Embolic Protection System: A Randomized, Prospective, Multicenter, Clinical Trial (PROXIMAL)</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>Kerberos Proximal Solutions, Inc.</td>
<td>$10,523.00</td>
<td>RINSE: RINspiration of Saphenous vein graft Emboli trial</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>Edwards Lifesciences</td>
<td>$28,146.00</td>
<td>Coronary Artery Bypass &amp; Ischemic Mitral Regurgitation (Edwards Mitral Valve)</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Grant</td>
<td>Cardiva Medical, Inc</td>
<td>$53,186.00</td>
<td>Clinical Study of the VasoStasis Vascular Closure System II</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>Edwards Lifesciences</td>
<td>$2,706.00</td>
<td>Edwards LifeScience Percutaneous Mitral Annuloplasty Repair System: A Phase I Feasibility, Non-Randomized, Multi-Center, Prospective, Consecutive Registry. A Percutaneous Interventional Treatment of Mitral Regurgitation</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Webb</td>
<td>Clinical Trial</td>
<td>Medtronic (USA)</td>
<td>$28,187.00</td>
<td>Medtronic EMPIRIC Study - Evaluation of EMPIRIC Programming to Improve Patient Management</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Chittock</td>
<td>Grant</td>
<td>VHHSC: VGH/UBC Fdn Special Opportunities Research Fund</td>
<td>$34,345.00</td>
<td>The Vancouver Interaction and Calmness Scale in Mechanically Ventilated Patients: A Prospective Randomized Controlled Trial of the Effect of Measuring Sedation and Agitation on the Duration of Mechanical Ventilation (VAP) A Randomized Trial of Empiric Broad Spectrum Antibiotics and Invasive Diagnostic Techniques in the Setting of Ventilator Associated Pneumonia</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Chittock</td>
<td>Clinical Trial</td>
<td>CIHR</td>
<td>$17,200.00</td>
<td>VASST: Randomized Controlled Trial of Vasopressin vs. Norepinephrine in Septic Shock</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Chittock</td>
<td>Clinical Trial</td>
<td>CIHR: Randomized Controlled Trials (Clinical Trials)</td>
<td>$1,400.00</td>
<td>VICS: Effect of Measuring Sedation and Agitation on Duration of Mechanical Ventilation</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dhingra</td>
<td>Grant</td>
<td>UBC Department of Medicine</td>
<td>$15,000.00</td>
<td>Survival using glucose algorithm regulation (SUGAR) trial</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dhingra</td>
<td>Clinical Trial</td>
<td>Canadian Intensive Care Fdn &amp; University of Ottawa</td>
<td>$5,000.00</td>
<td>(FINESS) Fluids in Early Severe Sepsis Retrospective Review</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dodek</td>
<td>Grant</td>
<td>HC/CIHR: Research Project</td>
<td>$2,150.00</td>
<td>Improving the quality and end of life care in Canada: Understanding the perspectives of seriously ill patients and their caregivers</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dodek</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-62778</td>
<td>$50,758.00</td>
<td>Geographic variation in outcomes of critical care in BC: The role of ICU organizational factors</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dorscheid</td>
<td>Grant</td>
<td>MSFHR: Career Investigator Program C1-SCH-31 (01-2)</td>
<td>$37,500.00</td>
<td>Airway epithelial injury as a result of corticosteroid-induced apoptosis</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dorscheid</td>
<td>Grant</td>
<td>BC Lung: Project Grant</td>
<td>$27,000.00</td>
<td>Airway epithelial damage, viral infection and excessive apoptosis</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dorscheid</td>
<td>Grant</td>
<td>MSFHR: Matching Establishment Grant C1-SCH-31 (01-2)</td>
<td>$22,000.00</td>
<td>Airway epithelial injury as a result of corticosteroid-induced apoptosis</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Dorscheid</td>
<td>Grant</td>
<td>MSFHR: Career Investigator Program C1-SCH-31 (01-2) (Fellow: Dorscheid, Delbert)</td>
<td>$80,000.00</td>
<td>Airway epithelial injury as a result of corticosteroid-induced apoptosis</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Fenwick</td>
<td>Clinical Trial</td>
<td>Eli Lilly Canada Inc.</td>
<td>$30,223.00</td>
<td>Protocol F1K-MC-EVBR: Randomized Double-Blind Placebo-Controlled Trial of Prophylactic Heparin in Patients with Severe Sepsis &amp; Higher Disease Severity Who Are Undergoing Treatment with Drotrecogin Alfa (Activated)</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Fenwick</td>
<td>Clinical Trial</td>
<td>Chiron Corporation</td>
<td>$13,383.00</td>
<td>Protocol TFP008: Phase 3 Multicenter Randomized Placebo-Controlled Double-Blind Three-Arm Study to Evaluate the Safety &amp; Efficacy of Tifacogin (recombinant tissue factor pathway inhibitor) Administration in Subjects with Severe Community...</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>Sponsor/Institution</td>
<td>Amount</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>----------------------------------------------------------</td>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Altana Pharma, Inc.</td>
<td>$9,287.00</td>
<td>BY2001-M1-007 (VALID Study): Venticute (rSP-C Surfactant) in Patients with Pneumonia or Aspiration of Gastric Contents Leading to Intubation Mechanical Ventilation and Severe Oxygenation Impairment</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Eli Lilly Canada Inc.</td>
<td>$14,369.00</td>
<td>Protocol F1K-MC-EVCL: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Early Stage Severe Sepsis</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>GlaxoSmithKline Inc.</td>
<td>$2,500.00</td>
<td>EMD20001: Prospective Randomized Double-Blind Placebo-Controlled Dose Ranging Multicenter Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270733 in the Treatment of Suspected or Confirmed Gram-Negative Ss</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Novo-Nordisk</td>
<td>$8,012.00</td>
<td>F7CBI-1600: Randomized Double-Blind Placebo-Controlled Multicenter Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (novoSevenNiaStase) in Subjects with Brain Contusions</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Novo-Nordisk</td>
<td>$8,157.00</td>
<td>F7CBI-1587: Multicenter Observational Study to Evaluate the Incidence and Magnitude of Hemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>VCHRI: Mentored Clinical Scientist</td>
<td>$50,000.00</td>
<td>Salary: Survival using glucose algorithm regulation (SUGAR) trial for Henderson Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>MRC: Clinical Trials</td>
<td>$8,000.00</td>
<td>LOVS: A randomized trial of a Lung Open Ventilation Strategy in Acute Lung Injury (MRC #78042)</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Fujisawa Canada Inc.</td>
<td>$11,000.00</td>
<td>MYC-001: Canadian ICU Infection Survey for Critical Care Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>Cdn Diabetes Assoc.: Charles H. Best Fund/Grant-in-Aid</td>
<td>$67,500.00</td>
<td>Survival using glucose algorithm regulation (SUGAR) trial for Ronco Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Mallinckrodt Medical, Inc.</td>
<td>$4,500.00</td>
<td>Puritan Bennett Model 840 Ventilator System with Proportional Assist Ventilation field Evaluation Protocol for Critical Care Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>VGH/UBC Foundation Special Opportunities Research Fund</td>
<td>$27,010.00</td>
<td>Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus; Removal of Catheter Followed by Two Days Compared with Seven Days of Vancomycin for Critical Care Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>MSFHR: Junior Graduate Studentship Award ST-JGS 222(03-1) CLIN (Fellow: Sutherland, Ainsley)</td>
<td>$2,292.00</td>
<td>Genetic Determinants of the Host Response to Infection in Critically Ill Adults with Systemic Inflammatory Response Syndrome for Critical Care Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Contract</td>
<td>MRC: Clinical Trials</td>
<td>$10,500.00</td>
<td>A randomized trial of a lung open ventilation strategy in acute lung injury for Critical Care Russell Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Clinical Trial</td>
<td>Eli Lilly and Company, US</td>
<td>$33,445.00</td>
<td>Efficacy and safety of Drotrecogin Alfa (activated) in adult patients with early stage severe sepsis for Critical Care Russell Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>MSFHR: Postdoctoral Trainee Fellowship (Fellow: Manocha, Sanjay)</td>
<td>$39,000.00</td>
<td>Clinical Outcomes of Acute Lung Injury: Role of Cytokine Gene Polymorphisms as Predictors for Critical Care Russell Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>MSFHR: Junior Graduate Studentship Award (Fellow: Shaw, David)</td>
<td>$30,000.00</td>
<td>Endothelins and the mechanism of hypoxemia in acute pulmonary embolism for Critical Care Tsang Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>MSFHR: Junior Graduate Studentship Award (Fellow: Shaw, David)</td>
<td>$625.00</td>
<td>Clinical outcomes of cardiac surgery are influenced by genetics of inflammatory mediators for Critical Care Walley Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>Heart &amp; Stroke Fdn of BC</td>
<td>$190,000.00</td>
<td>Genetic determinants of cognitive dysfunction following cardiopulmonary bypass surgery for Critical Care Walley Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>MSFHR: Distinguished Scholar Award CI-DSH-73(02-1)</td>
<td>$120,000.00</td>
<td>Translating mechanistic understanding of the systemic inflammatory response syndrome (SIRS) to clinical practice via genomics for Critical Care Walley Grant</td>
<td></td>
</tr>
<tr>
<td>Critical Care</td>
<td>Grant</td>
<td>Heart &amp; Stroke Fdn Cda: Research Fellowship - Bateman, Ryon</td>
<td>$38,000.00</td>
<td>Mechanism of myocardial dysfunction in sepsis for Critical Care Walley Grant</td>
<td></td>
</tr>
<tr>
<td>Division</td>
<td>Applicant</td>
<td>Type</td>
<td>Grant Source/ID</td>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
<td>------------</td>
<td>--------------------------------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Walley</td>
<td>Grant</td>
<td>MSFHR: Establishment Grant C1-DSH-73(02-1)</td>
<td>$37,500.00</td>
<td>Translating mechanistic understanding of the systemic inflammatory response syndrome (SIRS) to clinical practice via genomics</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Walley</td>
<td>Grant</td>
<td>MSFHR: Postdoctoral Trainee Fellowship ST-PDF 147(03-1)BM (Fellow: Bateman, Ryan)</td>
<td>$7,125.00</td>
<td>Mechanism of myocardial dysfunction in sepsis</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Walley</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-53051</td>
<td>$109,661.00</td>
<td>Myocardial Dysfunction Induced by ICAM-1 binding</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Walley</td>
<td>Contract</td>
<td>Sirius Genomics Inc.</td>
<td>$91,520.00</td>
<td>CRA: Association of the influence of inflammatory mediator polymorphisms with outcomes in systemic inflammatory response syndrome (SIRS) and multiple organ system failure (MOSF)</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Walley</td>
<td>Grant</td>
<td>H&amp;SFBC: Research</td>
<td>$83,000.00</td>
<td>Mechanism of Myocardial Dysfunction during Sepsis</td>
</tr>
<tr>
<td>Critical Care</td>
<td>Walley</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-67186</td>
<td>$80,952.00</td>
<td>Influence of polymorphisms in coagulation pathway in inflammatory mediator genes on phenotype post-cardiopulmonary bypass surgery</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Dutz</td>
<td>Grant</td>
<td>National Alopecia Areata Fdn (US)</td>
<td>$40,896.00</td>
<td>Screening for cytotoxic T lymphocyte epitopes in alopecia areata</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Dutz</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-69004</td>
<td>$114,332.00</td>
<td>Modifying islet antigen presentation to treat diabetes</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Dutz</td>
<td>Grant</td>
<td>CIHR/Strategic: Request for Applications NSM-66117 in collaboration with: Institute of Musculoskeletal Health and Arthritis (CIHR)</td>
<td>$63,979.00</td>
<td>Chemo-immunotherapy and CTL priming to treat malignant melanoma</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Dutz</td>
<td>Grant</td>
<td>JDFI: Research 5-2004-223</td>
<td>$59,956.00</td>
<td>RFA: New Discoveries - High Risk Grant: Tolerance induction by skin immunization</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Abbott Laboratories</td>
<td>$8,467.00</td>
<td>Protocol M02-529: Phase II Multicenter Extension Study of the Safety &amp; Efficacy of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque Psoriasis</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Centocor Inc.</td>
<td>$130,193.00</td>
<td>C0168T44: Phase III Multicenter Randomized Double-Blind Placebo-Controlled Trial Evaluating the Efficacy and Safety</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$3,000.00</td>
<td>CASM981C2442: 12 Week Multicenter Study Consisting of a 6 Week Double-Blind Randomized Vehicle Controlled Parallel Group Dose-Finding Core Study Followed by a 6 Week Open Label Phase to Assess the Safety &amp; Efficacy of Elidel Cream 1% in Mild to Moderate ...</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$1,690.00</td>
<td>Extension 1 to ASM981 C201: A Safety Extension Study of Patients Treated in a 12 Week Randomized Double-Blind Placebo-Controlled Multicenter Parallel-Group Dose-Finding Core Study to Determine the Dose-Response Safety &amp; Tolerability of 3 ...</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Fujisawa Canada Inc.</td>
<td>$5,600.00</td>
<td>FG-506-06-33: Long-Term Non-Comparative Study to Evaluate the Safety and Efficacy of Tacrolimus Ointment in Pediatric Patients</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Fujisawa Canada Inc.</td>
<td>$28,250.00</td>
<td>FG-506-06-32: Randomized Multicentre Double-Blind Pharmacokinetic Study of Tacrolimus Ointment (0.03%) in Pediatric Patients (aged 3 months to 24 months) with Atopic Dermatitis Following First and Repeated Once Daily or Twice Daily ...</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Abbott Laboratories, Limited (Canada)</td>
<td>$4,388.00</td>
<td>Protocol M03-658: Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study with Adalimumab</td>
</tr>
<tr>
<td>Department</td>
<td>Name</td>
<td>Type</td>
<td>Grantor</td>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>------------------</td>
<td>------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Fujisawa Healthcare Inc.</td>
<td>$44,793.00</td>
<td>Protocol FG 03-0-166: Phase 3 Randomized Double-Blind Study Comparing Twice Daily Tacrolimus Cream 0.03% vs Cream Vehicle in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$33,579.00</td>
<td>CASM981C2315: 26-week Randomized Multicenter Parallel-Group Double-Blind Vehicle-Controlled Study to Evaluate the Incidence of Atopic Dermatitis Flares When ASM981 (pimecrolimus) Cream 1% is Used at the First Signs and/or Symptoms of Atopic…</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Ho</td>
<td>Clinical Trial</td>
<td>Abbott Laboratories, Limited (Canada)</td>
<td>$791.00</td>
<td>Protocol M02-528: Phase 2 Multicentre Study of the Safety and Efficacy of Adalimumab (D2E7) in Subjects with Moderate to Severe Chronic Plaque Psoriasis</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Li</td>
<td>Grant</td>
<td>NCIC: Research Grant 01424</td>
<td>$123,264.00</td>
<td>Functional role of p33ING1 phosphorylation in cellular stress response to DNA damage</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Li</td>
<td>Grant</td>
<td>MSFHR: Doctoral Trainee</td>
<td>$2,500.00</td>
<td>Functional role of p33ING1 phosphorylation in cellular stress response to DNA damage</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Li</td>
<td>Grant</td>
<td>NCIC: Research Grant 014029</td>
<td>$129,912.00</td>
<td>Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA and Apaf-1</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Li</td>
<td>Grant</td>
<td>CIHR: Operating Grant DOP 62280</td>
<td>$9,375.00</td>
<td>Mechanisms of the novel tumour suppressor p33ING1 in UV-induced apoptosis of melanoma cells</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Li</td>
<td>Grant</td>
<td>MSFHR: Junior Graduate Studentship Award ST-JGS 31(03-1)BM</td>
<td>$2,292.00</td>
<td>Enhancement of melanoma chemosensitivity by adenoviral delivery of PUMA</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Li</td>
<td>Grant</td>
<td>NCIC/CCS: Research Scientist 012443</td>
<td>$88,539.00</td>
<td>Role of p33ING1 in repair of uv-damaged dna</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Lui</td>
<td>Clinical Trial</td>
<td>Biogen Idec, Inc.</td>
<td>$22,297.00</td>
<td>Protocol C-733: An Open-Label Multicentre Study to Evaluate the Safety &amp; Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients with Chronic Plaque Psoriasis</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Lui</td>
<td>Clinical Trial</td>
<td>Fujisawa Canada Inc.</td>
<td>$67,928.00</td>
<td>Protocol FG 03-0-171: Phase 3 Long-Term Open-Label study to Evaluate the Safety of Once Daily 0.3% Tacrolimus Gel in the Treatment of Psoriasis</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Lui</td>
<td>Clinical Trial</td>
<td>QLT PhotoTherapeutics Inc.</td>
<td>$10,095.00</td>
<td>Protocol VFI MBCC 02: A Randomized, Placebo-Controlled, Masked, Multicentre, Phase III Study of Photodynamic Therapy with Verteporfin for Injection (VFI) for the Treatment of Multiple Basal Cell Carcinoma</td>
</tr>
<tr>
<td>Dermatology</td>
<td>McElwee</td>
<td>Grant</td>
<td>Dean of Medicine: Spring Start Up Funds</td>
<td>$60,000.00</td>
<td>Mechanisms of hair disease</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Prendiville</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$4,000.00</td>
<td>A 5-year, multicenter, open-label, parallel group, randomized study to demonstrate the short and long-term safety of Elidel (pimecrolimus, ASM981) cream 1% in the treatment of mild to moderate atopic dermatitis in infant ($&lt;12$ months of age)</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Rivers</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$39,615.00</td>
<td>CASM981M2301: 6 Week Randomized Multicenter Double-Blind Placebo-Controlled Parallel Group Study to Investigate the Efficacy &amp; Safety of Elidel Cream 1% in Patients With Mild to Moderate Chronic Hand Dermatitis Followed by a 6 Week Open …</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Shapiro</td>
<td>Clinical Trial</td>
<td>Isotechnika, Inc.</td>
<td>$16,080.00</td>
<td>ISA04-03: Phase III Randomized Multicentre Double-Blind Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Shapiro</td>
<td>Clinical Trial</td>
<td>Leo Laboratories Canada Ltd</td>
<td>$41,270.00</td>
<td>Protocol MBL 0401 INT: Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Shapiro</td>
<td>Clinical Trial</td>
<td>QLT PhotoTherapeutics Inc.</td>
<td>$75,441.00</td>
<td>Protocol T0074 AGA 002: Phase II Treatment Optimization Study of Photodynamic Therapy for Androgenetic Alopecia with Topical QLT0074</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Zhou</td>
<td>Grant</td>
<td>VCHRI: Scholar Award</td>
<td>$30,000.00</td>
<td>Molecular Pathogenesis of Sezary Syndrome - Gene Signatures of Sezary Cells</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Zhou</td>
<td>Grant</td>
<td>Cdn Dermatology Fdn: Research</td>
<td>$50,000.00</td>
<td>Endothelin-3 in malignant melanoma</td>
</tr>
<tr>
<td>Division</td>
<td>Name</td>
<td>Type</td>
<td>Grantor</td>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Zhou</td>
<td>Grant</td>
<td>National Rosacea Society: Research Grant</td>
<td>$47,953.00</td>
<td>Molecular Disease Markers</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Dawson</td>
<td>Clinical Trial</td>
<td>Hoechst-Roussel Pharmaceuticals, US</td>
<td>$1,370.00</td>
<td>HOPE Study: Heart Outcomes Prevention Evaluation</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Elliott</td>
<td>Clinical Trial</td>
<td>Eli Lilly Canada Inc.</td>
<td>$10,000.00</td>
<td>Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Elliott</td>
<td>Clinical Trial</td>
<td>National Institutes of Health</td>
<td>$221,754.00</td>
<td>Action to control Cardiovascular Risks in Diabetes (ACCORD) Trial</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Elliott</td>
<td>Grant</td>
<td>VCHRI: Interdisciplinary Grant</td>
<td>$9,945.00</td>
<td>Post-operative Glicemic Control in Surgical Patients (POGS) - A Feasibility Study to Determine the Frequency of Hypoglycemia when Principles of Intensive Insulin Therapy are Applied to Post-Operative Surgical Patients 502.397 (AMADEO): Prospective Randomized Double-Blind Double-Dummy Forced-Titration Multicentre Parallel-Group 1 Yr Treatment Trial to Compare Micardis (telmisartan) 80mg vs Cozaar (Losartan) 100mg in Hypertensive Type 2 Diabetic Patients with..</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Elliott</td>
<td>Clinical Trial</td>
<td>Boehringer Ingelheim (Canada) Ltd.</td>
<td>$23,777.00</td>
<td>Action to control Cardiovascular Risks in Diabetes (ACCORD) Trial</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Elliott</td>
<td>Clinical Trial</td>
<td>Bristol-Myers Squibb Company (Cda)</td>
<td>$8,453.00</td>
<td>CV131169: Irbesartan vs Placebo in Combination with Standard Cardiovascular Protection ACE-1 Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk NAVIGATOR: Multinational Randomized Double-Blind Placebo-Controlled Forced-Titration 2x2 Factorial Design Study of the Efficacy &amp; Safety of Long Term Administration of Nateglinide &amp; Valsartan in the Prevention of Diabetes &amp; Cardiovascular..</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Elliott</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$27,369.00</td>
<td>NAVIGATOR: Multinational Randomized Double-Blind Placebo-Controlled Forced-Titration 2x2 Factorial Design Study of the Efficacy &amp; Safety of Long Term Administration of Nateglinide &amp; Valsartan in the Prevention of Diabetes &amp; Cardiovascular..</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Kreisman</td>
<td>Agreement</td>
<td>NIH (US): Research Grant 5R01-DK058356-03, PO Q643711310 in collaboration with: University of Minnesota CIHR/Rx&amp;D: Research Program</td>
<td>$519.00</td>
<td>Diabetes Therapy to Improve BMI and Pulmonary Function in CF Subjects with Abnormal Glucose Tolerance</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Prior</td>
<td>Grant</td>
<td>CIHR/Rx&amp;D: Research Program</td>
<td>$38,800.00</td>
<td>(CAMOS) Canadian multicentre osteoporosis study - a cross sectional and prospective observational study of bone density, bone strength and fracture risk Youn g women and osteoporosis: building our knowledge and resources</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Prior</td>
<td>Grant</td>
<td>Vancouver Foundation</td>
<td>$13,564.00</td>
<td>Youn g women and osteoporosis: building our knowledge and resources</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Prior</td>
<td>Grant</td>
<td>VCHRI: Interdisciplinary Grant</td>
<td>$8,574.00</td>
<td>Community Pharmacists’ Knowledge about Progesterone: Knowledge Translation within the Vancouver Coastal Health Authority</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Prior</td>
<td>Grant</td>
<td>Various Sources</td>
<td>$5,877.00</td>
<td>Centre for Menstrual Cycle and Ovulation Research (CEMCOR)</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Prior</td>
<td>Grant</td>
<td>Donations for Health Science Research</td>
<td>$3,887.00</td>
<td>Exercise, Reproduction and Health Research Fund</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Prior</td>
<td>Grant</td>
<td>MSFHR: Institutional Infrastructure Support Program INS002031</td>
<td>$3,600.00</td>
<td>Validation of perimenopause experiences project (PEP) tool using interpersonal comparisons</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Sadar</td>
<td>Grant</td>
<td>CIHR: Doctoral Research Awards JMO 58977 In collaboration with: Canadian Prostate Cancer Research Initiative (Fellow: Quayle, Steven)</td>
<td>$1,000.00</td>
<td>Identification of new targets for the treatment of androgen-independent prostate cancer</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Sadar</td>
<td>Grant</td>
<td>MSFHR: Doctoral Trainee Research Award 75(02-1)BM (Fellow: Quayle, Steven)</td>
<td>$2,500.00</td>
<td>Identification of new targets for the treatment of androgen-independent prostate cancer</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Sadar</td>
<td>Grant</td>
<td>Health Canada</td>
<td>$100,000.00</td>
<td>Androgen independence</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>Sadar</td>
<td>Grant</td>
<td>Health Canada</td>
<td>$103,000.00</td>
<td>Potential new therapy for androgen independent Protocol ELN100226-CD351: Phase III Multicenter Open-Label Long-Term Study of the Safety Tolerability &amp; Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects who have Previously Participated in Studies CD251</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Elan Pharmaceuticals Inc.</td>
<td>$11,322.00</td>
<td>Development of a new therapy for ulcerative Colitis (CD351) Protocol ELN100226-CD351: Phase III Multicenter Open-Label Long-Term Study of the Safety Tolerability &amp; Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects who have Previously Participated in Studies CD251</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Bristol-Myers Squibb Pharmaceutical Group (Cda)</td>
<td>$11,300.00</td>
<td>Protocol AI463-026: A Phase 3 Study of the Comparison of Entecavir to Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Current Lamivudine Therapy</td>
</tr>
<tr>
<td>------------------</td>
<td>----------</td>
<td>----------------</td>
<td>-----------------------------------------------</td>
<td>----------</td>
<td>---------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Bristol-Myers Squibb Company (Cda)</td>
<td>$10,000.00</td>
<td>A1463-022: Phase III study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hepatitis B infection who are positive for hepatitis B E antigen</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Schering Canada Inc.</td>
<td>$47,907.00</td>
<td>Protocol No. P02370: PEG-Intron Plus Rebetol for the Treatment of Subjects with Chronic Hepatitis C who Failed to Respond to Previous Combination Therapy (Any alpha Interferon Treatment in Combination with Ribavirin)</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Centocor Inc.</td>
<td>$11,141.00</td>
<td>Protocol C016B37 (ACT 1): Randomized Placebo-Controlled Double-Blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Bristol-Myers Squibb Company (Cda)</td>
<td>$11,440.00</td>
<td>Protocol AI463-901: A Preliminary Assessment of Safety and Antiviral Activity of Open-Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic Hepatitis B Who Have Viremia on Monotherapy in Other Entecavir Trials</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Protein Design Labs, Inc.</td>
<td>$70,631.00</td>
<td>Protocol No. P02370: PEG-Intron Plus Rebetol for the Treatment of Subjects with Chronic Hepatitis C who Failed to Respond to Previous Combination Therapy (Any alpha Interferon Treatment in Combination with Ribavirin)</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Protein Design Labs, Inc.</td>
<td>$3,944.00</td>
<td>ZAF-707: Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-y Monoclonal Antibody (HuZAF) Administered to Patients with Moderate to Severe Ulcerative Colitis, Protocol No. AI463-022: Phase III study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hepatitis B infection who are positive for hepatitis B E antigen</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Bristol-Myers Squibb Company (Cda)</td>
<td>$161.00</td>
<td>Protocol AI463-022: Phase III study of the safety and antiviral activity of entecavir vs lamivudine in adults with chronic hepatitis B infection who are positive for hepatitis B E antigen</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Anderson</td>
<td>Clinical Trial</td>
<td>Tillotts Pharma AG</td>
<td>$2,578.00</td>
<td>Protocol TP0308: EPIC-2 Phase III Randomized Placebo-Controlled Double-Blind Parallel Group Multicentre Study to Assess the Efficacy &amp; Safety of Omega-3 Free Fatty Acids (Epanova) for the Maintenance of Symptomatic Remission in Subjects</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns</td>
<td>Clinical Trial</td>
<td>Abbott Laboratories</td>
<td>$4,660.00</td>
<td>(M04-690) A multi-Centre, Open-label Study of the Human Anti-TNF Monoclonal Adalimumab in Subjects with Crohn's Disease</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns</td>
<td>Clinical Trial</td>
<td>Abbott Laboratories</td>
<td>$131,956.00</td>
<td>A multi-center, randomised, double-blind, placebo-controlled study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of clinical remission in subjects with Crohn's disease, Clinical Study Protocol M02-403</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns</td>
<td>Clinical Trial</td>
<td>AstraZeneca Canada Inc</td>
<td>$11,432.00</td>
<td>A 4-week, randomised, double-blind, multicentre, dose-finding phase Ib study with AZD0865 25, 50, 75mg and esomeprazole 20mg, given orally once daily for the treatment of GERD without erosive esophagitis according to the LA classification in adults...</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns</td>
<td>Clinical Trial</td>
<td>AstraZeneca Canada Inc</td>
<td>$9,370.00</td>
<td>A randomized, double-blind, multicentre dose-finding, phase Ib study for up to 8 weeks' treatment with AZD0865 25, 50, 75mg and esomeprazole 40mg, given orally once daily for the healing of erosive esophagitis in adult subjects with GERD...</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns</td>
<td>Grant</td>
<td>Elan Pharmaceuticals Inc.</td>
<td>$295,945.00</td>
<td>A Phase III Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Studies CD251, CD301,CD303, CD306 (Substudy)</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns</td>
<td>Grant</td>
<td>Parexel International Corporation</td>
<td>$18,245.00</td>
<td>A Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome (CI 0600-004)</td>
</tr>
<tr>
<td>Division</td>
<td>Investigator</td>
<td>Sponsor</td>
<td>Amount</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------------------</td>
<td>--------------------------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Otsuka America Pharmaceutical Inc.</td>
<td>$17,820.00</td>
<td>A prospective, randomized, double-blinded placebo (sham)-controlled study to evaluate the safety and effectiveness of the Adacolumn Apheresis system for the treatment of moderate to severe ulcerative colitis (512-04-205)</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Tillotts Pharma AG</td>
<td>$16,123.00</td>
<td>A phase III randomized, placebo-controlled, double-blind, parallel group, multi-centre study to assess the efficacy and safety of Omega-3 free fatty acids (Epanova(TM)) for the maintenance of symptomatic remission in subjects with Crohn's Disease (M04-061)</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Altana Pharma, Inc.</td>
<td>$7,350.00</td>
<td>A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease Who Have Lost Response…</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Altana Pharma, Inc.</td>
<td>$3,745.00</td>
<td>Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80mg od in comparison to pantoprazole-sodium sesquihydrate 40mg</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>NDO Surgical, Inc</td>
<td>$39,167.00</td>
<td>Study of the NDO endoscopic plication system for the treatment of symptomatic gastroesophageal reflux disease</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Celltech Research Ltd.</td>
<td>$7,284.00</td>
<td>A phase III multi-national, multi-centre, double-blind, placebo-controlled, parallel-group, 26-week study to assess the maintenance of clinical response to humanised anti-TNF PEG conjugate, CDP870 400mg sc, (dosed 4-weekly from weeks 8 to 24)</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Abbott Laboratories</td>
<td>$34,761.00</td>
<td>A multi-center, randomised, double-blind, placebo-controlled study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of clinical remission in subjects with Crohn's disease. Clinical Study Protocol M02-0433</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Enns Clinical Trial</td>
<td>Abbott Laboratories</td>
<td>$239,301.00</td>
<td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in subjects with Crohn's Disease</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gray Clinical Trial</td>
<td>AstraZeneca Canada Inc</td>
<td>$12,655.00</td>
<td>D9770C00012: Randomized Double-Blind Multicentre Dose-Finding Phase IIb Study for up to 8 Weeks Treatment with AZD0865 25,50,75mg and Esomeprazole 40mg Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects with…</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gray Clinical Trial</td>
<td>AstraZeneca Canada Inc</td>
<td>$10,124.00</td>
<td>D9770C00011: 4 Week Randomized Double-Blind Multicentre Dose-Finding Phase IIb Study With AZD0865 25, 50, 75mg &amp; Esomeprazole 20mg Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification…</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gray Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$3,000.00</td>
<td>CHTF919G2203: 6 Week Randomized Double-Blind Double-Dummy Placebo-Controlled Multicenter Study to Assess the Effect of Tegaserod 2mg tid and 6mg tid on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gray Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$3,175.00</td>
<td>CHTF919A2417: 4 Week Multicenter Double-Blind Placebo-Controlled Randomized Parallel-Group Clinical Study to Evaluate the Efficacy of Tegaserod in Relieving in the Symptoms of Female Patients with IBS Excluding Those With Predominant Diarrhea…</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gray Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc</td>
<td>$3,750.00</td>
<td>CHTF919E2309: Randomized Double-Blind Placebo-Controlled Multicenter Evaluation of the Efficacy and Safety of Tegaserod (6mg bid) Administered Orally for 12 Weeks in Male Patients With Chronic Constipation</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gray Clinical Trial</td>
<td>Janssen-Ortho Inc.</td>
<td>$6,875.00</td>
<td>RAB-GRD-3001: Randomized Controlled Parallel-Group Open-Label Study to Evaluate Different Dosing Regimens of Rabeprazole in Controlling Nocturnal Heartburn Symptoms in Patients with Gastroesophageal Reflux Disease</td>
<td></td>
</tr>
<tr>
<td>Department</td>
<td>Grant Type</td>
<td>Sponsor/Institution</td>
<td>Amount</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------</td>
<td>--------------------------------------------</td>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Idenix Pharmaceuticals, Inc.</td>
<td>$4,214.00</td>
<td>NV-02B-010: Phase Ib Extension Study of LoT (Telbivudine) Lamivudine or LoT plus Lamivudine in Subjects with Chronic Hepatitis B Who Have Completed Study NV-02B-003</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Idenix Pharmaceuticals, Inc.</td>
<td>$1,957.00</td>
<td>Protocol NV-02B-007: Randomized Double-Blind Trial of LoT (Telbivudine) vs Lamivudine in Adults with Compensated Chronic Hepatitis B</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Broncus Technologies, Inc.</td>
<td>$7,504.00</td>
<td>Feasibility Study of the Broncus Alair System for the treatment of asthma</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>CIHR: Operating Grant</td>
<td>$98,276.00</td>
<td>Pathogenesis of atherosclerosis</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>Geraldine Dow Ferry Endowment Fund</td>
<td>$75,000.00</td>
<td>Endowment for inflammatory bowel disease research and education</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>Canadian Liver Fdn : Summer Studentship Program Fellow: Parhar, Kuljit</td>
<td>$4,000.00</td>
<td>Modulation of survival pathways in Kupffer cells by oxidized LDL</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>Donation</td>
<td>$500.00</td>
<td>Clinical Research in Chronic Liver Diseases</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>CAG/CIHR: New Operating Grant</td>
<td>$40,000.00</td>
<td>Genome-wide analysis reveals a novel gene involved in chemotherapy resistance in colorectal cancers</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>Various Sources</td>
<td>$37,688.00</td>
<td>Laboratory start-up fund</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Grant</td>
<td>CSIR: Research Grant</td>
<td>$25,000.00</td>
<td>Dissecting chemotherapy resistance in colorectal cancer using a genome-wide approach</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Micrologix Biotech Inc</td>
<td>$15,000.00</td>
<td>HCV-04-001: Phase II Randomized Dose-Ranging Open-Label Multicentre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients with Chronic Hepatitis C Infection</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Hoffmann-La Roche</td>
<td>$1,300.00</td>
<td>An extension Protocol to Evaluate the Long-term Effects of Treatment with Peginterferon Alpha-2a (PEG-IFN) or Roferon A for Patients with Chronic Hepatitis C in Original Studies NV15495, NV15496 and NV 15497</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Gilead Sciences</td>
<td>$3,309.00</td>
<td>Protocol GS-01-550: Phase 3b Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients with Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Human Genome Sciences, Inc.</td>
<td>$65,088.00</td>
<td>ALFR-HC-03CA: Double Injection Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Albuferon (Recombinant Human Albumin-Interferon alfa fusion protein) in Interferon Alfa Naive Subjects with Chronic...</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Ortho Biotech</td>
<td>$8,250.00</td>
<td>HEPC-AN-2: Prospective Study to Evaluate the Hemoglobin Levels of Hepatitis C Virus Infected Patients Receiving Treatment with Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon</td>
<td></td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Clinical Trial</td>
<td>Hoffmann-La Roche Ltd (Canada)</td>
<td>$8,900.00</td>
<td>BV16209 A Multicenter Open Label Expanded Access Program of Peginterferon alfa-2a (ra 25-8310) Monotherapy and Combination Therapy with Ribavirin (Ro20-9963) in Patients with Chronic Hepatitis C</td>
<td></td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Grant</td>
<td>MSFHR: Institutional Infrastructure Support Program INS002031</td>
<td>$3,600.00</td>
<td>Prevalence and Mortality from eating disorders</td>
<td></td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Grant</td>
<td>RCPCSC: Medical Education Research Grant</td>
<td>$21,350.00</td>
<td>Evaluation of a modified mini-clinical evaluation exercise as a high stakes assessment of clinical competence</td>
<td></td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Grant</td>
<td>MSFHR: Scholar Award CI-SCH-57(02-1)</td>
<td>$80,000.00</td>
<td>CHIPS (control of hypertension in pregnancy study): a pilot trial</td>
<td></td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Grant</td>
<td>MSFHR: Matching Establishment Grant C1-SCH-57(02-1)</td>
<td>$25,000.00</td>
<td>CHIPS (control of hypertension in pregnancy study): a pilot trial</td>
<td></td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Grant</td>
<td>MSFHR: Matching Establishment Grant C1-SCH-57(02-1)</td>
<td>$37,500.00</td>
<td>CHIPS (control of hypertension in pregnancy study): a pilot trial</td>
<td></td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Grant</td>
<td>MSFHR: Senior Scholar Award CI-SSH-083(03-1)POPN</td>
<td>$66,250.00</td>
<td>Health research of vulnerable urban populations</td>
<td></td>
</tr>
<tr>
<td>Division</td>
<td>Name</td>
<td>Grant Type</td>
<td>Project Title</td>
<td>Funding Amount</td>
<td>Description</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Palepu</td>
<td>Grant</td>
<td>CIHR: New Investigator Award (CIHR Scholarship) # HNI-50103</td>
<td>$ 24,000.00</td>
<td>Social determinants and HIV: a community-based intervention in injection drug users (IDUs)</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Palepu</td>
<td>Grant</td>
<td>CIHR: Operating Grant HPI-66923</td>
<td>$ 61,635.00</td>
<td>Development of a Quality of Life Instrument for Homeless Persons and Street Youth</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Palepu</td>
<td>Grant</td>
<td>CIHR: New Investigator Award (CIHR Scholarship) # HNI-50103</td>
<td>$ 1,000.00</td>
<td>Social Determinants and HIV: an evaluation of a community-based intervention in injection drug users (research allowance)</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Studney</td>
<td>Clinical Trial</td>
<td>Sanofi-Synthelabo Canada Inc. CHARISMA</td>
<td>$ 3,670.00</td>
<td>Protocol EFC4505: CHARISMA - Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Studney</td>
<td>Clinical Trial</td>
<td>Aventis Pharma Inc</td>
<td>$ 1,000.00</td>
<td>HOE 901/3502: Open-Label, Multicentre, Randomized Study to Assess an Early Insulization Strategy with Insulin Glargine vs a Standard Oral Strategy in the Management of Type 2 Diabetes</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Van Eeden</td>
<td>Grant</td>
<td>BC Lung: Project Grant 869231</td>
<td>$ 60,000.00</td>
<td>Development of an in vitro method for the controlled delivery of one or more particles to a single human lung cell: measurement of cytokine expression at the per cell per particle level</td>
</tr>
<tr>
<td>General Internal Med.</td>
<td>Magee</td>
<td>Grant</td>
<td>Sunnybrook Health Science Centre</td>
<td>$ 12,100.00</td>
<td>Control of hypertension in pregnancy - pilot study</td>
</tr>
<tr>
<td>Geriatric Medicine</td>
<td>Adler</td>
<td>Grant</td>
<td>BCMSF: Research Grant BCM03-0128</td>
<td>$ 47,755.00</td>
<td>Access to health services: The experience of newer, older immigrants to Greater Vancouver</td>
</tr>
<tr>
<td>Geriatric Medicine</td>
<td>Adler</td>
<td>Grant</td>
<td>Various Sources</td>
<td>$ 25,000.00</td>
<td>Research support: Addressing the root causes of genocide</td>
</tr>
<tr>
<td>Geriatric Medicine</td>
<td>Beattie</td>
<td>Grant</td>
<td>MSFHR Health Research Network Proposal Development Award IN-NTC-006-045</td>
<td>$ 24,600.00</td>
<td>BC’s aging network research program (BCANRP)</td>
</tr>
<tr>
<td>Geriatric Medicine</td>
<td>Beattie</td>
<td>Agreement</td>
<td>CIHR: Operating Grant MOP-57668 in collaboration with University Health Network</td>
<td>$ 14,400.00</td>
<td>Canadian Alzheimer's disease quality of life study</td>
</tr>
<tr>
<td>Geriatric Medicine</td>
<td>Meneilly</td>
<td>Grant</td>
<td>Cdn Diabetes Assoc.: Charles H. Best Fund/Grant-in-Aid</td>
<td>$ 74,737.00</td>
<td>Diabetes in the Elderly</td>
</tr>
<tr>
<td>Hematology</td>
<td>Hogge</td>
<td>Grant</td>
<td>CIHR: Operating Grant IC1 - 70245</td>
<td>$ 45,836.00</td>
<td>Optimization of the use of diptheria toxin-growth factor fusion proteins for treatment of acute leukemia</td>
</tr>
<tr>
<td>Hematology</td>
<td>Hogge</td>
<td>Clinical Trial</td>
<td>Janssen-Ortho Inc.</td>
<td>$ 2,088.00</td>
<td>Protocol R115777-INT-21: Open-Label Phase 2 Study of the Farnesyl Transferase Inhibitor Zarnestra (R115777) as Postconsolidation Therapy for Acute Myeloid Leukemia (AML) in Subjects 60 Years and Older C-300-01 CML: Phase II Study of AG-858 Plus Gleevec in Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase who are Cytogenetically Positive After Treatment with Gleevec</td>
</tr>
<tr>
<td>Hematology</td>
<td>Hogge</td>
<td>Clinical Trial</td>
<td>Antigenics, Inc.</td>
<td>$ 3,864.00</td>
<td>Characterization of the role of MEIS1 in hematopoiesis</td>
</tr>
<tr>
<td>Hematology</td>
<td>Humphries</td>
<td>Grant</td>
<td>MSFHR: Postdoctoral Trainee Fellowship STPDF 163021 (Fellow: Hirose, Koichi)</td>
<td>$ 11,000.00</td>
<td>Molecular mechanisms linking Hox transcription factors to leukemia</td>
</tr>
<tr>
<td>Hematology</td>
<td>Humphries</td>
<td>Grant</td>
<td>NCE/Stem Cell Network: Research</td>
<td>$ 396,846.00</td>
<td>HOXB4 target-genes specifying hematopoietic stem cell self-renewal</td>
</tr>
<tr>
<td>Hematology</td>
<td>Humphries</td>
<td>Grant</td>
<td>NCE/Stem Cell Network: Research Student Award - Argiropoulos, Bob</td>
<td>$ 20,000.00</td>
<td>Characterization of the role of MEIS1 in hematopoiesis</td>
</tr>
<tr>
<td>Hematology</td>
<td>Lansdorp</td>
<td>Grant</td>
<td>CFI Infrastructure Operating Fund 3857</td>
<td>$ 5,000.00</td>
<td>Molecular mechanics linking Hox transcription factors to leukemia</td>
</tr>
<tr>
<td>Hematology</td>
<td>Lansdorp</td>
<td>Grant</td>
<td>CFI Infrastructure Operating Funds - Stem Cell Centre - Operations</td>
<td>$ 67,000.00</td>
<td>Characterization of the role of MEIS1 in hematopoiesis</td>
</tr>
<tr>
<td>Year</td>
<td>Department</td>
<td>Award Type</td>
<td>Grant ID</td>
<td>Amount</td>
<td>Project Description</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------</td>
<td>-------------------------------------</td>
<td>---------------------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Lansdorp Grant</td>
<td>CIHR: Operating Grant</td>
<td>$113,500.00</td>
<td>Replicative Shortening of Telomeres in Human Cells</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Lansdorp Grant</td>
<td>CIHR: Canadian Graduate</td>
<td>$5,000.00</td>
<td>Molecular mechanism of genome stability and telomere shortening in dog-1 mutants</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Lansdorp Grant</td>
<td>MSFHR: Doctoral Trainee</td>
<td>$2,000.00</td>
<td>Molecular mechanisms of genomic instability and telomere shortening in Dog-1 mutants</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Lansdorp Grant</td>
<td>NCE/Stem Cell Network:</td>
<td>$20,000.00</td>
<td>The effect of artificial Telomere Elongation using lentiviral based transduction of hTERT in Human hematopoietic stem cells</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Lavoie Grant</td>
<td>MSFHR: Institutional</td>
<td>$2,250.00</td>
<td>Risks and outcomes of invasive Aspergillus infections in allogenic stem cell</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Schrader Grant</td>
<td>Canada Research Chair</td>
<td>$2,406.00</td>
<td>A phase III study of ST1571-106 versus Interferon-a (IFN-A) combined with</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Schrader Grant</td>
<td>Canada Research Chair</td>
<td>$15,612.00</td>
<td>Phase III Study of Concurrent Tretinoin and Chemotherapy With/Without Arsenic T include As203 (NSC#706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin vs Intermittent Tretinoin and Mercaptopu..</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Schrader Grant</td>
<td>Canada Research Chair</td>
<td>$100,000.00</td>
<td>Canada Research Chair in cell therapies for Dr. Clayton Smith</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Smith Grant</td>
<td>AnorMed Inc.</td>
<td>$9,000.00</td>
<td>Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Vickars Grant</td>
<td>Bristol-Myers Squibb, US</td>
<td>$1,500.00</td>
<td>Protocol CV185-010: A Phase 2 Randomized, Double-blinded (BMS-562247 and</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Vickars Grant</td>
<td>Heart and Stroke Foundation</td>
<td>$1,256.00</td>
<td>REVERSE (REcurrent Venous thromboembolism Risk Stratification Evaluation) A study to develop a clinical prediction rule to predict low recurrence risk in patients with idiopathic venous thromboembolism</td>
</tr>
<tr>
<td>2004</td>
<td>Hematology</td>
<td>Vickars Grant</td>
<td>Bayer Inc.</td>
<td>$95,077.00</td>
<td>Oral direct factor Xa inhibitor BAY 59-7939 in the prevention of VTE in patients undergoing total knee replacement.OCTXa-knee-a randomised, controlled, double-blind, double-dummy phase Ib dose-ranging trial Exclaim study - A double blind, placebo controlled, parallel, multi center study on extended VTE Prophylaxis in acutely ill medical patients with prolonged immobilization</td>
</tr>
<tr>
<td>Department</td>
<td>Award Type</td>
<td>Organization</td>
<td>Amount</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>------------</td>
<td>-------------------------------------</td>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>Clinical Trial</td>
<td>Aventis Pharmaceuticals Inc.</td>
<td>$8,346.00</td>
<td>An open-label, parallel-group, multi-center study to evaluate the efficacy and safety of enoxaparin versus unfractionated heparin in the prevention of venous thromboembolism in patients following acute ischemic stroke</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>Grant</td>
<td>Canadian Apheresis Group</td>
<td>$600.00</td>
<td>A comparison of solvent detergent vs cryosupernatant plasma in TTP and viral surveillance in apheresis</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>Clinical Trial</td>
<td>Sanofi-Synthelabo Canada Inc.</td>
<td>$69,003.00</td>
<td>The Van Gogh-DVT trial, a multicenter, international, randomized, open-label, assessor-blind, non-inferiority study comparing the efficacy and safety of once weekly subcutaneous SanOrg34006 with the combination of (LMW) Heparin and vitamin K and...</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>Clinical Trial</td>
<td>Boehringer Ingelheim (Canada) Ltd.</td>
<td>$1,500.00</td>
<td>A Phase III Randomized, Parallel-Group, Double-Blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150mg Day 2 - Completion, and 110mg Day 1 Followed by 220mg Day 2…</td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>Clinical Trial</td>
<td>Organon Inc</td>
<td>$5,089.00</td>
<td>The VanGogh extension trial, a multicenter, international, randomized, double-blind study comparing the efficacy and safety of once-weekly subcutaneous SanOrg34006 with placebo in the long-term prevention of symptomatic venous thromboembolism</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>CIHR: New Investigator Award</td>
<td>$25,000.00</td>
<td>Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary)</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>BC Lung/CIHR Investigator</td>
<td>$25,000.00</td>
<td>Molecular Analysis of Mycobacterium Tuberculosis Cell Signaling Elements (Salary),</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>Various Sources</td>
<td>$1,000.00</td>
<td>Role of Cholesterol in Tuberculosis Infection</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>MND Diagnostics Ltd</td>
<td>$16,103.00</td>
<td>Cloning and examination of Rhinovirus and SARS 3C protease as a diagnostic tool for viral infections</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>BC Lung: Project Grant Research</td>
<td>$30,000.00</td>
<td>Mycothiol dependent isoniazid resistance in Mycobacterium tuberculosis</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>NCE/Canadian Bacterial:</td>
<td>$33,302.00</td>
<td>Agilent 2100 Bioanalyzer (Equipment)</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>CIHR: Operating Grant MOP - 68857</td>
<td>$47,549.00</td>
<td>Molecular analysis of Mycobacterium tuberculosis protein kinases and phosphatases</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>VGH &amp; UBC Hospital Fdn</td>
<td>$61,294.00</td>
<td>TB Research - Various Sources</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>NCE/Canadian Bacterial: Research Phase III</td>
<td>$90,500.00</td>
<td>Phase III: Mycobacterium tuberculosis protein kinases and phosphatases as novel drug targets</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Contract</td>
<td>Nanobac Pharmaceuticals Inc</td>
<td>$162,108.00</td>
<td>Biochemical characterization of calcified particles originated from human and bovine area</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Av-Gay Grant</td>
<td>TB Vets; VH Foundation</td>
<td>$8,706.00</td>
<td>TB research support</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Brunham Grant</td>
<td>Aventis Pasteur</td>
<td>$100,000.00</td>
<td>Investigate protective efficacy &amp; immunogenicity in mice of Serovar D Pal antigen - Chlamydia trachomatis vaccine</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Brunham Grant</td>
<td>Aventis Pasteur</td>
<td>$37,500.00</td>
<td>DNA vaccine for Chlamydia trachomatis</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Brunham Grant</td>
<td>NIH/U. Washington</td>
<td>$98,000.00</td>
<td>Chlamydia and gonococcal infection: Immunobiology in the female reproductive tract</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Brunham Grant</td>
<td>CIHR</td>
<td>$121,470.00</td>
<td>Immunochemistry of Chlamydia trachomatis infection</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Brunham Grant</td>
<td>TIGR/NIH</td>
<td>$135,000.00</td>
<td>Comparative genomics of the Chlamydiaceae family of obligate intracellular parasites</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Cherkasov Grant</td>
<td>Dean of Medicine - Faculty Start Up funds</td>
<td>$9,700.00</td>
<td>In Silico Discovery of Novel Antibiotic Candidates</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Cherkasov Grant</td>
<td>VHHSC: Scholar Award</td>
<td>$30,000.00</td>
<td>Bioinformatics study of microbial pathogens</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Cherkasov Grant</td>
<td>MSFHR: Junior Graduate Studentship Award (Hsing, Michael)</td>
<td>$1,458.00</td>
<td>Modelling and simulating intra-cellular signalling systems in response to pathogen invasions by semantic networks</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Chow Grant</td>
<td>NCE/Canadian Bacterial:</td>
<td>$41,653.00</td>
<td>Multi-task gel documentation system (Equipment)</td>
<td></td>
</tr>
</tbody>
</table>
### UBC Department of Medicine
### Awards by Division for 2004-2005

**Infectious Diseases**

<table>
<thead>
<tr>
<th>Chow</th>
<th>Grant</th>
<th>Research</th>
<th>Amount</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>NCE/Canadian Bacterial Research</td>
<td>$98,020.00</td>
<td>Phase III: D4: Diagnosis of Intracellular Pathogens in Community-Acquired Pneumonia HSP60 Gene Sequences</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR: Operating Grant MT-7630</td>
<td>$98,278.00</td>
<td>Pathogenesis of Staphylococcal Toxic Shock Syndrome</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR/Strategic Training: Strategic Training Program Grant STI-63299 in collaboration with Institute of Infection and Immunity (CIHR)</td>
<td>$310,500.00</td>
<td>UBC Training program for translational research in infectious diseases</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>VCHRI</td>
<td>$10,000.00</td>
<td>Pilot Project: Heat shock protein 60 in staphylococcal pathogenesis: a new paradigm</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>MRC: MD/PhD Studentship: Lee, Jimmy</td>
<td>$1,000.00</td>
<td>Phagosome biogenesis</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>MRC: MD/PhD Studentship: Rauh, Michael</td>
<td>$1,000.00</td>
<td>Cytokine-mediated signal transduction in leukemia</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>MRC: MD/PhD Studentship: Yong, Paul</td>
<td>$1,000.00</td>
<td>Chromosomal abnormalities in reproduction failure and development</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR: MD/PhD: Coburn, Bryan</td>
<td>$1,000.00</td>
<td>The pathogenic of salmonella infection</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR: MD/PhD: Brunham, Liam</td>
<td>$1,000.00</td>
<td>Identification and validation of genes modulating LDL cholesterol in humans</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR: MD/PhD: Tan, Clara</td>
<td>$1,000.00</td>
<td>The regulation of transcription factors by integrin linked kinase in cancer cells</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>MSFHR: Senior Graduate Studentship Award: Kalyan, Shirin</td>
<td>$2,291.00</td>
<td>Role of yo T cells and HMG-1 in staphylococcal toxic shock syndrome</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR: MD/PhD Program Studentship: Heine, Heather</td>
<td>$1,000.00</td>
<td>Myocardial regeneration with hematopoietic stem cells</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>CIHR: MD/PhD Program Studentship: Joe, Aaron</td>
<td>$1,000.00</td>
<td>Molecular determinants of stem cell trafficking</td>
</tr>
<tr>
<td>Chow</td>
<td>Grant</td>
<td>MRC: MD/PhD Studentship: Sheldon, Claire</td>
<td>$1,000.00</td>
<td>Neuronal pH: Regulation in health and disease</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-64388 in collaboration with: Institute of Infection and Immunity (CIHR)</td>
<td>$92,816.00</td>
<td>Toxoplasma Surface Antigens and Immunity</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>CIHR: New Investigator Award (CIHR Scholarship) MSH-61790 (Fellow: Grigg, Michael, Infectious Diseases - Med, Van Coastal Health Research Inst.)</td>
<td>$43,875.00</td>
<td>Toxoplasma Surface Antigens and Immunity</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>VHHSC: Scholar Award</td>
<td>$30,000.00</td>
<td>Molecular Basis of Toxoplasma Pathogenesis</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>MSFHR: Career Investigator Program C1-SCH-26(01-2)</td>
<td>$36,500.00</td>
<td>Molecular basis of Toxoplasma Pathogenesis</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>CIHR: Proof of Principle PPP-67408</td>
<td>$87,487.00</td>
<td>Role of T regs in Toxoplasma pathogenesis. Co applicant M. Levings</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>CF: New Opportunities 9147</td>
<td>$260,000.00</td>
<td>Laboratory of Molecular Imaging and Parasite Pharmacogenomics</td>
</tr>
<tr>
<td>Grigg</td>
<td>Grant</td>
<td>MSFHR: Doctoral Trainee Research Award (STPHD 60021) - Brumme, Zabrina</td>
<td>$2,000.00</td>
<td>Factors impeding the success of HIV antiretroviral therapy today: genetic variation, viral evolution and drug resistance, and cellular reservoirs of HIV</td>
</tr>
<tr>
<td>Harrigan</td>
<td>Grant</td>
<td>CIHR: Doctoral Research Awards (CGD-65030) - Brumme, Zabrina</td>
<td>$5,000.00</td>
<td>An investigation into challenges faced in antiretroviral (anti-HIV) therapy today: human and viral genetic variation, HIV antiviral resistance and the existence of viral reservoirs</td>
</tr>
<tr>
<td>Division</td>
<td>Grant Type</td>
<td>Grant/Program Name</td>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------------------</td>
<td>----------------------------------------------------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Hmama Grant</td>
<td>Matching Establishment Grant CI-SCH-26(01-2)</td>
<td>$14,583.00</td>
<td>Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Hmama Grant</td>
<td>BC Lung: Project Grant</td>
<td>$30,000.00</td>
<td>Alteration of the macrophagic endosomal compartment by Mycobacteria. Role of the surface glycolipid lipoarabinomannan and the mycobacterial urease</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Hmama Grant</td>
<td>Postdoctoral Fellowship MFE-70513 (Fellow: Deghmane, Ala-Eddine)</td>
<td>$35,000.00</td>
<td>Identification and characterization of a mycobacterial secreted protein that interact with the actin binding protein coronin-1/TACO in human macrophages</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Hmama Grant</td>
<td>Career Investigator Program C1-SCH-26(01-2)</td>
<td>$45,000.00</td>
<td>Molecular study of interaction between Mycobacterium tuberculosis and the macrophage endosomal compartment: an approach to identify mycobacterial virulence factors.</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Hmama Grant</td>
<td>New Investigator Award (CIHR Scholarship)</td>
<td>$58,500.00</td>
<td>Cell signaling regulating mycobacterial-macrophae interactions</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Hmama Grant</td>
<td>Operating Grant MOP - 67232</td>
<td>$87,168.00</td>
<td>Identification of mycobacterial factors that inhibit phagosome maturation in human macrophages</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>TB Vets; VH Foundation</td>
<td>$70,000.00</td>
<td>TB research support</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Clinical Trial DCT-48206</td>
<td>$2,274.00</td>
<td>An Open Label, Randomized Study to Evaluate the Antiretroviral Effect, Tolerability, Safety and Pharmacokinetics of Squinavir SGC/Ritonavir QD vs. Indinavir/Norvir BID in HIV Infected Patients</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Clinical Trial Hoffmann-La Roche Ltd (Canada)</td>
<td>$375.00</td>
<td>An extension protocol to evaluate the long-term effects of treatment with Peginterferon Alpha-2a (PEG-IFN) or Interferon (IFN) based therapies for patients with chronic hepatitis C (Protocol NV15908B)</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Ontario HIV Treatment Network</td>
<td>$450.00</td>
<td>Non-invasive assessment of atherosclerosis and its determinants in HIV-infected people</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Clinical Trial Hoffmann-La Roche Ltd (Canada)</td>
<td>$3,240.00</td>
<td>A phase III open-label, randomized, active-controlled study assessing the efficacy and safety of T-20/Ro 29/9800 (HIV-1 fusion inhibitor) in combination with an optimized background regimen, versus optimized background regimen alone, in patients...</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Clinical Trial Bristol-Myers Squibb Company (Cda)</td>
<td>$3,300.00</td>
<td>A study to compare long-term safety and tolerability of Stavudine (d4T) extended release (ER) versus conventional (immediate release, IR) formulations, each in combination with Lamivudine (3TC) and Efavirenz (EFV) in subjects who have...</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Clinical Trial Janssen-Ortho Inc.</td>
<td>$4,145.00</td>
<td>A Phase II Randomized, Controlled, Partially Blinded, 48-Week Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced, Multi PI- Experienced HIV-1 Infected Subjects (TMC114-C213)</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Abbott Laboratories, Limited (Canada)</td>
<td>$5,000.00</td>
<td>A randomized controlled trial of once-daily tenofovir, 3TC and lopinavir/r versus remaining on the same regimen in HIV-infected patients virologically suppressed on their first PI-containing HAART regimen</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Clinical Trial Serono Inc.</td>
<td>$18,784.00</td>
<td>A phase III, multi-center, randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of serosim (mammalian cell-derived recombinant human growth hormone, r-HGH) in the treatment and maintenance of Human Immuno...</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Boehringer Ingelheim (Canada) Ltd.</td>
<td>$75,000.00</td>
<td>Ritonavir-boosted Tipranavir and Lopinavir: A Preliminary Pharmacokinetic Evaluation</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montaner Grant</td>
<td>Tibotec Pharmaceuticals Ltd</td>
<td>$78,625.00</td>
<td>Protocols TMC125-C203 and TMC125-C209</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Montessori Grant</td>
<td>Pfizer Canada Inc.</td>
<td>$43,938.00</td>
<td>Alanine Aminotransferase Elevations and Ishak-Knodell Scores in HIV/Hep C Co-Infected Patients</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Nandan Grant</td>
<td>Operating Grant MOP 38005</td>
<td>$82,162.00</td>
<td>Molecular Mechanism of Leishmania Pathogenesis</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Phillips Grant</td>
<td>Canadian Dermatology Association</td>
<td>$20,000.00</td>
<td>Abacavir hypersensitivity reaction: Investigations of immunopathogenesis</td>
</tr>
<tr>
<td>Department</td>
<td>Name</td>
<td>Grant Type</td>
<td>Fund/Grant Code</td>
<td>Amount</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------</td>
<td>-------------------------------------</td>
<td>-----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Reiner</td>
<td>Grant VPR Research Development Fund</td>
<td></td>
<td>$7,500.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Reiner</td>
<td>Grant UBC/PWIAS: Exploratory Workshop Grants</td>
<td>67408</td>
<td>$16,500.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Reiner</td>
<td>Grant CIHR: Proof of Principle PPP-8633</td>
<td>MOP-8633</td>
<td>$100,000.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Reiner</td>
<td>Grant CIHR: Operating Grant MOP-8633</td>
<td></td>
<td>$123,147.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Reiner</td>
<td>Grant MSFHR Fdn 57(02-1)BM:</td>
<td></td>
<td>$2,000.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Rekart</td>
<td>Grant CIDA</td>
<td></td>
<td>$855,988.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Steiner</td>
<td>Grant VHHSC Scholar Award</td>
<td></td>
<td>$50,000.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Steiner</td>
<td>Grant CIHR: New Investigator Award MSH 69156</td>
<td></td>
<td>$43,875.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Steiner</td>
<td>Grant CFI: Infrastructure Operating Fund 4453</td>
<td></td>
<td>$835.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Steiner</td>
<td>Grant CIHR: Operating Grant MOP-6435 in collaboration with: Institute of Infection and Immunity (CIHR)</td>
<td></td>
<td>$96,648.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Tyndall</td>
<td>Grant BC Centre for Excellence in HIV</td>
<td></td>
<td>$125,157.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Tyndall</td>
<td>Grant CIHR</td>
<td></td>
<td>$45,030.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Tyndall</td>
<td>Grant VCHA</td>
<td></td>
<td>$200,000.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Tyndall</td>
<td>Grant VCHA</td>
<td></td>
<td>$490,000.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Wood</td>
<td>Grant NIH (US): Research Grant (2-R01-DA011591-04A1)</td>
<td></td>
<td>$566,301.00</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Wood</td>
<td>Grant CIHR: Operating Grant (HHP-6726)</td>
<td></td>
<td>$158,355.00</td>
</tr>
<tr>
<td>Medical Oncology</td>
<td>Chi</td>
<td>Agreement US Army DAMD17-02-0226, PC011011 in collaboration with OncoGenex</td>
<td></td>
<td>$377,720.00</td>
</tr>
<tr>
<td>Medical Oncology</td>
<td>Chi</td>
<td>Grant Ontario Clinical Oncology Group</td>
<td></td>
<td>$32,000.00</td>
</tr>
<tr>
<td>Nephrology</td>
<td>Chiu</td>
<td>Clinical Trial AstraZeneca Canada Inc</td>
<td></td>
<td>$41,341.00</td>
</tr>
<tr>
<td>Nephrology</td>
<td>Duncan</td>
<td>Clinical Trial AstraZeneca Canada Inc</td>
<td></td>
<td>$8,720.00</td>
</tr>
<tr>
<td>Nephrology</td>
<td>Duncan</td>
<td>Clinical Trial Ortho Biotech</td>
<td></td>
<td>$55,523.00</td>
</tr>
<tr>
<td>Nephrology</td>
<td>Duncan</td>
<td>Clinical Trial Merck &amp; Co., Inc.</td>
<td></td>
<td>$37,839.00</td>
</tr>
<tr>
<td>Division</td>
<td>Grantor</td>
<td>Amount</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------</td>
<td>--------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Jastrzebski Clinical Trial</td>
<td>$4,200.00</td>
<td>Hoffmann-La Roche Ltd (Canada) BA16736B: An Open-Label Randomized Multicentre Parallel-Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821 in Patients with Chronic Kidney Disease who are on Dialysis</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Jung Clinical Trial</td>
<td>$22,477.00</td>
<td>AstraZeneca UK Limited A study to evaluate the use of rosvastatin in subjects on regular hemodialysis: An assessment of survival and cardiovascular events (AURORA)45222IL-0096; a double-blind, randomised, multicentre, phaseIIb, parallel-group study to compare the…</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Landsberg Grant</td>
<td>$3,600.00</td>
<td>MSFHR: Institutional Infrastructure Support Program INS002031 Living anonymous donation clinical pilot study</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Landsberg Grant</td>
<td>$44,400.00</td>
<td>Kidney Foundation: Biomedical Scholarship The humoral immune response in kidney allograft rejection</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Grant</td>
<td>$55,000.00</td>
<td>CIHR: Postdoctoral Fellowship MFE-63502 in collaboration with: Institute of Circulatory &amp; Respiratory Health (CIHR) (Fellow: Khan, Nadia) The value of cardiac specific troponin in predicting cardiac outcomes in an asymptomatic chronic kidney disease population</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Clinical Trial</td>
<td>$7,500.00</td>
<td>Merck Frosst Canada Inc. STPDF240021 (Fellow: Khan, Nadia) The value of cardiac specific troponin in predicting cardiac outcomes in an asymptomatic chronic kidney disease population</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Grant</td>
<td>$76,790.00</td>
<td>Janssen-Ortho Inc. IICT: A study of the interaction of Vascular Reactivity and Program Hemoglobin in End Stage Diabetic Dialysis Patients</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Grant</td>
<td>$88,651.00</td>
<td>Various Sources Care prior to dialysis: A multicentre prospective cohort study in renal insufficiency to assess the impact of elements of care on patient outcomes (CREDA)</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Clinical Trial</td>
<td>$12,500.00</td>
<td>Kidney Foundation of Canada An Open Label, Randomized, Multicentre, Parallel Group Study To Demonstrate Correction Of Anemia Using Subcutaneous Injections Of RO0503821 In Patients With Chronic Kidney Disease Who Are Not On Dialysis</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Clinical Trial</td>
<td>$4,200.00</td>
<td>Hoffmann-La Roche IICT: A study of the interaction of Vascular Reactivity and Program Hemoglobin in End Stage Diabetic Dialysis Patients</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Clinical Trial</td>
<td>$76,790.00</td>
<td>Merck Frosst Canada Inc. STPDF240021 (Fellow: Khan, Nadia) The value of cardiac specific troponin in predicting cardiac outcomes in an asymptomatic chronic kidney disease population</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Clinical Trial</td>
<td>$1,320,107.00</td>
<td>University of Oxford Study of Heart and Renal Protection (SHARP)</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Levin Clinical Trial</td>
<td>$104,236.00</td>
<td>Johnson &amp; Johnson An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) in Patients Receiving Epoetin Alfa Therapy</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Quamme Grant</td>
<td>$166,250.00</td>
<td>CIHR: Operating Grant # MOP-53288 Studies of Renal Magnesium Transport</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Quamme Grant</td>
<td>$50,000.00</td>
<td>Kidney Fdn: Biomedical Research Grant Characterization of MagT, a Novel Family of Renal Magnesium Transporters</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Wong Grant</td>
<td>$25,000.00</td>
<td>Canadian Apoptosis Research Foundation (NEW) Accelerated neuronal aging caused by transient exposure to toxin.</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>Yeung Clinical Trial</td>
<td>$28,187.00</td>
<td>Medtronic USA Medtronic EMPIRIC Study - Evaluation of EMPIRIC Programming to Improve Patient Management</td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>Barton Grant</td>
<td>$239,956.00</td>
<td>CFI: Canada Research Chairs Infrastructure Fund 202111 The UBC neuropsychology laboratory for investigation of human visual processing and ocular motor control</td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>Barton Grant</td>
<td>$8,750.00</td>
<td>MSFHR: Senior Scholar Award CI-SSH-035(03-1) CLIN Neuropsychology of vision and eye movements</td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>Barton Grant</td>
<td>$58,333.00</td>
<td>Canada Research Chair Tier II (CIHR) 950-202111 Canada Research Chair for Dr. Jason Barton in Neuropsychology of vision and eye movements</td>
<td></td>
</tr>
<tr>
<td>Neurology</td>
<td>Barton Grant</td>
<td>$330,000.00</td>
<td>NIMH Grant National Institute of Mental Health, 1R01 MH069898: &quot;Perceptual encoding and imagery in prosopagnosia&quot;</td>
<td></td>
</tr>
<tr>
<td>Subject</td>
<td>Grantor</td>
<td>Type</td>
<td>Source</td>
<td>Amount</td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>Neurology</td>
<td>Calne</td>
<td>Grant</td>
<td>Various sources 16-017292-7</td>
<td>$267,520.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Calne</td>
<td>Grant</td>
<td>MRC: Operating Grant</td>
<td>$58,324.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Calne</td>
<td>Grant</td>
<td>MRC: Group Grant MGC 36035</td>
<td>$24,358.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Chapman</td>
<td>Clinical Trial</td>
<td>Wyeth-Ayerst Canada Inc</td>
<td>$86,681.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Devonshire</td>
<td>Grant</td>
<td>Donations for Health Science Research</td>
<td>$37,052.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Doudet</td>
<td>Contract</td>
<td>Schering Ag</td>
<td>$108,905.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Doudet</td>
<td>Grant</td>
<td>Titan Pharmaceuticals Inc.</td>
<td>$75,720.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Doudet</td>
<td>Grant</td>
<td>MRC: Group Grant MOP-14535</td>
<td>$52,258.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Doudet</td>
<td>Grant</td>
<td>Titan Pharmaceuticals Inc.</td>
<td>$41,927.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Doudet</td>
<td>Agreement</td>
<td>Titan Pharmaceuticals Inc.</td>
<td>$18,183.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Doudet</td>
<td>Grant</td>
<td>MSFHR: Senior Graduate Studentship Award ST-SGS 128(03-1)BM (Fellow: Strome, Elissa)</td>
<td>$2,292.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Eisen</td>
<td>Clinical Trial</td>
<td>Various Pharmaceutical Companies LTS 3069, EFC 2491 (in collab. with Sanofi Canada Inc. &amp; Quintiles Canada Inc.)</td>
<td>$22,800.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Eisen</td>
<td>Clinical Trial</td>
<td>Aventis Pharma Inc. RP54274/CA1.401</td>
<td>$64,524.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Grant</td>
<td>Donations for Health Science Research</td>
<td>$50.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Grant</td>
<td>CIHR: Institute of Aging (Pilot Project Grant)</td>
<td>$50,000.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Grant</td>
<td>Various Pharmaceutical Companies</td>
<td>$195,000.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Grant</td>
<td>Various Pharmaceutical Companies</td>
<td>$76,400.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Clinical Trial</td>
<td>Pfizer Canada Inc. A2581078</td>
<td>$52,357.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Contract</td>
<td>Pfizer Canada Inc.</td>
<td>$15,332.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Grant</td>
<td>MSFHR: Postdoctoral Trainee Fellowship, 117(02-01) BM (Fellow: Hsiung, Ging-Yuek)</td>
<td>$9,750.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Clinical Trial</td>
<td>Janssen-Ortho Inc.</td>
<td>$585.00</td>
</tr>
</tbody>
</table>
Patients Who Participated in Clinical Trials of Galantamine

<table>
<thead>
<tr>
<th>Division</th>
<th>Researcher</th>
<th>Sponsor</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Clinical Trial University of California, San Diego</td>
<td>$13,369.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Clinical Trial Janssen-Ortho Inc.</td>
<td>$4,485.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Clinical Trial Sanofi-Synthelabo Canada Inc.</td>
<td>$6,000.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Feldman</td>
<td>Clinical Trial Sanofi-Synthelabo Canada Inc.</td>
<td>$135,901.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Gibson</td>
<td>Clinical Trial Eli Lilly Canada Inc.</td>
<td>$22,608.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Gibson</td>
<td>Clinical Trial Eli Lilly Canada Inc.</td>
<td>$13,494.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Gibson</td>
<td>Clinical Trial Bayer Corp</td>
<td>$13,292.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Hashimoto</td>
<td>Clinical Trial Biogen Idec, Inc.</td>
<td>$8,090.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Johnston</td>
<td>Clinical Trial Sanofi-Synthelabo Canada Inc.</td>
<td>$6,972.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Jones</td>
<td>Clinical Trial Pfizer Canada Inc.</td>
<td>$2,178.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Jones</td>
<td>Clinical Trial Pfizer Canada Inc.</td>
<td>$8,625.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Jones</td>
<td>Clinical Trial UCB Pharma</td>
<td>$9,807.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Jones</td>
<td>Clinical Trial Pfizer Canada Inc.</td>
<td>$6,630.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Jones</td>
<td>Clinical Trial UCB Pharma</td>
<td>$1,081.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Kastrukoff</td>
<td>Contract Chemokine Therapeutics Corp</td>
<td>$7,554.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Kastrukoff</td>
<td>Grant Donations for Health Science Research</td>
<td>$200.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Kim</td>
<td>Grant Canadian Myelin Research Initiative</td>
<td>$25,762.00</td>
</tr>
<tr>
<td>Neurology</td>
<td>Krieger</td>
<td>Clinical Trial Novartis Pharmaceuticals Canada Inc</td>
<td>$62,349.00</td>
</tr>
<tr>
<td>Division</td>
<td>Name</td>
<td>Type</td>
<td>Funding Source</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>---------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>Neurology</td>
<td>Lee</td>
<td>Grant</td>
<td>Pacific Parkinson's Research Institute</td>
</tr>
<tr>
<td>Neurology</td>
<td>Lee</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP 69382</td>
</tr>
<tr>
<td>Neurology</td>
<td>Lee</td>
<td>Clinical Trial</td>
<td>Eisai Co. Ltd. In collaboration with: Pharmaceutical Research Associates, Inc.</td>
</tr>
<tr>
<td>Neurology</td>
<td>Lee</td>
<td>Grant</td>
<td>MSFHR: Senior Scholar Award CI-SSH-038(03-1)BIOM</td>
</tr>
<tr>
<td>Neurology</td>
<td>Li</td>
<td>Contract</td>
<td>Various Sources</td>
</tr>
<tr>
<td>Neurology</td>
<td>Li</td>
<td>Grant</td>
<td>Donations for Health Science Research</td>
</tr>
<tr>
<td>Neurology</td>
<td>Martzke</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-62966</td>
</tr>
<tr>
<td>Neurology</td>
<td>McKeown</td>
<td>Grant</td>
<td>Whitaker Fdn: Biomedical Engineering Research Grant RG-04-0004 in collaboration with: University of North Carolina at Chapel Hill Duke University</td>
</tr>
<tr>
<td>Neurology</td>
<td>McKeown</td>
<td>Agreement</td>
<td>National Parkinson Foundation, US</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc.</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Agreement</td>
<td>Berlex Canada Inc</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Clinical Trial</td>
<td>Biogen, Inc C-1801</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Grant</td>
<td>MSSC: Career Development Award (Fellow: Tremlett, Helen)</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Clinical Trial</td>
<td>Biogen Inc.</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Clinical Trial</td>
<td>Berlex Canada Inc</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Grant</td>
<td>MSFHR: Postdoctoral Trainee Fellowship ST-PDF 262(03-1) CLIN (Fellow: Tremlett, Helen)</td>
</tr>
<tr>
<td>Neurology</td>
<td>Oger</td>
<td>Clinical Trial</td>
<td>Neurocine Biosciences Ltd. NBI-5788-0201</td>
</tr>
<tr>
<td>Division</td>
<td>Project Details</td>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>Neurology</td>
<td>Protocol C-867: Multicentre Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of Avonex (Interferon beta 1a) Administered Intramuscularly to Patients with Relapsing/Remitting Multiple Sclerosis</td>
<td>$12,768.00</td>
<td>Biogen Inc C-867</td>
</tr>
<tr>
<td>Neurology</td>
<td>Protocol 304747: Double-Blind Placebo-Controlled Randomized Parallel Group Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of 8 MIU Interferon Beta-1b (Betaseron) in Patients with a First Demyelinating Event Suggestive of MS</td>
<td>$7,640.00</td>
<td>Berlex Canada Inc. 304747</td>
</tr>
<tr>
<td>Neurology</td>
<td>Neuro-Immunology Research</td>
<td>$6,398.00</td>
<td>Oger Grant Donation</td>
</tr>
<tr>
<td>Neurology</td>
<td>GA-O&amp;I/001: Pharmacogenomics of Glatiramer Acetate: Study of the Genetic Basis of Responsiveness to Glatiramer Acetate in Multiple Sclerosis Patients</td>
<td>$2,807.00</td>
<td>Teva Neuroscience, GP</td>
</tr>
<tr>
<td>Neurology</td>
<td>Myasthenia Gravis Research</td>
<td>$2,760.00</td>
<td>Oger Grant Donations for Health Science Research</td>
</tr>
<tr>
<td>Neurology</td>
<td>Protein kinase pathways in seastar oocyte cell cycle control</td>
<td>$107,531.00</td>
<td>Pelech Grant MRC: Operating Grant MOP 38062</td>
</tr>
<tr>
<td>Neurology</td>
<td>DDMP Core B: Positron Emission Tomography</td>
<td>$258,184.00</td>
<td>Ruth Grant MRC: Group Grant MGC 36035</td>
</tr>
<tr>
<td>Neurology</td>
<td>Development of radiotracers based on oligonucleotides labelling</td>
<td>$76,314.00</td>
<td>Ruth Grant CFI: Infrastructure Operating Fund 5034</td>
</tr>
<tr>
<td>Neurology</td>
<td>CFI Infrastructure Operating Funds - Functional Imaging in Basic Biomedical Research Operations</td>
<td>$46,360.00</td>
<td>Ruth Grant MRC: Multi-User Maintenance Grant</td>
</tr>
<tr>
<td>Neurology</td>
<td>CFI Infrastructure Operating Funds - Functional Imaging in Basic Biomedical Research - Centre Share</td>
<td>$12,915.00</td>
<td>Ruth Grant MRC: Group Grant MT - 14535</td>
</tr>
<tr>
<td>Neurology</td>
<td>In it for Life: Mentored Clinician Scientist Salary - Paroxysmal neurological disease: the role of the human P/Q type calcium channel</td>
<td>$5,000.00</td>
<td>Spacey Grant MSFHR: Institutional Infrastructure Support Program</td>
</tr>
<tr>
<td>Neurology</td>
<td>The role of the human P/Q-type calcium channel in the pathogenesis of ataxia</td>
<td>$34,710.00</td>
<td>Spacey Grant National Ataxia Foundation</td>
</tr>
<tr>
<td>Neurology</td>
<td>Research: Paroxysmal neurological disease: The role of the human P/Q type calcium channel</td>
<td>$10,000.00</td>
<td>Spacey Grant VCHRI: Mentored Clinical Scientist</td>
</tr>
<tr>
<td>Neurology</td>
<td>Canada Research Chair Tier I (CIHR)</td>
<td>$200,000.00</td>
<td>Stoessl Grant National Parkinson Fdn: Research</td>
</tr>
<tr>
<td>Neurology</td>
<td>National Parkinson Foundation, Centre of Excellence</td>
<td>$138,375.00</td>
<td>Stoessl Agreement US National Parkinson Fdn: Research</td>
</tr>
<tr>
<td>Neurology</td>
<td>Protocol ACT5288: Phase II Randomized Multicentre Multinational Double-Blind Placebo-Controlled Study of the Effect of SR57676B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients with Early Parkinson's Disease</td>
<td>$135,750.00</td>
<td>Stoessl Clinical Trial Sanofi-Synthelabo Canada Inc</td>
</tr>
<tr>
<td>Neurology</td>
<td>Studies on fluctuations in response to dopaminergic therapy</td>
<td>$127,761.00</td>
<td>Stoessl Grant CIHR MGP 15126</td>
</tr>
<tr>
<td>Neurology</td>
<td>GDNF 20020168: PET Scanning in Association with a Multicentre Randomized Double-Blind Placebo-Controlled Parallel-Group Trial of Lateralin (r-metHuGDNF) Administered by Bilateral Intraputaminal (Ipu) Infusion of Subjects with Idiopathic...</td>
<td>$90,000.00</td>
<td>Stoessl Clinical Trial Amgen, Inc 20020168-901</td>
</tr>
<tr>
<td>Neurology</td>
<td>Neuroimaging investigation of early markers for nigrostriatal cell damage in patients with a high genetic risk of developing Parkinson's disease</td>
<td>$45,000.00</td>
<td>Stoessl Grant Parkinson Society Canada</td>
</tr>
</tbody>
</table>
### Neurology

**Stoessl Clinical Trial**
- **Boehringer Ingelheim (Canada) Ltd**
  - SCEPTRE - 1198.100: Fourteen Week Placebo-Controlled Dose-Response Efficacy & Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor) $31,923.00

**Neurology**
- **Stoessl Grant**
  - **MRC: Group Grant MT-14751 Smithkline Beecham Pharmaceuticals (Canada) 101468/170**
    - A non-interventional follow-up study to observe the long term outcome of Parkinson's Disease in patients who completed study SK & F 101468/056 or study SK&F 101468/125 (STUDY 101468/170) $28,383.00

**Neurology**
- **Stoessl Clinical Trial**
  - **Kyowa Pharmaceutical, Inc in collaboration with: Lineberry Research Associates**
    - 6002-US-005 in collaboration with: Lineberry Research Associates $13,169.00

**Neurology**
- **Stoessl Grant**
  - **CIHR MGP 15126**
    - Degenerative Disorders of the Motor Pathways $323,354.00

**Neurology**
- **Teal Clinical Trial**
  - **Boehringer Ingelheim (Canada) Ltd.**
    - 6002-018: A 12 Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy or 40mg/day KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy $11,635.00

**Neurology**
- **Teal Clinical Trial**
  - **AstraZeneca Canada Inc**
    - Protocol SA-NXY-0007: Double-Blind Randomized Placebo-Controlled Parallel-Group Multicenter Phase IIb/III Study to Assess the Efficacy & Safety of Intravenous NXY-059 in Acute Ischemic Stroke $64,000.00

**Neurology**
- **Teal Clinical Trial**
  - **Aventis Pharma Inc.**
    - IRP4563H/4001 - PREVAIL: An Open Label Randomized Parallel-Group Multicenter Study to Evaluate the Efficacy & Safety of Enoxaparin vs Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke $7,800.00

**Neurology**
- **Teal Clinical Trial**
  - **Sanofi-Synthelabo Canada Inc.**
    - Protocol EFC4505: (CHARISMA) Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance $26,057.00

**Neurology**
- **Teal Clinical Trial**
  - **ONO Pharma USA, Inc**
    - Protocol 2506/INT0104: Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of the Effects of ONO-2506 IV Infusion on the Amelioration of Neurological Damage and Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic Stroke $51,535.00

**Neurology**
- **Teal Clinical Trial**
  - **Bayer Inc.**
    - RECT: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke $170,799.00

**Neurology**
- **Teal Clinical Trial**
  - **Wake Forest University - School of Medicine**
    - Vitamin Intervention for Stroke Prevention $5,000.00

**Neurology**
- **Teal Clinical Trial**
  - **Eli Lilly Canada Inc.**
    - Protocol C0116T41 AbESTT-II: Aboctiimab (ReoPro) in Acute Ischemic Stroke: A Phase III Multinational Multicentre Randomized Double-Blind Placebo-Controlled Trial $19,749.00

**Neurology**
- **Traboulsi Clinical Trial**
  - **Teva Neuroscience, GP 9014**
    - Protocol GA 9014: Multicentered Randomized Double-Blind Placebo-Controlled Parallel Study Assessing the Add-On Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated with Glatiramer Acetate (GA) $46,591.00

**Neurology**
- **Tremlett Grant**
  - **MSSC: Research Grant**
    - The Impact of Beta-interferon Therapy on MS: Effectiveness and Toxicity $32,160.00

**Neurology**
- **Tsui Clinical Trial**
  - **Elan Pharmaceuticals Inc. AN072-401CD**
    - An Open Label Safety and Immunogenicity Study of MYOBLOC (NEUROBLOC; BOTULINIM TOXIN TYPE B) Injectable Solution in Patients with Cervical Dystonia. $11,688.00
<table>
<thead>
<tr>
<th>Neurology</th>
<th>Tsui</th>
<th>Grant</th>
<th>MSFHR: Institutional Infrastructure Support Program INS002031</th>
<th>$3,600.00</th>
<th>Occupational Risk Factors in Parkinson's Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurology</td>
<td>Tsui</td>
<td>Clinical Trial</td>
<td>Allergan Inc.</td>
<td>$2,124.00</td>
<td>191622-064-01: An Observational Study of the Prevalence of Migraine and Other Primary Headache Disorders and Headache Attributed to Craniovascular Dystonia in a Population of Subjects with Cervical Dystonia</td>
</tr>
<tr>
<td>Neurology</td>
<td>Wang</td>
<td>Grant</td>
<td>CIHR: Doctoral Research Awards DDS 61947 In Collaboration With: Institute of Circulatory &amp; Respiratory Health (CIHR) Fellow: Liu, Yitao</td>
<td>$600.00</td>
<td>AMPAR trafficking in models of cerebral ischemia</td>
</tr>
<tr>
<td>Neurology</td>
<td>Wong</td>
<td>Clinical Trial</td>
<td>ONO Pharma USA, Inc</td>
<td>$13,801.00</td>
<td>A randomized, double-blind, placebo-controlled, parallel group, multi-center study of the effects of ONO-2505 intravenous on the improvement of strokes and improvement in the stroke assessment scales scores in patients with acute ischemic strokes</td>
</tr>
<tr>
<td>Neurology</td>
<td>Woelfenden</td>
<td>Clinical Trial</td>
<td>Novo-Nordisk</td>
<td>$35,979.00</td>
<td>Protocol F7ICH-1371: Randomized Double-Blind Placebo-Controlled Multicentre Parallel Groups Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (Nastas/NovoSeven) in Acute Intracerebral Haemorrhage</td>
</tr>
<tr>
<td>Neurology</td>
<td>Woelfenden</td>
<td>Clinical Trial</td>
<td>National Institutes of Health</td>
<td>$28,119.00</td>
<td>Warfarin Aspirin symptomatic intracranial disease (WASID) study</td>
</tr>
<tr>
<td>Physical Medicine &amp; Rehabilitation</td>
<td>Dhawan</td>
<td>Grant</td>
<td>Allergan Inc</td>
<td>$2,537.00</td>
<td>Protocol 191622-056: Multicenter Open-Label Study of the Safety of Repeated Doses of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Focal Upper Limb Poststroke Spasticity</td>
</tr>
<tr>
<td>Physical Medicine &amp; Rehabilitation</td>
<td>Van Rijn</td>
<td>Grant</td>
<td>Vancouver Coastal Health Authority</td>
<td>$104,101.00</td>
<td>Salary: Research Nurse</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Abboud</td>
<td>Grant</td>
<td>Donations for Health Science Research</td>
<td>$70.00</td>
<td>Donations</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Abboud</td>
<td>Agreement</td>
<td>Workers’ Compensation Board of British Columbia</td>
<td>$18,464.00</td>
<td>Evaluation of Electronically Recorded Occupational Peak Flow Monitoring and Weekly Occupational Change in Spirometry as Substitutes for Inhalation Challenge Testing in Red Cedar Asthma</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>VCHRI: VGH &amp; UBC Hospital Fdn In it for Life (Operating)</td>
<td>$50,000.00</td>
<td>The Impact of CPAP Therapy for Obstructive Sleep Apnea Hypopnea on Cardiovascular Risk Factors: A Randomised Crossover Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>MSFHR: Establishment Grant CI-SCH-060(03-1) HSR</td>
<td>$37,500.00</td>
<td>MSFHR/WCB Scholar Award: The public health impact of obstructive sleep apnea hypopnea. A focus on work productivity, occupational injuries and motor vehicle crashes</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Clinical Trial</td>
<td>Respiromics Inc</td>
<td>$12,632.00</td>
<td>ICT: REMStar Auto with C-Flex: In Laboratory Performance vs Conventionally Titrated CPAP Therapy: Performances and Preferences</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>MSFHR: Institutional Infrastructure Support Program INS002031</td>
<td>$3,600.00</td>
<td>The public health and safety impacts of obstructive sleep apnea</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>BCLA</td>
<td>$21,750.00</td>
<td>The societal consequences of sleep apnea</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>MSFHR: Scholar Award CI-SCH-060(03-1) HSR</td>
<td>$33,750.00</td>
<td>The public health impact of obstructive sleep apnea hypopnea</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>CIHR: New Investigator Award (CIHR Scholarship) JBN-56261</td>
<td>$25,000.00</td>
<td>Investigation of the diagnosis and treatment of sleep disordered breathing</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ayas</td>
<td>Grant</td>
<td>BC Lung/CIHR Investigator</td>
<td>$25,000.00</td>
<td>Investigation of the diagnosis and treatment of sleep disordered breathing</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Bai</td>
<td>Grant</td>
<td>CIHR: Operating Grant MOP-42537</td>
<td>$81,302.00</td>
<td>Modulation of airway function by neurotrophic cytokines</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Bai</td>
<td>Grant</td>
<td>UBC Killam Fellowship</td>
<td>$3,000.00</td>
<td>UBC Killam Memorial Faculty Research Fellowship</td>
</tr>
<tr>
<td>Subdivision</td>
<td>Name</td>
<td>Grant Type</td>
<td>Sponsor</td>
<td>Amount</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>------</td>
<td>------------</td>
<td>---------</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Bai</td>
<td>Clinical Trial</td>
<td>Intermune Pharmaceuticals, Inc.</td>
<td>$4,760.00</td>
<td>An open-label study of the safety of subcutaneous recombinant interferon gamma-1b (IFN-γ1b) in patients with idiopathic pulmonary fibrosis. GIPF-006</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Bai</td>
<td>Clinical Trial</td>
<td>Intermune Pharmaceuticals, Inc.</td>
<td>$4,692.00</td>
<td>An open-label study of the safety and efficacy of subcutaneous recombinant interferon gamma-1b (IFN-γ1b) in patients with idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Cook</td>
<td>Grant</td>
<td>Vancouver Coastal Health Research Institute</td>
<td>$40,000.00</td>
<td>Implementation &amp; Evaluation of Strategies to Control</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Duronio</td>
<td>Grant</td>
<td>CIHR Operating Grant</td>
<td>$119,354.00</td>
<td>Cytokine regulated signalling pathways in inflammatory cells</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Duronio</td>
<td>Grant</td>
<td>MSFHR: Postdoctoral Trainee Fellowship ST-PDF 164(3-1)BM (Fellow: Germain, Marc)</td>
<td>$29,250.00</td>
<td>Analysis of nuclear and cytoplasmic Mcl-1 protein complexes</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Duronio</td>
<td>Grant</td>
<td>MSFHR: Senior Graduate Studentship Award ST-SGS125(03-1)BM: (Fellow: Scott, Alexander)</td>
<td>$2,500.00</td>
<td>The roles of apoptosis and IGF-1 in tendinosis of the rotator cuff</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Duronio</td>
<td>Grant</td>
<td>MSFHR: Senior Scholar Award 70(CI-2001)</td>
<td>$100,000.00</td>
<td>Key Signalling Pathways Controlling Survival and Death of Hemopoietic Cells</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Grant</td>
<td>Healthshares Holdings, Inc. in collaboration with: Vancouver Coastal Health Authority</td>
<td>$121,975.00</td>
<td>Initiative for the Study and Implementation of Systems (ISIS)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>Merck Frosst Canada &amp; Co.</td>
<td>$8,900.00</td>
<td>005-00 Double-Blind Randomized Placebo-Controlled Multicentre Parallel-Group Dose-Ranging Study of L-000883191 in Patients with COPD</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Contract</td>
<td>Centers for Disease Control and Prevention 200-2001-00094, Task #1</td>
<td>$67,219.00</td>
<td>CDC Tuberculosis Epidemiology Study Group</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>Novartis Pharmaceuticals Canada Inc.</td>
<td>$50,119.00</td>
<td>Protocol CQAB149A2208: Randomized Double-Blind Placebo-Controlled 4 Period Incomplete Block Cross-Over Multicenter Multiple Dose (7 days) Dose-Ranging Study Followed by a Single Day's Treatment with Formoterol 12ug bid to Assess the Efficacy…</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Grant</td>
<td>BC Lung/CIHR Investigator JBC-56221</td>
<td>$42,000.00</td>
<td>Bringing evidence to the patient</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Grant</td>
<td>CIHR/BC Lung Asn.: Investigator JBC-56221</td>
<td>$40,950.00</td>
<td>Bringing evidence to the patient</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Contract</td>
<td>Centers for Disease Control and Prevention 200-2001-00094, Modification #3</td>
<td>$34,611.00</td>
<td>Task 13: Factors associated with acceptance of adherence to toxicity from treatment for Latent Tuberculosis Infection (TLTBI) and pilot study of TLBIEffectiveness</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Grant</td>
<td>GlaxoSmithKline</td>
<td>$30,000.00</td>
<td>Risk factors for LOS and re admission for COPD exacerbations</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Agreement</td>
<td>CIHR: Randomized Controlled Trials (Clinical Trials) in collaboration with: Ottawa Health Research Institute</td>
<td>$27,350.00</td>
<td>Optimal Therapy of COPD to Prevent Exacerbations and Improve Quality of Life: A Randomized Double-Blind Placebo-Controlled Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Contract</td>
<td>Centers for Disease Control &amp; Prevention 200-2001-00094, Task Order 0009</td>
<td>$13,441.00</td>
<td>Enhanced surveillance to identify missed opportunities for TB prevention in foreign-born populations in the United States and Canada</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>GlaxoSmithKline Inc</td>
<td>$12,500.00</td>
<td>Can Advair and Flovent Reduce Systemic Inflammation Related to COPD? A Multicentre Randomized Controlled Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>Boehringer Ingelheim (Canada) Ltd. 205.259</td>
<td>$12,161.00</td>
<td>SAFE: Spiriva Randomized Controlled Trial. The Effect of Inhaled Tiotopium Bromide (18 mcg Once Daily) on the Change in FEV1 and Symptoms During Long-Term Treatment in Patients with COPD. A 1 yr Parallel Group Double-Blind Randomized Placebo Controlled Study</td>
</tr>
<tr>
<td>Division</td>
<td>Investigator</td>
<td>Type</td>
<td>Description</td>
<td>Amount</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>GlaxoSmithkline SAM40056: Randomized Double-Blind Double-Dummy Parallel Group Study of a Standard Dosing Regimen with Salmeterol/Fluticasone Combination 50/250ug bid (via the Diskhaler inhaler) vs a Symptom-Driven Variable Dosing Regimen with Fluticasone Propionate (750ug bid) in moderate to Severe Asthma Patients Well Controlled Under High Doses of inhaled Corticosteroids</td>
<td>$11,550.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>Altana Pharma, Inc: Protocol BY9020/M1-134 STAR: Comparison of Ciclesonide (640 ug/day) and Fluticasone Propionate (750 ug/day) in moderate to Severe Asthma Patients Well Controlled Under High Doses of inhaled Corticosteroids</td>
<td>$7,075.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>Merck Frosst Canada &amp; Co: Protocol 005-00: Double-Blind Randomized Placebo-Controlled Multicenter Parallel-Group Dose-Ranging Study of L-000883191 in Patients with COPD</td>
<td>$8,900.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>GlaxoSmithkline Inc: Protocol SAS40068: PACE-IMT 24 Week Multicentre Randomized Double-Blind Parallel Group Trial to Compare the Efficacy &amp; Tolerability of Salmeterol/Fluticasone Propionate Diskus Combination (Advair) 50/100 mcg bid with Fluticasone Propionate</td>
<td>$5,125.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Grant</td>
<td>Vancouver Coastal Health Authority: Salary: Clinical Trials Research Coordinator</td>
<td>$1,980.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fitzgerald</td>
<td>Clinical Trial</td>
<td>AstraZeneca Canada Inc D5890L00004: Comparison of Symbicort Single Inhaler Therapy (Symbicort 200 Turbuhaler 1 Inhalation bid plus as needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults: 26 Week Randomized Ope...</td>
<td>$1,500.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fleetham</td>
<td>Grant</td>
<td>MSFHR: Scholar Award CI-DSH-059/03-1 CLIN: Bringing evidence to the patient</td>
<td>$39,038.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fleetham</td>
<td>Grant</td>
<td>Vancouver Coastal Health Authority: Sleep Disorders Program Fellowship</td>
<td>$65,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fleetham</td>
<td>Grant</td>
<td>Various Pharmaceutical Companies: Respiratory Division Education Fund</td>
<td>$9,500.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Fleetham</td>
<td>Clinical Trial</td>
<td>Various Sources: CRA: Transforming growth factor beta 1 regulation of vascular smooth muscle proliferation and fibrosis</td>
<td>$2,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Khalil</td>
<td>Contract</td>
<td>iCell Therapeutics Inc: Transforming growth factor beta regulation of pulmonary fibrosis</td>
<td>$10,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Khalil</td>
<td>Grant</td>
<td>Various Sources: Transforming Growth Factor Beta Regulation of Pulmonary Fibrosis and Airway Remodeling</td>
<td>$60,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>NCI - USA: A Phase II Trial of ACAPHA in Former Smokers with IEN</td>
<td>$1,366,127.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>NIH - USA: Chemoprevention of Lung Cancer</td>
<td>$592,524.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>NIH - USA: EDRN: Novel Reagents and New Biomarkers in Lung Cancer</td>
<td>$54,824.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>Genome Canada: Cancer Genomics: A multi-disciplinary approach to the large scale, high-throughput identification of genes involved in early stage cancers</td>
<td>$4,200,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>NCI - USA: Phase I Study of the Safety and Potential Efficacy of MyoInositol as a Lung Cancer Chemopreventive Agent</td>
<td>$30,909.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>BC Lung Association: UTSW SPORE in Lung Cancer</td>
<td>$11,917.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Lam</td>
<td>Clinical Trial</td>
<td>Genome Canada: Novel Xenograft Models of Early Stage Human Lung Cancer and Preneoplastic Lesions</td>
<td>$25,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Levy</td>
<td>Clinical Trial</td>
<td>Vancouver Hospital Foundation: Application of Pharmacogenomics for the Rational Chemotherapy of Lung Cancer</td>
<td>$50,000.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Levy</td>
<td>Clinical Trial</td>
<td>NIH - USA: Detection of Early Lung Cancer by Serum Protein Expression Profiling</td>
<td>$397,497.00</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Levy</td>
<td>Clinical Trial</td>
<td>Encysive, L.P. in collaboration with: Research Point: Protocol FP03 STRIDE III: Long-Term Open-label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension</td>
<td>$33,792.00</td>
<td></td>
</tr>
</tbody>
</table>
## Respiratory Levy Grant

<table>
<thead>
<tr>
<th>BC Lung Assn.: Dr. Stefan Gryzbowksi Fellowship (Fellow: De Jong, Pim)</th>
<th>$25,000.00</th>
<th>Early detection of bronchiolitis obliterans following lung transplantation with high resolution CT scan imaging</th>
</tr>
</thead>
</table>

## Respiratory Levy Clinical Trial

<table>
<thead>
<tr>
<th>Encysive, L.P. in collaboration with: Research Point</th>
<th>$17,812.00</th>
<th>Protocol FP06: Double-Blind Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension Who Have Failed Bosentan Therapy</th>
</tr>
</thead>
</table>

## Respiratory Levy Clinical Trial

<table>
<thead>
<tr>
<th>GlaxoSmithKline Inc.</th>
<th>$2,314.00</th>
<th>An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with Ariflo (cilomilast) to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise) as well</th>
</tr>
</thead>
</table>

## Respiratory Levy Clinical Trial

<table>
<thead>
<tr>
<th>A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis</th>
<th>$9,666.00</th>
<th>Relationship between cardiovascular risks and systemic inflammation in chronic obstructive pulmonary disease</th>
</tr>
</thead>
</table>

## Respiratory Man Grant

<table>
<thead>
<tr>
<th>CIHR: Operating Grant MOP - 62865</th>
<th>$218,352.00</th>
<th>Relationship between cardiovascular risks and systemic inflammation in chronic obstructive pulmonary disease</th>
</tr>
</thead>
</table>

## Respiratory Ostrow Clinical Trial

<table>
<thead>
<tr>
<th>Pfizer Canada Inc.</th>
<th>$2,813.00</th>
<th>IMPACT: Integrated and mentored pulmonary and cardiovascular training</th>
</tr>
</thead>
</table>

## Respiratory Ostrow Clinical Trial

<table>
<thead>
<tr>
<th>United Therapeutics Corporation</th>
<th>$8,500.00</th>
<th>A double-blind randomized parallel placebo controlled comparison of the safety and efficacy of chronic subcutaneous UT-15 plus conventional therapy to conv. therapy in patients with pulmonary hypertension: A 12-week study</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>CIHR: Operating Grant GEI-53960</th>
<th>$673,725.00</th>
<th>Inflammatory Gene Haplotypes and Susceptibility to Cardiac, Vascular and Pulmonary Disease</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>CIHR/Strategic Training: Strategic Training Program Grant STR-63308 in collaboration with: Heart &amp; Stroke Foundation of Canada, Institute of Circulatory &amp; Respiratory Health (CIHR)</th>
<th>$273,507.00</th>
<th>IMPACT: Integrated and mentored pulmonary and cardiovascular training</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>MSFHR: Distinguished Scholar Award 60(CI-2001):</th>
<th>$120,000.00</th>
<th>Molecular and Genetic Mechanisms of Obstructive Lung Disease</th>
</tr>
</thead>
</table>

## Respiratory Pare Agreement

<table>
<thead>
<tr>
<th>Ontario Genomics Institute in collaboration with: Genome British Columbia</th>
<th>$95,041.00</th>
<th>Mapping and isolation of genes influencing severity of disease in cystic fibrosis</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>MR : Operating Grant MOP 37924</th>
<th>$67,766.00</th>
<th>Human airway smooth muscle function and bronchial hyperresponsiveness</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>American Thoracic Society, Inc</th>
<th>$64,360.00</th>
<th>Molecular mechanisms and genetic determinants of mediator mobilization and release from neutrophil azurophilic granules as it relates to COPD</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>Parker B. Francis Fellowship in Pulmonary Research (Fellow: Mahmudi-Azer, Salahaddin)</th>
<th>$52,000.00</th>
<th>Mediator mobilization and release from neutrophil azurophilic granules in association with Asthma and COPD</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>Heart/Stroke Fdn Cda/CIHR: Strategic Training Initiatives PG-03-0191</th>
<th>$36,968.00</th>
<th>IMPACT: Integrated and mentored pulmonary and cardiovascular training</th>
</tr>
</thead>
</table>

## Respiratory Pare Grant

<table>
<thead>
<tr>
<th>BC Lung: Investigator in collaboration with: St. Paul's Hospital (Fellow: Sin, Don)</th>
<th>$32,500.00</th>
<th>BC Lung Association/St. Paul's Hospital Investigator Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>Division</td>
<td>Grant</td>
<td>Status</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>--------</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Pare</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Pare</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Pare</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Pare</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Road</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Road</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Road</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Road</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Road</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Road</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ryan</td>
<td>Agreement</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Sanford</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Sanford</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Sanford</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Sanford</td>
<td>Grant</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Sanford</td>
<td>Grant</td>
</tr>
<tr>
<td>Division</td>
<td>Grant Type</td>
<td>Department</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Grant</td>
<td>CIHR: New Investigator Award (CIHR Scholarship)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Grant</td>
<td>CIHR: Canada Research Chairs Infrastructure Fund</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Grant</td>
<td>CIHR: Randomized Controlled Trials (Clinical Trials)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Grant</td>
<td>CIHR</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Clinical Trial</td>
<td>GlaxoSmithKline Inc.</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Grant</td>
<td>BC Lung: Project Grant 7568-GR0001</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Grant</td>
<td>BC Lung/CIHR Investigator</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Clinical Trial</td>
<td>Intermune Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Clinical Trial</td>
<td>Boehringer Ingelheim Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Clinical Trial</td>
<td>Boehringer Ingelheim Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Grant</td>
<td>CAN</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Grant</td>
<td>CAN</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>WCB</td>
<td></td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Clinical Trial</td>
<td>Hoffmann-La Roche</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Clinical Trial</td>
<td>Alexion</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Clinical Trial</td>
<td>Bristol-Meyers Squibb</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Grant</td>
<td>TAS</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Grant</td>
<td>CIHR: Clinician Scientist MC2-69188</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Grant</td>
<td>CIHR: Clinician Scientist MC2-69188</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Grant</td>
<td>CIHR</td>
</tr>
<tr>
<td>Division</td>
<td>Grant</td>
<td>Type</td>
</tr>
<tr>
<td>----------</td>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Cibere</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Cibere</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Cibere</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Esdaile</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Esdaile</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Esdaile</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Esdaile</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Esdaile</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Esdaile</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Garbuz</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Greidanus</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kelsall</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kelsall</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Klinkhoff</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Klinkhoff</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Klinkhoff</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Klinkhoff</td>
<td>Clinical Trial</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kopec</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kopec</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kopec</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kopec</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kopec</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Kopec</td>
<td>Salary Award</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lacaille</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lacaille</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lacaille</td>
<td>Grant</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lacaille</td>
<td>Salary Award</td>
</tr>
</tbody>
</table>
## UBC Department of Medicine Awards by Division for 2004-2005

<table>
<thead>
<tr>
<th>Division</th>
<th>Name</th>
<th>Award Type</th>
<th>Award Source</th>
<th>Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatology</td>
<td>Lacaille</td>
<td>Salary Award</td>
<td>TAS, CIHR - New Investigator Award</td>
<td>$50,000.00</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lacaille</td>
<td>Salary Award</td>
<td>VHHSC - Research Scholar Award</td>
<td>$10,000.00</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lehman</td>
<td>Salary Award</td>
<td>CIHR - Fellow Award</td>
<td>$20,000.00</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Lehman</td>
<td>Salary Award</td>
<td>MSFHR - Fellow Award</td>
<td>$2,667.00</td>
</tr>
<tr>
<td>Rheumatology</td>
<td>Shojaia</td>
<td>Salary Award</td>
<td>TAS</td>
<td>$3,750.00</td>
</tr>
</tbody>
</table>

**Totalawards:** $40,713,125.00